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1.1. Multiple primary cancers 
 
The extent of the problem 
The number of cancer survivors has been increasing dramatically and is expected to keep 
growing in the near future. In the Netherlands, a 38% increase of cancer survivors is 
estimated from 2005 to 2015, representing an increase from 500,000 to 692,000 (ex-) 
patients in this period.1 It is well known that individuals who suffered from cancer exhibit a 
20% higher risk of subsequent primary malignancies.2 Thus, as the number of cancer 
survivors increases, the number of patients with multiple primary cancers will increase as 
well. Because cancer is more frequent among the elderly, the ageing of the Dutch population 
will cause a further increase in the number of cases with multiple cancers: Only 5%-12% of 
cancer patients aged 50-64 were previously diagnosed with cancer, versus 12%-26% of 
those aged over 803. Other forces, including increased awareness of (second) malignancies, 
the higher use and sensitivity of diagnostic/detection methods, and the recent improvements 
in cancer treatment and survival will further lead to higher prevalence of multiple cancers. 
Cancer survivors who develop a second malignancy have a higher risk of dying4 and 
experience a worsening in their quality of life. Thus, increased interest in second cancer from 
the epidemiological and clinical perspective is highly relevant.  
 
Breast cancer 
The incidence of breast cancer among women has increased by 50% during the last 30 
years. On the other hand, data from the Eindhoven cancer registry in the southwest of the 
Netherlands indicate that breast cancer mortality has been decreasing by 2% every year 
since 19955 due to earlier diagnosis and better treatment. These trends have led to a 
marked increase in the number of female cancer survivors who are at risk of developing 
another primary cancer. Breast cancer has been the most prevalent malignancy in women,6 
and also the most commonly occurring multiple malignancy.7 Of all prevalent malignancies 
among women, 25% of them are breast cancer.7  
 
Women with breast cancer do not only have an increased risk of second breast cancer. 
Studies indicate that these women also have an increased risk of developing other female 
genital, oesophageal, salivary gland and soft tissue cancers. On the other hand, women with 
a breast cancer have a lower risk compared to the general population, of developing cancer 
of the cervix, pancreas, lung, non-Hodgkin Lymphoma and chronic lymphocytic leukaemia8.  
 
Skin cancer 
In industrialized countries, we have witnessed an increasing trend in the incidence of skin 
cancer over the last few decades.9, 10 In 2005, there were 18,715 cases of newly diagnosed 
basal cell carcinoma (BCC) of the skin, 4,212 cases of squamous cell carcinoma (SCC) of 
the skin, and 3042 cases of cutaneous melanoma (CM) in the Netherlands11, corresponding 
to 19%, 4% and 3% of the total number of incident cancers, respectively.3 Due to the low 
case-specific mortality rates of skin cancer, the prevalence of skin cancer has increased 
dramatically, providing opportunities for the analysis on the incidence of multiple cancers 
(see chapter 10 of this thesis).   
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Recent studies have shown that although sun exposure increases the risk of skin cancer, it 
may have a protective effect against some major cancers including that of the breast as well 
as colorectal and prostate cancer, through the formation of vitamin D.12-14 Patients with skin 
cancer constitute a good cohort to indirectly test this hypothesis. Examining the risk of 
second cancer among skin cancer patients can provide clues in this paradoxical effect of sun 
exposure: If more exposure to sunlight increases the risk of skin cancer but reduces the risk 
of breast, prostate and colorectal cancer, skin cancer patients should have a lower incidence 
of these cancers compared to the general population. Although cancer registry data do not 
provide individual information on sun exposure, examining the risk of a second cancer by 
various host and tumour characteristics may give further idea on the protective role of sun 
exposure (table 1.1). It is known that cumulative sun exposure is associated with an 
increased risk of SCC. The association of sun exposure is less strong for BCC, which has 
been hypothesized to be etiologically more similar to melanoma. Therefore a cohort of 
patients with SCC should show the highest protective effect against breast, prostate and 
colorectal cancer and cohort of patients with CM the lowest. Similarly, skin cancers occurring 
in the head and neck region and those diagnosed at older age are usually associated with 
chronic exposure and thus a lower risk of second breast, prostate and colorectal cancer skin 
cancers is expected in this group of patients.  
 
Table 1.1. Associations between sun exposure pattern and skin cancer features9, 15 
Sun Exposure Host and tumour feature 
Intermittent Chronic 
Skin cancer type   
     Squamous Cell Carcinoma + +++ 
     Basal Cell Carcinoma ++ ++ 
     Melanoma +++ + 
Age at diagnosis   
     Young +++ + 
     Old + +++ 
Subsite   
     Head and neck + +++ 
     Trunk and extremities +++ + 
 
In order to interpret the risk pattern of multiple cancers it is necessary to identify the factors 
that influence an individual’s risk of developing a second cancer including: internal factors, 
e.g., genetic predisposition towards cancer; and external factors, e.g., lifestyle, treatment of 
the first cancer. Hereditary genetic predispositions may increase an individual risk of multiple 
malignancies.16 Genetic factors have been more commonly related to an increased risk 
among those who were diagnosed with a first cancer at an early age. Other factors such as 
lifestyle should influence mainly the risk of second malignancy among the older age groups 
because of the long exposure time that is needed until such factors cause carcinogenic 
changes in a human body. Treatment of a first cancer may also be related to the occurrence 
of a second cancer. Comparing a group of patients who were exposed to a certain treatment 
to those who were spared from the treatment may further give light on this issue. 
Furthermore, increased monitoring may also elevate the risk of a second primary cancer.  
 
Because the above mentioned factors have changed over time (except for genetic 
disorders), the risk of a second cancer among cancer patients also changes, thus 
continuous monitoring of second cancer risk is of utmost importance. Study of multiple 
cancers will provide information on the necessary guidelines to follow-up cancer patients. 
Chapter 1 
 14 
Through such studies the patient group at high risk of developing a second cancer can be 
identified. In addition, the type of the second cancer with the highest risk and length of time 
where such risk is increased can be determined. Consequently, screening strategies for the 
early detection of a second cancer or lifestyle advise to reduce risk of developing a second 
cancer can be developed. Assessing the pattern of diseases has tremendously increased 
our knowledge on their causes, the same applies for multiple cancer studies.  
 
1.2. Research questions 
The study of multiple cancers is important from an etiological as well as from a clinical point 
of view. This thesis aims to explore both perspectives by assessing the risk of multiple 
cancers in breast and skin cancer patients, the two most prevalent cancers in the 
Netherlands. The specific study questions addressed in this thesis are: 
 
1. What are the determinants of breast cancer incidence and survival? 
2. What is the risk of second cancer among patients previously diagnosed with a primary 
breast cancer? 
3. Is there a reduced risk of colorectal, breast and prostate cancers among skin cancer 
patients? 
 
1.3. Methods 
 
Study population 
The studies in this thesis are performed using the data from the population-based cancer 
registry in Eindhoven (ECR).  Cancer registries in the Netherlands receive lists of newly 
diagnosed cases on a regular basis from the pathology and haematology departments in the 
region (PALGA). In addition, lists of all hospitalised cancer patients based on data from the 
national Registry of Hospital Discharge Diagnosis were also used in the cancer registration 
process. Following the notification from these sources, the medical records of newly 
diagnosed patients (and tumours) are collected and abstracted by trained tumour registrars. 
Data of patients who live in the area of ECR, but are diagnosed in hospitals outside the ECR 
territory, are regularly retrieved from the other Dutch cancer registries since 1989. Before 
this year it was done directly through retrievals at all cancer centres particularly from 
Nijmegen, Rotterdam, Utrecht, and Amsterdam. 
 
The following data were used in our studies: gender, date of birth, date of primary cancer 
diagnosis, order of cancer diagnosis, date of death, clinical and pathological staging, 
morphology, body site and initial treatment (i.e. treatment given or planned within the first 6 
months after diagnosis, including surgery, radiotherapy, chemotherapy, and hormonal 
treatment). Topography and morphology are coded according to the International 
Classification of Diseases for Oncology (ICD-O). Staging of the tumours is done according to 
the most recent TNM classifications.17 For coding of multiple tumours, the rules from the 
International Agency for Research on Cancer (IARC) were adopted.18  
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Methods of analysis 
 
Incidence rates 
Incidence rates are calculated by dividing the numbers of incident cases by the number of 
person-years at risk.19 When we computed the incidence rate of second cancer, the person-
years at risk extend from the date of the initial cancer diagnosis to the date of a second 
cancer, date of death, loss to follow-up, or end of the study, whichever occurred first. The 
role of changes in age structure over time was assessed by adjusting rates to the European 
Standard Population.19 
 
Relative excess of cancer risk 
In order to calculate the relative excess risk of a cancer (chapter 3), we assumed that the 
lowest incidence of a specific cancer in a certain country represents the baseline rate of a 
cancer or the achievable minimum rate,20 presumably due to relatively low prevalence of risk 
factors.21 The excess of cancers (proportion of relative excess risk= RER) in a country of 
interest was obtained by subtracting this baseline rate from the cancer incidence rate of the 
country of interest and dividing this to the cancer incidence rate of the country of interest.20 
We assumed that the excess cancer cases were caused by high prevalence of behavioral, 
occupational and/or environmental risk factors. The absolute number of excess cases was 
calculated by multiplying the rate difference to the size of the population of the country of 
interest in the same period and age group, divided by 100,000.  
 
Measures used for multiple cancer studies 
In order to determine whether cancer patients were at a higher or lower risk of developing a 
new primary cancers than the general population, the incidence rates of subsequent tumours 
among these patients (observed incidence) was compared to the incidence rates of the 
same tumours in the reference population. The expected incidence was calculated adjusting 
for gender, age (in 5-year age categories) and calendar time at first cancer diagnosis. 
Dividing the observed incidence by the expected incidence produced the standardized 
incidence ratio (SIR).22 The 95% confidence intervals were calculated assuming a Poisson 
distribution.19  
 
Absolute excess risk (AER) measures the excess number of subsequent malignancies per 
10,000 patients per year.22 The AER is obtained by subtracting the expected from the 
observed number of second cancer cases, and dividing it by the number of person-years 
and then multiplying it by 10,000. The AER gives crucial information for public health 
planning, particularly regarding the allocation of health-care resources according to the 
demands in the population. 
 
Cumulative risk (CR) is the proportion of patients alive at time t who can be expected to 
develop a second cancer. The CR is estimated by using the life table method23. This method 
accounts for censoring in the data, allowing estimation of the proportion of patients that will 
develop a second cancer up to various time points during the follow up, conditional on 
surviving until that time point. The CR provides information on the average risk of multiple 
cancers among cancer patients.  
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1.4. Structure of the thesis 
In the introduction we review the epidemiology of multiple primary cancers (Part I, Chapters 
1 and 2). Furthermore, this thesis is structured in five additional parts: Part II (Chapter 3-5) 
discusses general epidemiological aspects of breast cancer. In Chapter 3 the correlation 
between average age of mothers at first childbirth, a major risk indicator of breast cancer, 
and current excess of breast cancer risk in 34 industrialized countries was assessed. 
Chapter 4 briefly describes the trend of breast cancer in the Netherlands as compared to the 
USA and discusses the role of hormone replacement therapy on the observed trends. 
Chapter 5 focuses on the prognostic factors of long-term breast cancer survivors. The 
current literature on determinants of breast cancer survival for 10 years or more was 
reviewed, and the influence of a second cancer on the prognosis of breast cancer patients is 
discussed. 
 
Part III (Chapter 6-9) examines the risk pattern of multiple cancers among breast cancer 
patients in four chapters: Chapter 6 assesses the incidence of breast cancer among female 
cancer survivors over the last decades. The following two chapters describe the risk pattern 
of second primary cancers among invasive (Chapter 7) as well as in situ (Chapter 8) breast 
cancer patients. Chapter 9 assesses the risk of second breast and urogenital cancer after 
breast cancer. This chapter also aims to identify those with the highest risk of second 
primary cancer, by examining the role of age at diagnosis, treatment of first cancer, and time 
after first breast cancer. 
 
Part IV (Chapter 10-12) focuses on the risk of second cancer among skin cancer patients, 
investigating the protective role of sun exposure on the occurrence of major cancers 
including breast, colorectal and prostate cancer. This section begins with a short description 
of the cohort of patients with skin cancer and of how examining the risk of multiple cancer 
among skin cancer patients can be used to explore hypotheses on the aetiology of cancer 
such as the role of sun exposure (Chapter 10). Chapter 11 and Chapter 12 assess the risk 
of colorectal, breast and prostate cancer in 3 groups of skin cancer patients (squamous cell 
carcinoma (SCC), basal cell carcinoma (BCC), and cutaneous malignant melanoma (CMM)). 
These chapters examine the relative risk of breast, colorectal and prostate cancer according 
to location of skin cancer, age at skin cancer diagnosis, and time since skin cancer 
diagnosis, as well as stage of breast, colorectal and prostate cancer at time of diagnosis.   
 
Part V concludes with a general discussion of the findings, their policy implications and 
recommendations for future research (Chapter 13).   
Introduction 
 17 
References 
 
1. Kanker in nederland. Trends, prognoses, en implicatie voor zorgvraag. 2004 
2. Fraumeni JFJ, Curtis R, Edwards BK, Tucker MA. Introduction. Bethesda, MD: National Cancer 
Institute; 2006. 
3. Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Maas HA, Coebergh JW. Prognostic 
impact of increasing age and co-morbidity in cancer patients: A population-based approach. Crit Rev 
Oncol Hematol. 2005;55:231-240 
4. Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic 
factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 2007 
5. Louwman M, Voogd AC, van Dijck JAAM, Nieuwenhuijzen GAP, Ribot JG, Pruijt JFM, Coebergh JW. 
On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975-2004: A long-
term population-based study in southeastern netherlands. 2007:37-52 
6. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108 
7. Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ. Multiple cancer prevalence: A growing 
challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev. 2007;16:566-571 
8. Curtis R, Ron E, Hankey BF, Hoover RN. New malignancies following breast cancer. In: Curtis R, 
Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JFJ, eds. New 
malignancies among cancer survivors: Seer registries, 1973-2000. Bethesda, MD: National Cancer 
Institute; 2006:181-205. 
9. de Vries E, Louwman M, Bastiaens M, de Gruijl F, Coebergh JW. Rapid and continuous increases in 
incidence rates of basal cell carcinoma in the southeast netherlands since 1973. J Invest Dermatol. 
2004;123:634-638 
10. de Vries E, Schouten LJ, Visser O, Eggermont AM, Coebergh JW. Rising trends in the incidence of and 
mortality from cutaneous melanoma in the netherlands: A northwest to southeast gradient? Eur J 
Cancer. 2003;39:1439-1446 
11. de Vries E, van de Poll-Franse LV, Louwman WJ, de Gruijl FR, Coebergh JW. Predictions of skin 
cancer incidence in the netherlands up to 2015. Br J Dermatol. 2005;152:481-488 
12. van der Rhee HJ, de Vries E, Coebergh JW. Does sunlight prevent cancer? A systematic review. Eur J 
Cancer. 2006;42:2222-2232 
13. Garland CF, Garland FC. Do sunlight and vitamin d reduce the likelihood of colon cancer? Int J 
Epidemiol. 1980;9:227-231 
14. Grant WB. A meta-analysis of second cancers after a diagnosis of nonmelanoma skin cancer: Additional 
evidence that solar ultraviolet-b irradiance reduces the risk of internal cancers. J Steroid Biochem Mol 
Biol. 2007;103:668-674 
15. Armstrong BK, Kricker A. The epidemiology of uv induced skin cancer. J Photochem Photobiol B. 
2001;63:8-18 
16. Fearon ER. Human cancer syndromes: Clues to the origin and nature of cancer. Science. 
1997;278:1043-1050 
17. Sobin LH, Fleming ID. Tnm classification of malignant tumors, fifth edition (1997). Union internationale 
contre le cancer and the american joint committee on cancer. Cancer. 1997;80:1803-1804 
18. International rules for multiple primary cancers (icd-0 third edition). Eur J Cancer Prev. 2005;14:307-308 
19. Breslow NE, Day NE. Statistical methods in cancer research. Volume ii--the design and analysis of 
cohort studies. IARC Sci Publ. 1987:1-406 
20. Soerjomataram I, de Vries E, Pukkala E, Coebergh JW. Excess of cancers in europe: A study of eleven 
major cancers amenable to lifestyle change. Int J Cancer. 2007;120:1336-1343 
21. Doll R, Peto R. The causes of cancer: Quantitative estimates of avoidable risks of cancer in the united 
states today. J Natl Cancer Inst. 1981;66:1191-1308 
22. van Leeuwen FE, Travis LB. Second cancers. Philadelphia: Lippincott Williams and Wilkins; 2005. 
23. Cutler SJ, Ederer F. Maximum utilization of the life table method in analyzing survival. J Chronic Dis. 
1958;8:699-712 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
Chapter 2 
 
 
Epidemiology of multiple primary cancers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Soerjomataram I, Coebergh JWW. Epidemiology of multiple primary cancers. In: Mukesh, 
V (ed.). Cancer Epidemiology. Humana Press: In press. December 2007.  
 
Chapter 2 
 20 
Abstract 
 
Cancer patients have a 20% higher risk of new primary cancer as compared to the general 
population. Approximately one third of cancer survivors aged more than 60 were diagnosed 
more than once with another cancer. As the number of cancer survivors and of older people 
increases, occurrence of multiple primary cancers is also likely to increase. An increasing 
interest from epidemiological and clinical perspectives seems logical. This chapter begins 
with the risk pattern of multiple cancers in the population of a developed country with high 
survival rates. Multiple cancers comprise two or more primary cancers occurring in an 
individual that originate in a primary site or tissue and are neither an extension, nor a 
recurrence or metastasis. Studies of multiple cancers have been mainly conducted in 
population-based settings, and more recently in clinical trials and case-control studies 
leading to further understanding of risk factors for the development of multiple primary 
cancers. These include an inherited predisposition to cancer, the usual carcinogenic or 
cancer promoting aspects of lifestyle, hormonal and environmental factors, treatment of the 
previous primary cancer, as well as increased surveillance of cancer survivors. Finally 
implication on research strategies and clinical practice are discussed: covering the whole 
range of epidemiological approach. 
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2.1. Introduction 
The number of cancer survivors has been increasing with the rising survival, tripling between 
1971 and in the United States. Individuals who were affected by cancer have a higher risk of 
subsequent primary cancers either in the same organ or in another one. Therefore the 
prevalence of patients with multiple cancers is expected to continue increasing. Accordingly, 
in the United States, an increased rate of new cancer diagnosis was observed among 
cancer survivors diagnosed in the most recent period (Relative risk (RR)=1.21 for those 
diagnosed from 1995 to 2000 vs. 1.14 for those diagnosed from 1990 to 1994).1 Likewise, 
the overall risk of subsequent malignancies among cancer survivors in Finland increased 
50% from the 1950s to the 1980s.2  
 
Overall, about 8% of newly diagnosed cancers are in individuals who already have had a 
previous primary cancer.3 Thus, annually we expect almost 900,000 new multiple cancer 
cases (8% out of 10.9 million4 new cases) worldwide. This number tends to increase among 
others because the growing proportion of the elderly whose prevalence of multiple cancer is 
highest: only 5%-12% of cancer patients aged 50-64 were previously diagnosed with cancer, 
versus 12%-26% among those aged over 80.5 Additionally, other forces increase the 
frequency of multiple cancers such as awareness of such cancers as well as use and 
sensitivity of screening and better treatment. Conversely, the diagnosis of a new primary 
cancer may confer to higher mortality6 and reduce quality of life of cancer survivors. 
Therefore, the phenomenon of multiple cancers have become of increasing epidemiological 
and clinical interest.  
 
Definitions 
Multiple cancers are defined as two or more primary cancers occurring in an individual that 
originate in a primary site or tissue and are neither an extension, nor a recurrence, nor 
metastasis (IARC). They may occur in the same tissue or organ or affect different tissue or 
organs. Multiple cancers can be categorized into: (1) synchronous, in which the cancers 
occur at the same time (no common rule exists, it maybe 2, 3, 6 months or even 1 or 2 
years); and (2) metachronous, the subsequent cancer occurs after the period covered for 
synchronous cancer.7 Most cancer registries adopt either the criteria suggested by the 
International Agency for Research on Cancer or of the SEER Program, the former being 
more strict, resulting in fewer multiple cancer cases.7-9 The term second (primary) cancer will 
be used often in the discussion of multiple malignancies and also in this chapter, because 
currently 75% of all multiple cancer cases were cancer survivors diagnosed with a second 
primary cancer.3 To distinguish a new primary tumour from recurrent tumours or metastatic 
lesions can be sometimes problematic, and may lead to misclassification especially in paired 
organs such as the breast or in organs having the same morphology such head and neck 
cancers (squamous cell carcinoma) or urinary tract cancers10, 11 (urothelial cell carcinoma). 
Distinguishing these entities is not only important to accurately assess the risk of multiple 
cancers, but also to determine appropriate treatment.7, 12 Tumour characteristics i.e. 
histology, location, stage or molecular signature provide guidelines in their categorization.12-
14  
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Epidemiology  
Nowadays, about 1 in every 6 cancer-survivors had once breast cancer. Thus, women with 
breast cancer also represent the largest proportion (25%) of the total multiple cancer 
prevalence reported in the United States in 2002 (Figure 2.1).3 The second and third largest 
group of multiple cancer cases were men and women whose first primary were colorectal 
cancer (15%) and men whose first primary were prostate cancers (13%).3 Generally, women 
have a slightly higher relative risk of a second cancer as compared to men (17% higher for 
women vs.11% for men), probably because common female cancers confer much better 
survival chances as compared to that of the males.1  
 
 
Figure 2.1. Multiple cancer cases according to first cancer types in the United States 1975-20013 
 
Data was based on 756,467 multiple primary cancer cases diagnosed among 9,606,460 first primary cancer patients in 
the United States in the last 27 years who were still alive at January 1, 2002. Subsequent cancers may be at the same 
site as the first primary cancer or at different site. Others include Hodgkin Disease, non-Hodgkin Lymphoma, kidney and 
renal pelvis and Leukaemia.  
 
Adapted from Mariotto, A. B., Rowland, J. H., Ries, L. A., Scoppa, S., Feuer, E. J. (2007) Multiple cancer prevalence: a 
growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev. 16, 566-71. With permission from 
American Association for Cancer Research. 
 
The absolute risk of multiple cancers is highest among the elderly, peaking among those 
aged 70-79 years i.e. 39% vs. 4%, 9%, 19% and 30% at 0-49, 50-59, 60-69 and 80+ years, 
respectively (Figure 2.2 a).1 However, when such risk is compared to cancer risk in the 
population, a striking trend was observed from the youngest to the oldest age group. This 
ranges from a relative risk of 6 among those first diagnosed with a cancer at the age of 0-17 
decreasing to 0.92 among those diagnosed with first cancer older than 80 years old (Figure 
2.2 b). Underreporting of second cancers and a shorter life expectancy in the highest age 
group may cause the observed lower absolute and relative risk.  
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Figure 2.2. Relative and absolute risk of subsequent primary cancers according to age at first cancer diagnosis 1  
 
Panel a shows relative risk of subsequent primary cancers in both sexes by age in the Unites States 1973-2000.  
Panel b shows absolute excess risk of subsequent primary cancers in both sexes by age in the Unites States 1973-
2000. 
Notes: Include all first primary cancer patients except non-melanoma skin. Subsequent primary cancers include 2nd, 3rd, 
and later cancers and encompass all cancer sites except non-melanoma skin and subsequent prostate cancers 
following first primary prostate cancer. The population at risk includes 2,036,597 patients who survived 2 or more 
months after initial cancer diagnosis during 1973 to 2000.  
Adapted from Fraumeni, J. F. J., Curtis, R., Edwards, B. K., Tucker, M. A. (2006) Introduction. Bethesda, MD: National 
Cancer Institute, NIH Publ. No. 05-5302. 1-7. 
 
 
Studies of geographic difference in incidence of multiple primaries have been hampered by 
the different registration methods used by various cancer registries.15, 16 In an international 
context with common registration methods multiple cancer studies present a unique 
opportunity to assess the aetiology of cancer.15, 17-20 Using the data of 13 worldwide cancer 
registries, the relative risk of second cancer was compared in patients with previous skin 
cancers in sunny countries compared to less sunny countries.20 Skin cancers increased with 
higher sun exposure, whereas the UV of sunlight through the production of vitamin D might 
protect against some cancers.21, 22 Concordantly, this study reported a significantly lower 
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relative risk of all second solid primary cancers (except skin and lip) after skin cancer in the 
sunny countries compared to the less sunny countries. 
 
2.2. Study Design and Method of Analysis of Multiple Cancer Studies 
 
Cohort Study 
In a cohort study, also referred as longitudinal study, a large group of cancer patients is 
followed forward in time to ascertain the occurrence of another primary cancer. It can be 
done in two ways: (1) prospective cohort study, in which the cohort is identified in the 
present and followed into the future, or (2) historical cohort study (often denoted as 
retrospective cohort study), in which the cohort is identified in the present (some may 
already exhibit the outcome of interest, in this context another primary cancers) and by 
means of medical records the cancer experience is reconstructed between the defined time 
in the past and the present.23-25 Data sources include population-based cancer registries, 
hospital-based cancer registries and clinical trial series. Population-based study gives large 
number of cases, allowing detection of even a small increase in risk as well of having 
determined reference population. However, detailed data on risk factors are usually lacking. 
Hospital-based studies may comprise large and extensive data, clinical trial databases even 
in more detail, but numbers of cases are usually smaller and occurrence of rare second 
cancer becomes much harder to ascertain.    
 
In order to determine whether cancer patients are at a higher or lower risk of developing 
cancers than the general population, the incidence of subsequent cancers among these 
patients (observed incidence) is compared to the incidence of such cancers in the general 
population. The expected incidence derived from calculating person-years of follow-up in the 
cohort stratified by gender, age and calendar year. Dividing the observed incidence by the 
expected incidence results in the standardized incidence ratio (SIR).23, 24, 26, 27 Examining SIR 
and its significance is a way to exclude the role of chance in assessing the risk of second 
primary cancer. Categorizing SIR in different follow-up time (after diagnosis of first cancers) 
may give clue to the excess cases due to heightened medical surveillance or to the role of 
cancer treatment. Excess risk only during the first years after first cancer diagnosis suggests 
a surveillance bias. Excess risk of solid second tumour occurs only after a latency time of 5-
10 years. Whether a subsequent cancer has a large burden in a cohort, absolute excess risk 
(AER) provides the measure of the excess number of subsequent malignancies per 10,000 
patients per year.23, 25 It is estimated by subtracting the expected number of second cancers 
from the observed number, and dividing this by the number of person-years, usually per 
10,000 cases. The last confers the cumulative risk, which is the proportion of patients who 
would develop a subsequent cancer conditional on survival. Cumulative risk can be 
calculated either using actuarial method 28 or cumulative incidence function.29   
 
When time trend of multiple cancers is the main study interest, one should adjust for factors 
that increase the risk of subsequent cancers such as length of follow-up after the diagnosis 
of the first primary. A fixed inception cohort method where risk of second cancer in different 
cohorts with the same follow-time is compared may overcome this problem.30 Multivariate 
regression adjusting for various factors may be employed to study determinants of interest 
corrected for confounding factors. 31 
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Case-control Study 
A nested case-control study within a cohort presents the opportunity to assess the role of 
risk factors in greater details, such as cancer therapy 23, 24, 32 or behavioural risk factors.33 
Detailed data could be ascertained through medical records or questionnaire to the therapist 
or patients themselves. Cases are patients with second cancer (or more). Controls are 
patients who do not develop the second cancer, randomly matched by age, gender, calendar 
year of diagnosis and naturally, length of follow-up time. Relative risk can then be calculated 
by comparing different exposures of interest among the cases and the cohort. Overmatching 
(of non-confounding factor(s)) would unnecessarily reduce statistical power and finally non-
association of exposure and cases.24 
 
2.3. Causes 
Multiple cancers arise in the same individual due to several following causes: (i) host factors 
such as genetic or hormonal factors, (ii) lifestyle, (iii), first cancer treatment, and (iv) 
environment. In most patients, a combination of several factors likely contributes to the 
occurrence of multiple cancers (figure 2.3).32, 34 Additionally, an elevated risk of multiple 
malignancies may also be caused by higher medical surveillance after a cancer diagnosis or 
merely due to chance (see study method to assess the role of risk factors).  
 
 
Figure 2.3. Factors related with risk of subsequent primary cancers 32 
Travis, L.B. Acta Oncologica 2002; 41:323-333, reprinted by permission of Taylor and Francis, Stockholm, Sweden. 
 
 
 
 
Chapter 2 
 26 
Genetic Predisposition 
About 5-10% of all cancers arise in individuals with an inherited genetic mutation conferring 
to heightened cancer-specific susceptibility.35 A short list of selected cancer inherited 
syndromes, their gene mutations and penetrance based on comprehensive review in these 
area are listed in table 2.1.35-37 Increased risk of multiple cancers have been consistently 
reported among patients with family history of cancer.38-44 Cancer in patients with heritable 
cancer susceptibility generally presents at early ages.42, 44 Among female breast cancer 
patients aged younger than 50 risk of ovarian cancer is fourfold among those with breast 
cancer diagnoses older than 50.19, 45-47 This is consistent with the presence of germline 
mutation BRCA1/2 and possibly also other mutations. In 10 years after breast cancer 
diagnosis 20% 48 to 30% 49 of patients carrying this mutation would be diagnosed with 
ovarian or contralateral breast cancer, respectively. Breast cancer patients younger than 45 
years may also carry a germline mutation in the TP53 (Li-Fraumeni syndrome), which is also 
related to higher incidence of soft tissue and sarcoma as well as brain tumours, adrenal 
cortical carcinoma and leukaemia.  
 
Table 2.1. Selected inherited cancer syndromes, reported in various multiple cancer cases (modified table from Fearon 
et al36 and Nagy R et al37)  
 
Syndrome  Affected sites  Penetrance  Gene(s) 
Familial breast cancer  Breast, ovary, male breast, 
pancreas, prostate, melanoma 
Up to 85% BRCA1, BRCA2 
Hereditary nonpolyposis colon cancer 
(HNPCC or Lynch syndrome)  
Colorectum, corpus uteri, ovary, 
hepatobiliary and unrinary tract, 
brain.  
Also Muir-Torre and Turcot variant-
related tumors.  
90% MLH1, MSH1, 
MSH2, PMS1, PMS2 
Hereditary retinoblastoma  Eyes, bone and soft tissue 
sarcoma  
90% RB 
Li-Fraumeni syndrome Sarcoma, breast, brain, leukaemia 
and adrenocortical cancer 
90-95% TP53 
Cowden syndrome Breast, thyroid corpus uteri ~ 50% PTEN (MMAC1) 
Familial melanoma  Melanoma, pancreas ~ 90% CDKN2A (p16) 
Multiple endocrine neoplasia type 1 Parathyroid, entero-pancreas, 
pituitary 
95% MEN1 
Familial adenomatous polyposis (FAP) Colorectum, thyroid, pancreas, 
liver, central nervous system, and 
other benign conditions  
~ 100% APC 
Bold refers to most affected sites (highest penetrance). More detailed table and overview please refer to 35-37, 50 
Adapted from Nagy, R., Sweet, K., Eng, C. (2004) Highly penetrant hereditary cancer syndromes. Oncogene. 23, 6445-
70 with permission from Nature Publishing Group and from Fearon, E. R. (1997) Human cancer syndromes: clues to the 
origin and nature of cancer. Science. 278, 1043-50 with permission from AAAS. 
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Early-onset of colon cancer has also been associated to Lynch syndrome (hereditary 
nonpolyposis colorectal cancer [HNPCC]) or familial adenomatous polyposis (FAP). In 
addition, HNPCC patients have a heightened risk of endometrial, ovarian, stomach and 
kidney cancer35, 50 and colorectal cancer patients may also have a higher breast cancer risk 
through inherited mutations of CHEK2.51 
 
Beside the role of single gene mutation, the polygenic model may explain part of the 
increased risk of multiple cancers in an individual,8, 52, 53 also interacting with other risk-
enhancing factors such as smoking, alcohol or even cancer treatment such as radiation. A 
polygenic model would explain the occurrence of cases with familial clustering of cancers 
without (detectable) specific germline mutation, i.e. only 70% of all families meeting the 
criteria of Li-Fraumeni syndrome showed a germline mutation in TP53.35, 42 
 
Common External Factors 
 
Smoking and Alcohol 
Smoking- and alcohol related second malignancies account for 35% of the total excess 
cases observed in the US cancer survivors.1 Most multiple cancer studies have used 
population-based registry and data on behavioural risk factors such as smoking or alcohol 
intake is not readily available. The clustering of smoking or alcohol related cancer in an 
individual designates them as common risk factors. The pattern of multiple cancers risk that 
share common etiologic factors is a useful tool to give insight of their aetiology, and should 
generally comply to the following rules; (1) significant reciprocal increased risk (increased 
risk of cancer A after cancer B and vice versa) (2) persistent increased of relative risk since 
diagnosis of the index tumour (3) role of first cancer treatment could be excluded, i.e. similar 
risk pattern between those who received surgical and radio-therapy.27 A consistent excess of 
subsequent primary smoking-related cancers (i.e. oral cavity, pharynx, pancreas, larynx, 
lung, kidney and bladder) has been reported among patients ever diagnosed with similar 
cancers.18, 54-57 And for alcohol, it is likely to have contributed to the increased risk of liver 
and oesophageal cancer among laryngeal cancer patients.57, 58  
 
Where individual behavioural history is available, cigarette smoking clearly increased risk of 
smoking-related second primary cancer (table 2.2).58-63 Patients with Hodgkin’s Disease 
(HD) who smoked exhibited an odds ratio of 6 to 13 for lung cancer as compared those who 
never smoked. Furthermore, studies indicated that smoking cessation following cancer 
diagnosis lowers the risk of new smoking-related malignancies.60, 64 Breast cancer patients 
with the highest alcohol intake exhibited almost a 2-fold higher risk of colorectal cancer as 
compared to non-drinkers.40 Likewise laryngeal and hypopharyngeal cancer survivors with 
the highest alcohol consumption (≥121 g/day) exhibited a 3-fold upper aero-digestive tract 
cancers compared to those with the lowest alcohol intake (0-40 g/day) (table 2.2).58  
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Table 2.2. Risk of lung and upper aerodigestive tract cancer following laryngeal/hypopharyngeal carcinoma, according 
to smoking and alcohol intake index58  
 
Lung UADT Site of 
second 
primary/ 
Risk factor Cases/total 
cohort 
HR 95%CI  Cases/total 
cohort 
HR 95%CI 
Pack-years of cigarette smoking Average alcohol drinking (g/day) 
0-20 3/115 1 - 0-40 4/197 1 - 
21-40 26/362 3.3 0.9-11.0 41-80 4/227 0.8 0.2-3.3 
41-60 15/264 2.4 0.7-8.6 81-120 12/206 3.0 0.9-9.5 
≥ 61 10/128 3.9 1.0-14.6 ≥ 121 17/246 3.5 1.1-11.2 
Stratified log-rank test,  p value 0.06    0.003 
HR = Hazard ratio. 95%Ci = 95% confidence interval. UADT: upper aerodigestive tract including lip, tongue, oral cavity, 
oropharynx, nasopharynx, hypopharynx, larynx, esophagus (ICD9 140-150). 
 
Data was based on 876 male primary larynx and hypopharynx cancer patients. Hazard ratio was adjusted for age, 
occupational group, alcohol drinking, cigarette smoking and site of first cancer (hypopharynx or larynx).58 Cancer, Vol. 
103, No. 11, 2326-33. Copyright  @2005 American Cancer Society. This material is reproduced with permission of 
Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc. 
 
Diet and Obesity  
Dietary factors including obesity, diet low of fruit and vegetable as well as high in fat 
accompanied by low physical activity have been related to occurrence of a large number of 
cancers in the general population 65, 66 and also appear to account for multiple cancers 
involving the breast, female reproductive organs and lower and upper digestive tract.19, 40, 45-
47, 67 Obese breast cancer patients had approximately 2-fold greater hazard of contralateral 
breast tumors relative to underweight/normal-weight women (table 2.3).40, 68, 69 Likewise, 
obesity and/or adult weight gain increased the risk of other second primary cancers including 
endometrial and colon cancer risk (table 2.3).40, 41, 69 Furthermore, very obese colon cancer 
patients (BMI > or = 35 kg/m2) showed greater risk of a recurrence or second primary tumor 
of the colon; hazard ratio [HR] = 1.38, 95% confidence interval [CI] = 1.10 to 1.73) than 
normal weight patients (BMI = 18.5-24.9 kg/m2).70 Finally, high citrus fruits and vegetable 
consumption may reduce lung cancer risk among patients previously diagnosed with 
laryngeal cancer by 10-60%.58 
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Table 2.3. Risk of primary breast, endometrial and colorectal cancer following breast cancer, according to body mass 
index before or at the diagnosis of first primary breast cancer 
 
Breast a Endometrial b Colorectal b Site of 
second 
primary / 
Risk factor HR 95%CI  HR 95%CI HR 95%CI 
BMI (kg/m2) BMI (kg/m2) 
≤ 24.9  1  < 22.5 1  1  
25.0-29.9  1.22 0.87-1.71 22.5-25.0 0.98 0.50-1.90 0.91 0.51-1.60 
≥ 30.0  1.58 1.10-2.25 25.1-28.8 1.07 0.55-2.07 1.54 0.92-2.59 
   ≥ 28.9 2.23 1.23-4.05 1.67 0.99-2.82 
 
BMI was defined weight in kilograms divided by height in meters squared. HR: Hazard Ratio. 95% CI: 95% Confidence 
Interval 
 
a Data was based on 193 newly diagnosed patients with contralateral breast cancer among 3,385 primary (early stage) 
breast cancer patients. Hazard ratio was adjusted for treatment, age, menopausal status, race, tumor size, estrogen 
receptor level and progesterone receptor level. Risk of contralateral breast cancer was similarly elevated by increasing 
BMI in women who were premenopausal and postmenopausal at study entry. 68 
Adapted from Dignam, J. J., Wieand, K., Johnson, K. A., Fisher, B., Xu, L., Mamounas, E. P. (2003) Obesity, tamoxifen 
use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst. 95, 1467-
76. With permission from Oxford University Press. 
 
b Data was based on 90 primary endometrial cancer cases among 5,724 postmenopausal breast cancer patients and 
127 primary colorectal cancer cases among 8,020 postmenopausal breast cancer patients. Regression models 
conditional on age and hazard ratio was adjusted for year of diagnosis, stage of breast cancer at initial diagnosis, family 
history of breast cancer, pack-years of cigarette smoking, recent alcohol intake, parity, postmenopausal hormone 
therapy. 40 
Adapted from Trentham-Dietz, A., Newcomb, P. A., Nichols, H. B., Hampton, J. M. (2006) Breast cancer risk factors and 
second primary malignancies among women with breast cancer. Breast Cancer Res Treat. With kind permission from 
Springer Netherlands. 
 
Hormonal Factor 
Hormonal and reproductive factors (age at birth of first child, at menarche and menopause, 
and parity, use of oral contraception and hormone-replacement therapy (HRT) are related to 
risk of several cancers such as breast, endometrial, ovarian and colon cancers. Cancer 
patients who had premature menopause i.e. due to chemotherapy exhibited a lower risk of 
second primary breast cancer.71 Breast cancer survivors who were older age at menarche 
and have few children showed an increased risk of second primary breast cancer.33, 40 
Furthermore a reduced colorectal cancer risk is observed among those who were older at 
menarche, younger at menopause and used HRT.40 The role of reproductive factors in 
relation did not seem to alter the effect of first cancer treatment.38, 71, 72  
 
Infection and Immunosuppresion 
Several infectious agents are considered to be causes of cancer in humans. Human 
Papillomavirus (HPV) infection is likely to play a role in case of multiple cancers of the tonsil, 
oropharynx, oesophagus, anus, cervix uteri, vagina and vulva. Among patients with cancer 
of the cervix, vulva and vagina a 3 to 5-fold increased risk of other HPV-related cancers was 
observed.73-75 A similar excess of HPV-related cancers was reported in women diagnosed 
with in-situ cervical cancer.74 Analysing the risk for in-situ and invasive cervical cancer 
patients separately gives the opportunity to assess and exclude the role cancer treatment 
i.e. radiation given to patients with invasive cervical cancer, provided the smoking patterns 
did or do not differ. Furthermore identical HPV DNA integration loci in tissue from the initial 
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cervical cancer and in the subsequent vaginal or vulvar cancers were detected, indicating 
common aetiology.76  
 
Epstein-Bass virus (EBV) has been linked to multiple cancers of the nasopharynx, non-
Hodgkin Lymphoma (NHL) as well as to Hodgkin’s Disease.18, 56, 77, 78 Among 1549 
nasopharyngeal cancer patients, a 14-fold increased risk of second head and neck cancers 
was reported, and 9% of the patients with multiple head and neck cancers had positive EBV 
infection compared to only 4% among the control group of patients with only a primary head 
and neck cancer.79 
 
Impairment of the immune system and thus lack of control of oncogenic viruses greatly 
elevates the risk of infection-related cancers.80 Patients with HIV or with organ 
transplantation exhibited more than a hundred-fold increased risks of NHL or Kaposi 
Sarcoma (KS) and to a lesser extent of HD, cervical and skin cancer.80, 81 Impaired immune 
function is supposed to explain the reciprocal increased risk multiple malignancies among 
patients NHL, HD, KS and melanoma.1, 77, 82, 83  
  
Treatment 
The etiologic role of cancer treatment for second primary malignancy has been extensively 
described by others.23, 32, 84 Chemotherapy, radiotherapy, and hormonal therapy are largely 
responsible. Acute sequelae are generally associated to chemotherapy, second cancers 
arising from as little as a few months to 9 years post-therapy. As for radio- and hormonal 
therapy, chronic sequelae usually develop after a longer latency time of  5 to 10 years. The 
risk may remain elevated for long period of time, though a lowering of the observed risk as 
compared to an earlier follow-up period became visible after 25 years following the treatment 
of HD.85, 86 Moreover, therapy-related second cancers may also arise due to combination of 
treatment modalities and genetic predisposition towards cancers or treatment and external 
factors such as lifestyle. Although a considerable proportion of second cancers can be 
therapy-related, one should always also consider the benefit of cancer treatment. Moreover, 
the knowledge on side-effects develops over time so that there is always a delay of at least a 
decade, before it affects the existing regimens and contributes to new ones that combine 
good survival chances with a lower risk of adverse effect.   
 
Radiotherapy 
Initiation and progression to cancer due to radiation induces cancer depend on several 
factors: (a) Dose of radiation, (b) sensitivity of the body tissue (c) exposure field (d) age at 
exposure and (e) interaction with other increasing- or decreasing-factor(s). Thyroid, breast 
and bone marrow are reported as the most radiosensitive tissue.24, 87 The effect of radiation 
is often amplified when such tissue received radiation at an early age. For example risk of 
breast cancer following HD is highest for those who were treated before age 30 (RR: 6-8), 
whereas risk after age 30 is only minimally elevated.59, 78, 86 Furthermore, the risk of lung 
cancer among HD survivors was significantly higher among smokers, based on a 
multiplicative relation between smoking and radiation (table 2.4).62, 63 Finally, radiation also 
attenuated the risk of sarcoma among retinoblastoma patients 88 who were positive for Rb1 
mutation (the cumulative risk at 50 years after diagnosis was 51%), whereas for those 
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without the mutation radiotherapy did not significantly affect their risk of second cancer 
(cumulative risk: 5%).89  
 
Table 2.4. Relative risk of subsequent lung cancer by treatment and smoking habits in 19,046 patients treated for 
Hodgkin’s Disease63 
 
Moderate-heavy smokers Treatment for 
Hodgkin’s Disease No. of Lung cancers Relative risk (95% CI) 
No 10 6 (1.9-20.4) 
Radiation > 5 Gy  20 20.2 (6.8-68) 
Chemotherapy 33 16.8 (6.2-53) 
RT+CT  24 49.1 (15.1 -187) 
Reference group was patients without radiation or chemotherapy who were non- or light smokers 5 years before lung 
cancer diagnosis. Moderate represents individuals who smoked one to two packs a day and heavy represents 
individuals who smoked two or more packs a day. 
Adapted from . Travis, L. B., Gospodarowicz, M., Curtis, R. E., Clarke, E. A., Andersson, M., Glimelius, B., Joensuu, T., 
Lynch, C. F., van Leeuwen, F. E., Holowaty, E., Storm, H., Glimelius, I., Pukkala, E., Stovall, M., Fraumeni, J. F., Jr., 
Boice, J. D., Jr., Gilbert, E. (2002) Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl 
Cancer Inst. 94, 182-92. With permission from Oxford University Press. 
 
Chemotherapy    
Chemotherapy is commonly related to the increase occurrence of leukaemia, and its 
leukaemogenic effect is more potent than radiation (table 2.5). As for solid tumours, firm 
evidence has been established between the excess risk of bladder cancer among NHL 
patients treated with cyclophosphamide; 3-7 excess cancers in 100 NHL cases treated from 
moderate to high dose of cyclophosphamide.90 There might also be an association between 
alkylating agents and bone sarcoma91 and lung cancer92, though not all could prove a dose-
response (chemotherapy cycle) relationship.93 Furthermore combination of chemotherapy 
with radiation may cause a higher risk of a second cancer than for the individual therapy 
alone.93-95 Lung cancer risk after chemo- and radiotherapy among HD patients was as 
expected as excess risks were added together. On the other hand the combination with 
chemotherapy reduced the increased breast cancer risk among patients with HD who 
received radiotherapy (RR: 5.9 with Radiotherapy; RR: 4.2 with Chemotherapy; RR: 8.0 with 
radio- & chemotherapy) 63, 94 Similarly breast cancer patients who received chemotherapy in 
combination with radiation exhibited half of the second breast cancer as compared to those 
who only received radiotherapy.46, 96 Chemotherapy induces early menopause, thus 
substantially reducing the risk of breast cancer.71  
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Table 2.5. Chemotherapy and related multiple cancers.* 
 
Chemotherapeutic agents Treatment for primary cancer Therapy-related cancer 
Alkylating agent (mechlorethamine, 
chlorambucil, cyclophosphamide, melphalan, 
semustine, lomustine, carmustine 
prednimustine, busulfan and dihydroxybusulfan. 
Lymphomas108  Breast13, 109  Leukemia a b 
Platinating agents (cisplatin and carpboplatin) Ovary110, 111  
Testis112, 113  
Leukemia a 
Topoisomerase II inhibitors 
(epipodophyllotoxins etoposide and teniposide) 
Lung, Testis,  
Solid114 and non-solid 
childhood cancers115 
Leukemia a c 
Intercalating topoisomerase II inhibitors 
(anthracycline, doxorubicin and 4-
epidoxorubicin) 
Lymphomas108  Breast13, 109  Leukemia a c 
Cyclophosphamide  NHL90   
Ovarian116 
Bladder cancer 
Alkylating agent  
MOPP regimen (mechloretamine, vincristine, 
procarbazine, prednisone) 
CHOP regimen (cyclophosphamide, 
doxorubicin, vincristine, prednisone) 
 
HD59, 62, 63  
 
NHL92  
 
Lung cancer 
Alkylating agent and anthracycline Childhood cancers91, 117 Bone sarcoma  
* Risk of second cancers due to a specific chemotherapeutic agent is difficult to separate because the common 
combination of several agents. Comprehensive review on the effect of these agents can be found in 23 
a Leukemia usually implies to acute myeloid leukaemia, so far only chronic lymphocytic leukaemia has not been linked 
to chemotherapy.23  
b > 50% preceded by myelodysplastic syndrome (MDS). Peak 5-10 years after start of chemotherapy. 
c Not preceded by MDS, peak 2-3 years after the start of chemotherapy. 
 
Hormonal Therapy 
Tamoxifen as breast cancer treatment has been consistently related to an elevated risk of 
endometrial cancer.72, 97, 98 Endometrial cancer risk increased by 2-fold among 2 years 
tamoxifen users and by 4-8-fold among 5 or more years users. Most studies have found no 
difference in the effect of tamoxifen on endometrial cancer risk between HRT users and non-
users or between obese and non-obese groups,68, 72, 99 although one stated otherwise.100 
Risk of endometrial cancer is greater among breast cancer patients who received tamoxifen 
as treatment and used HRT or were obese as compared to non-HRT users and thinner 
patients who received tamoxifen.72, 99  
 
On the other hand, hormonal therapy has demonstrated a protective effect against the 
normally increased risk of a second primary breast cancer among breast cancer patients.46, 
97 In the trials where patients took 1, 2, or about 5 years of adjuvant tamoxifen the 10-year 
proportional reductions in contralateral breast cancer were 13% (SD 13), 26% (SD 9), and 
47% (SD 9), respectively.101  
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2.4. Conclusions and Future Research  
Improvements in early detection, diagnosis and treatment of cancers have increased survival 
of patients with many types of cancer, however also carrying a significant increase in 
number of individuals with multiple malignancies. This problem is larger and will grow even 
larger in industrialized societies with increasing proportion of elderly persons. Study of 
occurrence and course of multiple malignancies will improve our insight in etiology and the 
genesis of cancer in general. Furthermore, human behaviour is and will be constantly 
changing, cancer treatment continuously improving either or not through emerging new 
therapies, therefore the need for continuous surveillance. Their effect on the risk of multiple 
cancers needs a certain period of time till it surfaces and is clarified unequivocally. 
Population-based data can serve very well for early warning and verification of ‘loose’ 
notifications. 
 
The agenda of guideline development for and research of multiple cancers might cover the 
following 6 major areas,34 including additional issues beyond what have been laid-out earlier:  
 
1. Development of a(n) (inter)national research infrastructure for studies of cancer 
survivorship; similar registration method is needed to facilitate international collaborative 
efforts.15-18, 55  
2. Creation of a coordinated system of tumour banking for biospecimen collection;102  
3. Development of new technology, bioinformatics and biomarkers to assess risk and 
etiologic pathway of multiple cancers; e.g. distinguishing second primary cancers from 
recurrent or metastatic lesions is important to determine therapy; advances in tumour 
molecular analysis will certainly improve classification.103-105 
4. Design of new epidemiologic method and studies; accurate projections of new primary 
cancer risk among cancers survivors are important to facilitate the surveillance 
recommendations and are now available for second cancers after childhood leukaemia 
and HD.106, 107  
5. Clinical studies assessing the impact of early detection and treatment of a second or 
higher order malignancy on cause of death and patients’ survival as well as quality of life. 
6. Development of evidence-based clinical practice guidelines: including intervention 
strategies such as behaviour modification to prevent occurrence of a new primary 
cancer; follow-up of cancer survivors; and tailored-therapy for the second, third or higher 
order primary cancer, which usually involved the elderly who are more fragile to cancer 
treatment. 
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Abstract 
 
Background and objectives: Breast cancer incidence continuous to increase. We 
examined at population level the association between the relative excess risk of breast 
cancer and previous age of mother at first birth.  
 
Methods: Incidence of breast cancer in 34 industrialized countries was obtained from the 
GLOBOCAN 2002 and SEER databases. Data on age of mother at first birth was collected 
through national statistics offices. National relative excess risk (RER) was calculated by 
subtracting the lowest age-specific incidence rate from the rate in each population, and 
dividing the difference by the latter.  
 
Results: The national RER in 2002 correlated closely with a higher average age at first birth 
in 1972, 1982, 1992 and also 2002, Pearson correlation [r] being 0.83, 0.79, 0.72 and 0.61, 
respectively; p<0.0001. RER of breast cancer in 2002 for those aged 15-44 years correlated 
closely with the mean age at first birth in 1982 and 1992 (r: 0.81 and 0.75; p<0.0001), 
whereas RER for those aged 45-54 years correlated strongly with age at first birth in 1972 
and 1982 (r: 0.81 and 0.76; p<0.0001), and for those aged 55-64 years with age at first birth 
in 1972 (r: 0.77; p<0.0001).  
 
Conclusions: The rising age at first childbirth of mothers has been followed by marked 
increases in breast cancer incidence. Later age at first birth seems to characterize secular 
diffusion of ‘modern’ lifestyles with a potentially large impact on increased breast cancer risk, 
and hence should be accompanied by greater opportunities for prevention through 
modifiable risk factors. 
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3.1. Introduction 
Global trends in breast cancer incidence have been attributed to various factors including 
reproductive history and hormonal factors, female body composition and nutritional factors, 
also alcohol consumption.1-3 Higher socioeconomic status has also been associated with a 
higher risk of breast cancer.4 Furthermore, increased use of mammography has increased 
the detection rate leading to a higher observed breast cancer incidence.5 Reproductive-
related factors including age at birth of first child and number of children has been suggested 
as one of the major determinants of breast cancer incidence,2 and has been attributed to 
28% of its incidence.6 Women who had their first birth at age 35 or older exhibit a 60% 
higher risk of breast cancer than women who had their first child at age 20-21.7 There are 
large differences between countries in the age of the mother at first birth8, as well as in the 
incidence of breast cancer9. Recent and historical data on national fertility patterns are 
available and comparable for most western populations. However the role of mother’s age at 
first birth in the past, marking current breast cancer risk has not yet been examined. Thus, 
we assessed the association between age at first birth and the excess risk of breast cancer 
a few decades later using data from 34 industrialized countries. 
  
 
3.2. Methods 
Materials 
We performed this study within the framework of the European collaborative project 
Eurocadet which estimates the future potential of cancer prevention based on recent trend in 
cancer incidence and its related risk factors.10 Incidence data was obtained from 
GLOBOCAN 200211 and the SEER database for white non-Hispanic Americans.12 We 
included European countries (Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, 
Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, 
Former Yugoslavic Republic of Macedonia, the Netherlands, Norway, Poland, Portugal, 
Romania, Serbia and Montenegro, Slovakia, Slovenia, Spain, Sweden, Switzerland and 
United Kingdom) as well as Australia, Canada, Israel, New Zealand and the USA. In 
GLOBOCAN 2002 incidence rates were estimated based on the best available data from 
national or regional cancer registries. Methods of estimation and correction for suspected 
under-recording have been described elsewhere.11 We included only countries with more 
than 1 million inhabitants. Data on mother’s average age at first birth in 1972, 1982, 1992 
and 2002 or approximately the same period were retrieved from EUROSTAT8 or National 
Statistics Institutes for non-European countries (table 3.1). In the United States, we only 
included data of non-Hispanic whites. 
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Table 3.1. Fertility pattern and relative excess risk of breast cancer by period 
 
Countries Average age at first birth (years) Relative excess risk in 2002 (%) 
 1972 1982 1992 2002 All ages Age group  
15-44 
Age group 
45-54 
Age group  
55-64 
Australia a n.a. 25.5 28.0 30.2 49.9 46.9 50.4 59.5 
Austria n.a. 24.1 c 25.0 27.4 45.9 47.0 36.7 48.9 
Belgium 24.3 24.9 26.7 27.6 i 59.1 59.8 58.9 59.3 
Bulgaria 22.1 21.9 21.9 23.9 21.1 25.2 11.7 18.3 
Canada n.a. 24.9 26.0 27.7 48.0 43.7 47.8 57.5 
Croatia n.a. 23.5 d 24.7 g 25.9 37.5 37.1 34.7 40.5 
Czech Republic 22.6 22.4 22.5 25.6 14.0  ref 27.6 37.4 
Denmark 24.0 25.0 26.9 28.5 j 48.8 43.2 51.3 63.0 
Estonia 23.9 23.3 22.8 24.6 19.4 19.2 21.5 17.8 
Finland 24.6 25.4 26.7 27.6 48.2 42.7 59.6 56.6 
France 24.3 25.3 27.4 27.9 k 57.4 56.7 58.8 61.2 
Germany 24.1 25.4 26.9 28.6 49.6 47.7 50.2 54.5 
Greece n.a. 24.2 26.0 27.9 22.0 19.1 27.4 21.6 
Hungary 22.7 22.6 23.3 25.6 29.3 21.9 36.2 41.6 
Ireland 25.8 25.6 26.7 28.0 41.5 35.6 49.9 54.7 
Italy 24.9 25.3 27.3 28.6 l 50.0 51.5 47.2 45.2 
Israel n.a. n.a. 24.4 h 25.8 46.5 38.1 55.5 62.9 
Latvia n.a. 22.9 22.8 24.9 16.6 20.6 8.7 ref 
Lithuania n.a. 24.2 23.1 24.3 0.9 1.4  ref 0.1 
Macedonia n.a. na 23.5 24.7 26.7 27.4 22.5 24.9 
New Zealand n.a. 25.6 28.4 30.4 55.3 53.7 52.2 66.4 
Norway n.a. 24.8 e  25.9 27.2 40.8 34.5 48.3 53.7 
Poland 23.0 23.4 23.4 25.0 17.5 12.0 30.4 22.7 
Portugal n.a. 24.0 25.2 26.8 33.3 35.5 35.1 26.2 
Romania 22.5 22.5 22.6 24.1 9.2 5.4 18.5 14.2 
Serbia & Montenegro n.a. 23.5 f 24.2 25.5 37.0 39.6 37.0 30.5 
Slovakia 22.7 22.7 22.6 24.7 17.1 15.1 18.2 13.7 
Slovenia 23.3 23.1 24.1 27.2 30.5 27.4 30.6 33.7 
Spain 22.5 25.4 27.5 29.2 25.1 25.4 28.4 23.3 
Sweden 26.0 25.6 26.7 28.3 47.6 41.3 51.8 64.6 
Switzerland 25.4 26.5 27.8 29.0 51.1 50.4 44.3 57.4 
The Netherlands 24.8 26.0 28.0 28.7 54.5 53.3 57.1 53.2 
United Kingdom 24.1 25.4 27.8 29.3 52.7 50.1 54.2 58.5 
United States b n.a. n.a. 25.1 26.1 52.9 48.1 51.3 64.6 
 
n.a.: not available; ref: reference group; a median age at first birth within marriage; b data was not categorized by non-
Hispanic white and Hispanic white before 1989; c data in 1984; d 1983; e median age at first birth within marriage in 
1976-1980; f data in 1983; g data in 1993; h data in 1994; i data in 1997; j data in 2001; k data in 2000; l data in 1998  
Statistical analysis 
Incidence rates for breast cancer were calculated by five-year age groups and age-adjusted 
(world standard population) for truncated age categories  (15-44, 45-54, 55-64 and 65+). 
Excess incidence was calculated by subtracting the lowest rate age-specific observed in the 
selected countries from the respective national rate. Incidence rate was lowest in Czech 
Republic for age group 15-44, in Lithuania for age groups 45-54 and 65+, and in Latvia for 
age group 55-64. Absolute numbers of excess cases were calculated by multiplying the 
excess incidence rates by the size of the population of the country of interest in the same 
period and age group.13 Relative excess risk (RER) was calculated as the ratio of excess 
incidence and observed incidence in a country. We used the Pearson correlation coefficient 
to quantify the relationship between national RER and current as well as past average age of 
the mother at first birth. We also examined the correlation of age at first childbirth in 1972 
and 1982, and 1992 with RER for those aged 45-54 and 15-44 years, respectively. We 
assumed that most women of 45-54 years in 2002 had their first childbirth between the 
1970s and the 1980s. The age group 15-44 years mostly comprised breast cancer cases 
older than 35 years, who typically had their first childbirth in between the 1980s and the 
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1990s. In addition, we correlated RER for those aged 55-64 years in 2002 to average age at 
first child in 1972. These women most likely had their first child between 1965 and 1975. 
Correlation analysis was performed only with the year 1972, because data of the 60s were 
scarce. In order to take the large variation of population sizes of the included countries into 
account, correlation coefficients were weighted by population sizes in the respective age 
groups.  
3.3. Results 
The highest overall age-adjusted relative excess risk of breast cancer was found for 
Belgium, France, New Zealand and the Netherlands (59%, 57%, 55% and 54%), whereas 
the lowest was in Romania and Czech Republic (9% and 14%) (Table 3.1). Incidence rates 
for two age groups (45-54 and 65+ years) were lowest in Lithuania, which explains the low 
RER for this population (1%). In countries with the highest RER in 2002, the average age at 
first birth was 24-25 years in 1972, 25-26 years in 1982, 27-28 years in 1992 and 28-29 
years in 2002. In contrast, mothers in countries with the lowest RER in 2002 had their first 
child at 23 years in 1972, 22-24 years both in 1982 and 1992 and 24-26 years in 2002 
(Table 3.1). Figure 3.1 illustrates the correlations between RER in 2002 for 15-44 years, 45-
54 years and 55-64 years with mean age at first child in 1972, 1982 and 1992.  Mean age at 
first childbirth in 1982 and 1992 correlated closely with RER of breast cancer in 2002 for 
those aged 15 to 44 years (r: 0.81 and 0.75; p-value < 0.0001). Among 45 to 54 year old 
breast cancer cases, the corresponding correlations were 0.81 for 1972, and 0.76 for 1982. 
The correlation for average age at birth of first child in 1972 and RER for those aged 55 to 
64 in 2002 was 0.77 (p-value < 0.0001). Finally, we found a decreasing magnitude of the 
correlation between RER in 2002 for 15+ years with increasing calendar year of mean age at 
first child (figure not shown); Pearson correlation coefficients (r) were 0.83 for 1972, 0.79 for 
1982, 0.72 for 1992 and 0.61 for 2002 (p-value < 0.0001). 
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3.4. Discussion  
We observed a strong correlation between the overall excess incidence of breast cancer in 
2002 and the average age of the mother at first birth in 1972-2002. Both current and past 
average age at first childbirth were related with recent excess risk of breast cancer. The 
earliest period of exposure assessment correlated best with the current excess risk of breast 
cancer. For those aged about 40 at breast cancer diagnosis in 2002, mean age at first 
childbirth in 1982 and 1992 correlated closely with their excess risk. For those aged about 50 
years at diagnosis, age at first birth in 1972 and in 1982 correlated with their current excess 
risk. Finally, for those aged about 60 years at diagnosis, age at first birth in 1972 strongly 
correlated with their current excess risk.  
 
We determined excess breast cancer incidence as the difference between national incidence 
rates and the lowest observed rate. Hence, the relative excess in 2002 is supposed to be 
largely due to variations in external risk factors across populations, such as age at birth of 
first child, and hardly to genetic differences.13 Though the latter may have played a 
interactive role, the prevalence of predisposing breast cancer genes is too low to explain 
these inter-population differences.14 Our results are consistent with previous studies15-17 and 
supported by biological evidence of the role of pregnancy in the pathogenesis of breast 
cancer.18  
 
In affluent countries, the higher excess risk of breast cancer may be caused by practices of 
early detection and screening programs, especially among women over 50.5 In such 
populations, age at first birth also tends to be higher. However, increasing breast cancer 
rates have also been observed in countries without national screening programs (e.g. Czech 
republic, Slovenia, Slovakia, Estonia and Norway).5 Moreover, in countries where organized 
screening is present such as in the Netherlands and in Finland, increasing rates of breast 
cancer have been observed before the screening period.5 Thus, it is unlikely that higher 
breast cancer rates in industrialized societies are entirely attributable to screening.  
 
The excess of cases of breast cancer in 2002 reflects past exposure to multiple risk factors. 
Availability of comparable data on other risk factors is limited for most countries, and we 
were therefore unable to adjust for possible confounders, such as parity or duration of 
hormonal contraception use, which are also related to breast cancer risk.19 Moreover as with 
any correlation study, observed correlations may be due to these other factors.20 However, 
studies have shown that after correcting for other breast cancer risk factors such as oral 
contraceptive use and number of children, age at first birth remained an independent 
indicator of higher breast cancer risk among women who were older at birth of their first 
child.17, 19   
 
We correlated average age of mother at first birth to breast cancer risk, hence our finding 
might not sufficiently apply to the increasing proportion of childless women with an even 
higher breast cancer risk.21 The proportion of women still childless at age 40 might therefore 
be an indicator for the proportion of nulliparous and be used in the analysis to adjust for it. 
However historical data for this indicator is limited and when available (e.g. in 2002), 22 we 
found a very high correlation with average age at first birth (r: 0.90, data not shown). The 
observed correlation in this study thus partly reflects the risk of childless women; nations in 
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which women were older at delivery of their first child also comprise a higher proportion of 
childless women and a higher excess breast cancer risk.  
 
We found the largest increase in age at first birth in countries with the highest relative risk of 
breast cancer between 1982-2002, being 3 to 4 years in the UK, the Netherlands, France 
Spain and Australia. By contrast, average age at first birth in countries like Bulgaria, 
Slovakia, Lithuania, Latvia and Poland hardly changed between 1982 and 1992, but 
increased by an average of 2 years between 1992 and 2002. Overall, the trend in 
postponing children seems to be continuing.22 Despite some flattening in the Netherlands, 
postponement of childbearing is likely to be resumed, and mean age at first birth is predicted 
to increase up to 33 years.23 A further increase of breast cancer incidence might be the 
result.  
 
We observed a marked relationship between average age at first birth in 1972, 1982, and 
1992 and excess risk among women diagnosed in 2002 with breast cancer aged 55-64, 45-
54 and 15-44. Most women diagnosed with breast cancer at age 45 to 54 in 2002 probably 
had their first child 20-30 years before 2002, thus mostly around 1980. For age groups 15-44 
and 55-64 years, year of first childbirth was mostly around 1990 and 1970, respectively. The 
correlation between RER in 2002 and age at first delivery is thus equally seen among pre-
menopausal and post-menopausal breast cancer.16 Furthermore, we observed the 
correlation to decrease with shorter time since exposure (age at first birth): the correlation 
between RER in 2002 for all age groups (15+) and mean age at first birth in 1972 was 0.83, 
continuously decreasing to 0.61 in 2002. Findings were similar across all age groups, 
suggesting a lag time of 20-30 years until variation in age at first birth is projected on the risk 
of breast cancer in the population.  
 
What about the association between age at first birth in 1992 and 2002 and excess breast 
cancer risk in 2002? Most women who gave birth to their first child in 1992 or 2002 were too 
young to account for the association with breast cancer risk in 2002. However, risk factors 
for breast cancer are generally clustered more in countries with a high incidence of breast 
cancer.16 For example; younger age at menarche (by 1.1 year) has been reported in 
countries with a high breast cancer risk, such as United States and Wales as opposed to 
Taiwan and Japan with a lower risk.16 Similarly, lower parity and higher prevalence of 
nulliparity was observed in high breast cancer risk countries.16 Furthermore, in countries with 
a higher risk of breast cancer higher body mass index was also observed,16 possibly also 
reflecting the combination of a diet high in calories and lack of exercise. Finally, wider use of 
alcohol among women24 and post-menopausal hormonal therapy25, 26 are generally observed 
in more affluent regions, thus also in populations with a higher incidence of breast cancer. 
To summarize, older age at first child delivery probably is also a risk indicator of clustering of 
risk factors in western populations. This implies that a part of excess cases might be 
preventable by other means. 
 
Basically, opportunities appear to be small of modifying some of the known risk factors for 
breast cancer, especially the timing of conceiving children. Delayed childbirth represents 
increasing educational opportunities and career choices for most women.22 As a 
consequence, enhancing the potential for altering modifiable risk factors becomes even 
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more important: minimizing alcohol intake27, avoiding weight gain by the combination of a 
balanced diet and enough physical activity28 and promoting breast-feeding29 should, to a 
certain extent, reduce the risk of breast cancer.  
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Recently Robbins and Clarke reported a sharp decrease in the incidence rate of first primary 
breast cancer in women over 50 years in the United States, which was attributed to a 
decrease in hormone-replacement therapy (HRT) since 20011, consistent to an earlier study 
that was also done in the United States.2 Although there was a similar decrease in HRT 
across Europe, such a remarkable decline in breast cancer rates has only been reported in 
Germany.3 Generally, women in Europe have shown a different pattern of HRT use than the 
USA, mostly less frequent use and of shorter durations.4, 5 Only 13% of women aged 49-70 
years used HRT in the Netherlands between 1993 and 1997,5 versus 38% in the USA.4 In 
the Netherlands HRT use decreased by 12 % between 2002 and 2003, followed by another 
26% between 2003 and 2004. By the end of 2005 there was a decrease of 42% as 
compared to 2001 of combined estrogen-progesterone and natural and semi-organic 
estrogen use. However the rate of first primary breast cancer among women aged 50-69 in 
the northwestern and southeastern Netherlands has not changed up till 2005 (figure 4.1). 
The impact of the sudden fall of HRT use would account for about a 6% fall of breast cancer 
incidence in the US versus only 0.4% in the Netherlands, using the following formula (p-
p*)(RR-1)/(p(RR-1)+1)6 (p=past prevalence, p*=current prevalence and RR=relative risk:1.07 
for the Netherlands for duration of use <5 years and 1.25 for the USA for duration of use ≥5 
years7). A similar small impact of decrease in HRT use on the breast cancer incidence is 
expected in Spain or Italy with a low use (5%-8%), contrasting countries with a high use 
such as Belgium or France (32%-38%).4 There is however another pitfall, HRT use has been 
related to increased breast density, thus reducing the specificity of mammography and 
delaying detection of 20% of breast cancer cases.8 The maximum benefit of HRT reduction 
should be evident within the next 2 years (data until 2007) in the Netherlands where biannual 
mass screening with more than 80% attendance rate is being practiced since the early 90’s, 
and might take longer in the USA having only opportunistic screening with lower 
coverage/attendance rate. 
 
The two cancer registries involved have proven to be a valuable source of data.9 Currently, 
only a flattening of the 40-year rising trend in breast cancer incidence following the decrease 
of HRT use has been observed, warranting more years of observation.  
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Figure 4.1. Annual Incidence of Female Breast cancer between the Ages of 50 and 69 Years in the Netherlands and in 
the United States.  
US data are from nine of the SEER registries and Netherlands data are from two registries (northwest and southeast 
Netherlands). Data of the Netherlands for 2004-2005 (northwest) and 2003-2005 (southeast) are corrected for extra 
regional cases by adding the average number of extra regional cases in preceding years. Rates were age adjusted to 
the European standard population. 
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Abstract 
 
Background and objectives: Numerous studies have examined prognostic factors 
for survival of breast cancer patients, but relatively few have dealt specifically with 
10+-year survivors.  
 
Methods: A review of the PubMed database from 1995 to 2006 was undertaken with 
the following inclusion criteria: median/mean follow-up time at least 10 years; overall 
survival and/or disease-specific survival known; and relative risk and statistical 
probability values reported. In addition, we used data from the long-standing 
Eindhoven cancer registry to illustrate survival probability as indicated by various 
prognostic factors.  
 
Results: 10-year breast cancer survivors showed 90% 5-year relative survival. 
Tumor size, nodal status and grade remained the most important prognostic factors 
for long-term survival, although their role decreased over time. Most studies agreed 
on the long-term prognostic values of MI (mitotic index), LVI (lymphovascular 
invasion), Her2-positivity, gene profiling and comorbidity for either all or a subgroup 
of breast cancer patients (node-positive or negative). The roles of age, 
socioeconomic status, histological type, BRCA and p53 mutation were mixed, often 
decreasing after correction for stronger prognosticators, thus limiting their clinical 
value. Local and regional recurrence, metastases and second cancer may 
substantially impair long-term survival. Healthy lifestyle was consistently related to 
lower overall mortality.  
 
Conclusions: Effects of traditional prognostic factors persist in the long term and 
more recent factors need further follow-up. The prognosis for breast cancer patients 
who have survived at least 10 years is favorable and increases over time. Improved 
long-term survival can be achieved by earlier detection, more effective modern 
therapy and healthier lifestyle.  
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5.1. Introduction 
Breast cancer (BC) is the most common cancer among women, with a lifetime risk of 
up to 12% and a risk of death of up to 5%.1 Its incidence has been increasing but 
after a period of continuous rise in many industrialized countries BC mortality has 
been stable or has even decreased in the last 10-15 years.2, 3 The introduction of 
mass mammographic screening programmes also resulted in earlier detection and 
diagnosis of small and less aggressive tumours. This, in combination with therapeutic 
improvements, has led to a substantial increase in breast cancer survivors over the 
last few decades (figure 5.1). A long-term survivor is commonly defined as a person 
who is still alive 5 years after cancer diagnosis.4 For breast cancer, the relative 
survival at five and ten years after diagnosis is 88% and 77%, respectively, both 
substantially higher than the 5-year relative survival of all cancers together (64%).4 
Thus, it seems logical to consider factors known to play an important role in 
predicting 5-year survival of BC patients and to question their importance in survival 
10 years after diagnosis and even longer. Furthermore, in recent years major 
advances in the prognostic value of several molecular markers have been achieved, 
hence the need to incorporate this data into our current knowledge. Therefore, we 
have summarized available knowledge on the determinants of survival 10 years or 
more after breast cancer diagnosis. We supported our analyses and considerations 
with data from the population-based, long-standing Eindhoven cancer registry in the 
Netherlands.  
 
 
 
Fig. 5.1. Proportion of breast cancer patients (3-year moving average) diagnosed between 1973 and 1993 
who survived 10 years or longer in Southeastern Netherlands  
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5.2. Methods 
We initially searched PubMed, using the search MESH term for ‘breast neoplasms’ 
AND ‘prognoses’ AND ‘long-term’. Only papers published in English between 1995 
and 2006 (September) which researched female adults (19+ years) were included. 
We retrieved 528 articles and studied the abstracts (sometimes also the methods 
section). We selected only articles that assess or show the results for those surviving 
10 years or longer with cohorts having a mean/median follow-up of 10 years or 
longer. If mean/median follow-up time was not reported, we examined the proportion 
of patients who survived 10 years after diagnosis, and this ought to be larger than 
50%. If, for a specific topic of interest, no relevant studies with a follow-up of at least 
10 years were found (such as BRCA mutation or gene profiling, which have been 
studied only during the last decade), then studies with the longest available follow-up 
were chosen. Furthermore, the following inclusion criteria were used: overall and/or 
breast cancer-specific survival was reported; relative risk or hazard rate and 
statistical probability values were given; at least 250 BC patients included at the 
beginning of study. We also searched the reference lists collected by this search 
strategy and selected those that were relevant to both our study question and 
inclusion criteria (list of studies, table 5.1). Reviews and books that gave general 
overviews were also included in the reference list.  
 
We present data from the Eindhoven Cancer Registry (ECR) to illustrate the role of 
factors such as age, tumour size, lymph node involvement and time since diagnosis. 
Within the Netherlands, ECR is unique because it has collected follow-up data since 
1970, including clinical aspects of cancer patients. This is a population-based cancer 
registry covering a population of almost 2.4 million people in 2004.5 Cumulative 
survival proportion was calculated using the Kaplan Meier method. Relative survival 
was calculated by comparing the survival of breast cancer patients to the general 
population.  
 
Throughout the text the term long-term and/or survival will frequently be mentioned; 
this corresponds to at least 10-year survival unless otherwise indicated. 
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5.3. Results and discussions 
 
5.3.1. Determinants of survival breast cancer 10 years or longer  
 
Patient characteristics 
Age at diagnosis 
Very young women, i.e. younger than 30/35 years,6, 7 exhibited a particularly poor 
survival as do those older than 70 (figure 5.2).8, 9 Young BC patients were more likely 
to have a more negative clinical presentation, such as affected lymph nodes, 
negative for oestrogen receptors, and have large tumour with a high fraction of p53 
nuclei and overexpression of c-erb-2 oncoprotein.6, 10, 11 However, current adjuvant 
treatment seems to diminish the poor prognostic value of young age;6 young women 
who did not receive adjuvant treatment had a significantly increased risk of dying; 
those diagnosed at 35-39 years and <35 years had a 1.4 and 2.2 higher risk of 
death, respectively, compared to those of 45-49 years.6 Older patients exhibited 
higher mortality rates,12 probably because of less extensive treatment (either related 
to advanced age itself or the presence of serious concomitant diseases 
(comorbidity)).13    
 
 
Fig. 5.2. Relative survival of breast cancer patients (n: 13,279) diagnosed in 1990–2002 and followed until 
2004, according to age at diagnosis in southeastern Netherlands 
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Comorbidity 
Concurrent health conditions (comorbidity) at the time of BC diagnosis have a 
significant impact on early13 as well as long-term survival of BC patients.12 The most 
prevalent conditions were cardiovascular disease (7%), previous cancer (7%) and 
diabetes mellitus (6%), all becoming more common with increasing age.13 Compared 
to those without comorbidity whose 5-year relative survival was 87%, those with 
diabetes mellitus or cardiovascular disease represented 78% and 83% of the 
respective survival estimates.13 Patients with severe comorbidity exhibited a 2.7-3.4 
higher risk of death in 10 years compared to those without comorbidity.12, 14  
Period of diagnosis 
Access to care and treatment of BC has improved over time in most industrialized 
countries, which is reflected in the higher long-term survival of BC cases across all 
age groups and the tumour characteristics of those diagnosed more recently.15-18 In 
Finland, relative survival 10 years after diagnosis among patients younger than 50 
years increased from 49% for those diagnosed in 1953-1959 to 68% for the 1983-
1989 cohort.15 Furthermore, 60% of node-positive BC patients diagnosed in 1978–
1979 in Italy survived 10 years or longer compared to the 50% probability 10-year 
survival for those diagnosed in 1968–1969.17 In addition, changes in BC diagnosis, 
e.g. screening19, 20 and better staging17, may partly be responsible for the observed 
increase in the proportion of survivors.  
Time after diagnosis  
The longer a woman survives BC the more the prognosis improves, illustrated by 
conditional survival.16, 21 Probably the subgroup of patients who survived longer had 
less aggressive tumours due to a different genetic make-up or better life-style. In 
Australia, 79% of women with localized BC survived 10 years after diagnosis, yet 
among those still alive 5 years after diagnosis 84% had a 10-year survival.16 The 
respective values for regional vs. advanced BC were 53% and 68%.16 Unlike other 
cancers, relative conditional survival remained stable below 100% after 12 years of 
survival and decreased again after about 19 years (figure 5.3).5 This may be a 
consequence of late recurrences and metastases, second cancers or late side-
effects of treatment.23  
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Fig. 5.3. Conditional 5-year relative survival (calculated using period analysis [22] of breast cancer patients 
diagnosed in southern Netherlands in 1985–2002 and followed until 2004, according to age. (Dashed line): 
diagnosed at 25–49 years, (solid line): diagnosed at 50–74 years  
Socioeconomic status (SES) and race 
A population-based study of breast cancer patients diagnosed in 1968-1999 in 
France showed a diminishing role of SES on excess mortality among women with BC 
over these periods.24 Long-term follow-up studies reported that women with BC from 
low social classes had a 20-50% poorer survival compared to patients from higher 
social classes,25, 26 although others contradicted this.27 Low SES patients were more 
likely to be diagnosed at a later stage, had more aggressive tumour characteristics 
and might have received sub-optimal treatment. However, differences in these 
prognostic factors did not fully explain the variation in survival according to social 
class.25 This is also the case when breast cancer survival is studied according to 
race/ethnicity. Ten years after treatment 58% of African Americans were still alive 
compared to 66% of the white Americans. After adjusting for other prognostic factors, 
41% excess mortality from all causes was still observed among African Americans 
compared to caucasians.28 This suggests other residual factors such as lifestyle 
(higher body weight was observed among African Americans), comorbidity,14 
genetics or variation in the delivery of treatment, which influence outcome beyond 
variation in tumour aggressiveness.29   
 
Tumour-related characteristics 
Tumour size   
Tumour size is one of the strongest prognostic indicators (figure 5.4),7, 30 even after 
20 years of follow-up.8, 31 A larger tumour has been related to more positive lymph 
nodes,32 thus their interaction further influences the survival from BC. Nonetheless, 
the independence of survival by node status is shown by the lower 10-year overall 
survival rate found for node-negative patients with a tumour of 2-5 cm compared to 
those with a tumour smaller than 1 cm, 66% vs. 79%, respectively.33 
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 Fig. 5.4. Cumulative survival proportion of breast cancer patients diagnosed in southern Netherlands in 1970–
1994 and followed until 2004, according to tumor size (based on pathological diagnosis). ■ tumor size: <2 cm 
(n: 3263) • tumor size: 2–5 cm (n: 3420)  tumor size: >5 cm (n: 474) x tumor size: involvement of skin (n: 
1133) and unknown/not applicable tumor size: 1410 
Histological type  
The prognostic value of histological type can be grouped into four: excellent, good, 
poor and very poor prognosis.34 BC with an excellent prognosis, such as invasive 
cribriform, tubular35, tubulo-lobular and mucinous 36, 37 showed >80% survival at 10 
years.9 Tubular mixed, mixed ductal with special type, atypical medullary38 and 
alveolar lobular carcinoma have a good prognosis with a 60-80% 10-year survival. 
Those with invasive papillary, classic lobular and medullary cancers have a worse 
prognosis. Finally, 10-year survival among those with ductal, solid lobular, mixed 
ductal and lobular carcinoma is below 50%.34 In most populations infiltrating ductal 
carcinoma covers about 70% of all diagnoses.36, 39 Inflammatory BC has a particularly 
poor prognosis: about 30% survived 10 years.40 
 
Histological grade  
The most widely used grading systems are Scarff-Bloom-Richardson classification, 
Fisher grading nuclear system and Nottingham Combined Histologic Grade 
(NCHG).41 The validity of grading has been subjected to inter-observer reproducibility 
and subjectivity.42 However, higher grades have been quite consistently associated 
with lower long-term survival.7, 8, 31, 43-45 Depending on other prognostic factors, such 
as nodal status or tumour size,46, 47 cumulative survival among patients with the 
lowest score was 90-94% 10 years after diagnosis and 30-78% among those with the 
highest score.37, 48 
 
Regional lymph node involvement 
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Lymph node involvement is a valuable indicator of long-term survival (figure 5.5).8, 32 
Node- positive patients have about a 4-8 times higher mortality than those without 
nodal involvement.8, 9, 49 The more nodes involved the worse the prognosis. 
Prognosis for patients with 10 or more involved axillary nodes showed 70% more 
deaths at 10 years than for those with 1-3 involved nodes.32 The survival of node-
positive patients improved due to better staging procedures and application of 
systemic treatment.7, 31, 50  
Fig. 5.5. Cumulative survival proportion of breast cancer patients diagnosed in southern Netherlands in 1970–
1994 and followed until 2004, according to nodal status (based on pathological diagnosis). ■ node negative (n: 
4452) • node status: 1–3 positive nodes (n: 3266)  node status: 4–9 positive nodes (n: 255) x node status: 
10+ positive nodes (n: 189), unknown/not applicable node status: 1538 
 
Lymphovascular invasion (LVI) and molecular markers of tumours angiogenesis 
At the St. Gallen meeting in 2005, LVI was added to the prognostics for node-
negative patients.51 Compared to patients having no LVI, a 60% higher breast cancer 
mortality was observed for node-negative BC patients having positive LVI,52, 53 
although others did not observe the independent role of LVI.46, 50 In this line of 
research, studies have also focused on the value of microvessel density,44 blood 
invasion (BVI)54 and markers of angiogenesis (VEGFR (vascular endothelial growth 
factor receptor), CD105, Tie-2)55, 56 in predicting long-term survival of BC patients, 
although the results are still conflicting.     
 
Grouped prognostic factors  
Some of the prognostic factors have been combined into a prognostic index, such as 
the TNM classification, as shown by the data of the ECR (figure 5.6), and also the 
more current Nottingham Prognostic Index (NPI), both highly predictive for estimating 
long-term survival.41 TNM staging consists of information on primary tumour size, 
involvement of the regional lymph node and the presence of distant metastasis. Only 
53% of patients with regional or locally advanced BC had survived 10 years after 
diagnosis compared to79% of those with localised BC16. Patients with metastasis 
(stage: M1) at diagnosis exhibited very poor 10-year survival (3.4%).57  
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Tumour size, grade and lymph node status make up the NPI.11, 46, 49 In a large series 
of 2879 BC patients, 10-year survival proportion was 85% for those with the lowest 
NPI score and 19% for those with the highest score.11 
 
 
 
Fig. 5.6. Cumulative survival of breast cancer patients diagnosed in southern Netherlands in 1970–1994 and 
followed-up until 2004, according to second cancer. Follow-up for patients with second cancer begins at the 
date of second cancer diagnosis. ■ no second cancer (n: 8137) • second breast cancer (n: 744)  second 
non-breast cancer (n: 819) 
 
 
Recurrence, metastasis and second cancer  
Patients with recurrent, metastasized or second cancer generally exhibited lower 
long-term survival than those without.9, 21, 58-61 Ten years after surgery, the probability 
for survival for another 10 years, thus 20 years after diagnosis, for node-negative 
patients aged ≥45 years, tumour ≤1 cm, grade 1 and without a recurrence or 
metastasis was 0.89. If a recurrence occurred, the probability of being alive at 20 
years dropped to 0.72. If a metastasis was observed the probability of survival was 
only 0.18.21 The prognosis decreases with larger primary tumour size, nodal 
involvement,62 higher grade,21 early recurrence (within 5 years of surgery)63, location 
of recurrence (regional rather than local ipsilateral)59 and inadequate primary cancer 
treatment.9, 64 In the dataset of the ECR, overall survival was better for women 
without second primary tumours than for women who developed a new primary 
cancer (figure 5.6). Only 68% of early BC patients with second malignancies had 
survived 10 years of follow-up compared to 78% of those without multiple cancers.65 
Younger breast cancer patients are reported to have poorer survival and a higher risk 
of second cancer.59 Corrected for race and grade, women in the 20-29 year old 
category who had a second breast cancer had a probability of 10-year survival 
probability of only 23% compared to 57% for those without multiple cancers.  
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Other tumour markers 
 
Hormone Receptors 
The presence of hormone receptors such as oestrogen (ER) and progesterone (PR) 
receptors predicts the long-term outcome of hormonal therapy,66 thus they have been 
more commonly used as a predictive marker rather than as a prognostic marker. 
Thus given a particular treatment, e.g. tamoxifen, ER-positive patients have a 
considerably better prognosis than ER-negative patients. The prognostic value is 
weak30, 43 or negligible,37 particularly in the early years after diagnosis.67 
 
HER-2 expression 
Node-positive patients with BC cells showing amplification of the gene for human 
epidermal growth factor receptor type 2 (HER2), and/or overexpression of its product 
had a lower 10-year overall survival proportion, 50% versus 65% for those without 
HER2 amplification.17, 68 After 10 years the difference in survival persisted, although it 
became somewhat smaller.17 Tumours that overexpress HER2 are more likely to 
contain p53 abnormalities, to be hormone receptor- and bcl-2-negative and to have 
lymphoid infiltration and a high mitotic index, all known to be markers of poor 
prognosis for breast cancer.17, 69, 70 As for patients with node- negative tumours, 
HER2 did not seem to affect long-term survival significantly.17, 37, 69 HER-2 expression 
has been valuable in predicting treatment responses to trastuzumab, certain 
endocrine therapies and chemotherapy, adding to it's role as a predictive marker.68            
 
MAI (Mitotic Activity Index)  
MAI is an indicator of tumour proliferative activity that represents the mitotic activity in 
a given area of the tumour. Combined with another prognostic factor (NCHG), MAI 
has proven to be an accurate tool for assessment of long-term survival.48 In a 
population-based study women with node-negative tumours < 5 cm and a MAI ≥ 10 
exhibited 80% survival at 10 years compared to 90% for an MAI <10.71  
 
Gene expression profile  
A very promising new finding is the microarrays method, in which a set of intrinsic 
genes is clustered and segregated into major subgroups; BC with a good and poor 
prognosis profile is correlated to the probability of distant metastases72 or a tumour 
with basal or luminal characteristics which are strongly associated with ER status.73 
In a study of 295 patients diagnosed with stage I or II breast cancer, those classified 
as having a good prognosis profile had a 95% overall 10-year survival rate compared 
to 55% for those with a poor profile.74 This classification predicted outcome 
regardless of the nodal status, implying that more accurate criteria have become 
available for administering adjuvant systemic treatment.  
 
Various molecular markers  
BRCA1 & 2 mutations were first identified in 1994 and are BC risk factors for some 
specific groups.75 Their role as prognostic indicator for long-term (more than 10-year) 
survival has not yet been established. A study of 496 women (median follow-up: 116 
months), 56 of whom (11%) carried a BRCA1/BRCA2 mutation, showed worse 
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breast cancer-specific survival for women with BRCA1 mutations than for those 
without (62% at 10 years versus 86%; P < 0.0001), but not for women with the 
BRCA2 mutation.76 However, another study which compared patients from BRCA1, 
BRCA2 and non-BRCA1/2 families as well as sporadic cases did not confirm the 
prognostic role of BRCA1/2.77  
 
Long-term follow-up studies have not demonstrated an independent effect of p53 
mutations on long-term survival. The P53 mutation was related to a poor clinical 
profile for patients, hence in multivariate analysis its role on survival diminished.10, 69, 
78, 79  
 
A high level of tissue urokinase-type plasminogen activator (uPA) and its inhibitors 
has been correlated with poor outcome for node-negative and node-positive patients. 
Those having the highest level of uPA have a 5 times greater risk of dying from 
breast cancer compared to those with the lowest level.69 Other factors such as Ki67 
(MIB-1), cathepsin-D, DNA ploidy and S-phase have been suggested as 
prognosticators of survival, with conflicting results, particularly among long-term 
survivors. Their use in general clinical settings is therefore not recommended.80, 81    
 
Miscellaneous  
 
Lifestyle  
Generally, increased death rates due to BC (13-20%), other causes (49-86%) and all 
causes (14-70%) have been observed among obese patients.82-85 Normal body 
weight tended be more beneficial in death from other causes than from BC:83, 84 9.5% 
of obese patients died from non breast cancer causes compared to 6.4% and 5.8%, 
respectively, of the normal or intermediate groups.82 Obesity was also related to a 2-
fold increased risk of postmenopausal contralateral BC and a 60% higher occurrence 
of second other cancers.84 Therefore, normal weight may reduce the risk of second 
post-menopausal BC, second other cancers and overall mortality.83, 84, 86  
 
Compared with women who engaged in less than 9 MET (metabolic equivalent task)-
hours per week of activity, women who engaged in 9 or more MET-hours per week 
had a 40% lower risk of death from all causes, translating into a 6% absolute 
(unadjusted) reduction in mortality,87 which emphasizes the need to advise physical 
activity.  
 
So far, although studies have not convincingly shown the positive influence of eating 
fruit, vegetables and soy bean on long-term BC survival,85, 88 diets high in fruits, 
vegetables, legumes, poultry, and fish and a low intake of red meat, desserts and 
high fat dairy products are likely to protect against mortality from non-BC causes.89 
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5.3.2. Modification of BC's prognostic factors 
Various studies have questioned the role of breast cancer risk factors in determining 
the biological tumour features as mentioned above. Indeed, breast cancer risk factors 
seem to differ according to histological type, grade, size, nodal status and ER/PR 
receptor status.90-93 For example, excessive alcohol intake and obesity increased the 
risk for the development of ER-positive tumours.92, 93 As for late age at first full-term 
birth and obesity are related to an increased risk of large tumours.91 Hence, risk 
factors for breast cancer may also affect breast biology and clinical behaviour, thus 
also BC prognosis.  
 
5.3.3. Changing importance of prognostic factors over time after diagnosis 
Commonly, the value of prognostic factors decreases depending on the length of the 
follow-up period.31, 94 Survival curves according to prognostic factors usually show a 
large drop in survival for all stages during the first 5 years; afterwards the curve 
stabilizes. Studies agreed on the long-lasting influence of tumour size at diagnosis on 
survival, albeit attenuating over time.31, 94, 95 Grade, nodal status and metastases 
were also valuable in predicting survival up to 20 years after diagnosis.31, 95 Although, 
others have reported that 10 years after diagnosis only tumour size94 or nodal status8 
or old age8 remained as an independent predictor of long-term survival. Similarly, 
ER/PR status and MAI only had a significant prognostic role in the first 5-10 years 
after diagnosis.67, 71, 96 Because even 10 years after BC diagnosis the probability of 
survival for BC patients does not seem to reach that of the general population, the 
role of other prognostic factors in determining survival for long-term survivors still 
needs to be determined.     
 
5.3.4. The role of early detection  
Increased awareness among women and improvement in diagnostic procedures 
have enabled earlier and better detection of BC. Trials on population screening have 
reported 21%-29% reduction in BC mortality for women invited for screening within 
14-16 years of follow-up.19, 97 Screening identified tumours at an early stage 
consequently, survival improved.98, 99 Screening also identified patients with slowly 
growing tumours who might receive unnecessarily aggressive cancer treatment. 
Thus, Joensuu et al100  examined recurrence rates among patients detected by 
screening compared to those detected outside screening. After adjusting for tumour 
aggressiveness (tumour size, nodal status, grade, age, treatment, PR status, HER-
2), hence eliminating bias towards detection of indolent cancers (length bias), the 
benefit of screening for the prognosis for BC patients remained evident.100 This 
suggests that other factors explain the indolent behaviour of BC detected by 
screening. Hence, until this factor is established, detection mode should probably be 
considered as a prognostic factor and thus be taken into account in patient 
management.        
 
5.3.5. The role of treatment 
Improvement in BC treatment has undoubtedly also increased the long-term survival 
of BC patients,101 as reflected by the improved overall survival across all BC stages.16 
Using historical data from population-based studies in periods when effective 
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treatment was not available, it was estimated that without treatment only 4% of BC 
patients would survive 10 years or longer.102 BC treatment guidelines have been 
modified continuously in the last 28 years, tailored to most of the prognosticators 
mentioned earlier.51 Effectiveness of various treatment modalities has been 
summarized by others who conclude that radiation, chemotherapy and hormonal 
therapy may reduce long-term mortality by up to 57%.66, 103-105 Emerging new 
therapeutic approaches using a monoclonal antibody directed against HER-2 have 
yielded improved short-term survival for advanced stage106 as well as operable BC 
patients.107 Quality of treatment as indicated by loco-regional failure108, surgeon 
workload109 or hospital volume110, may affect survival although its role on long-term 
survival still needs confirmation.  In conclusion, on the one hand we have observed a 
shift in stage towards less aggressive cancers; on the other hand, better and more 
(systemic) treatment has become available, leading to improved survival for breast 
cancer patients.  
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5.4. Conclusion 
The prognosis of breast cancer has become relatively good, with current 10-year 
relative survival about 70% in most western populations,16, 111 especially if up-to-date 
statistical method such as the period analyses is used.111 Even better, the longer 
patients survive their breast cancer the higher their survival chance.16 Our review 
shows conventional prognostic factors of survival, such as tumour size, lymph node 
status and grade, remain the most important determinants of 10-year survival for BC 
patients (table 5.2). Most studies agreed on the value of MAI and LVI for prediction of 
long-term survival. The influence of host factors including age, race/ethnicity or socio-
economic factors and tumor-related factors such as histological type and 
angiogenesis diminishes after correction for other factors. For most recent markers 
such as Her2, gene profiling, p53 mutation and uPA level longer follow-up is needed. 
Recurrence, metastases and a second cancer double the burden of disease thus 
increase risk of mortality. Similarly, co-occurrence with other diseases is in no doubt 
decrease survival.  
 
Healthier lifestyle generally increases long-term survival. Modifiable risk factors (such 
as alcohol consumption and obesity) not only affect incidence but also tumour’ 
clinical behaviour and thus survival.   
 
Although a lot is known about the prognosis for breast cancer patients, effect of 
traditional prognostic factors appears to attenuate over time, leaving room for studies 
on the role of other and newer factors for long-term survival.  
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Abstract 
 
Background and objectives: The number of female cancer survivors has been rising 
rapidly, resulting in an increasing number of women at risk of second breast cancer. Thus, 
we assessed the increase in breast cancer incidence among cancer survivors to determine 
the need for surveillance. 
 
Methods: We computed incidence of primary breast cancer in two cohorts of female cancer 
survivors with a first diagnosis of cancer at ages 30+ in the periods 1975-1979 and 1990-
1994. Cohorts were followed for 10 years through a population-based cancer registry.  
 
Results: Over a period of 20 years, the incidence rate of breast cancer among female 
cancer survivors doubled (rate ratio:1.9, 95%CI: 1.5-2.4). Age-adjustment reduced this 
increase by 43% (age-standardized rate ratio (RR-adj):1.5, 95%CI: 1.1-2.1). Increases over 
time were most marked for women who were first diagnosed with a non-breast cancer (RR-
adj:2.1, 95%CI: 1.1-3.9), for women with second breast cancer stage II (RR-adj:3.1, 95%CI: 
1.2-7.0) and for those diagnosed with a second breast cancer aged 75 years or more (RR-
adj:3.6, 95%CI: 2.0-6.3). The proportion of second breast cancer stage II and III among the 
non-breast cancer survivors was 62% contrasting to only 32% among the breast cancer 
survivors (p-value=0.005). 
 
Conclusions: A marked rise in breast cancer incidence among female cancer survivors was 
observed, particularly among survivors previously diagnosed with a non-breast cancer and 
those older than 75 years. Research to optimize follow-up strategies for these women to 
detect breast cancer at an early stage is warranted. 
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6.1. Introduction 
Breast cancer is the most common cancer among women in general, but also among 
women who previously diagnosed with any type of cancer1. During the past three decades, a 
four-fold increase in the incidence of contralateral breast cancer has been reported, which is 
much higher than that of first primaries2. However in the same period a 9% decrease in the 
incidence of second breast cancer among former breast cancer patients was reported in the 
USA3. The increasing prevalence of patients ever diagnosed with cancer should theoretically 
result in an increase in the incidence of new primary cancer4, i.e. breast cancer among 
cancer survivors. Changes in female reproductive behaviour and lifestyle, that underlie the 
increasing trend of first breast cancer, may also affect the increased risk of a second breast 
cancer5, 6. Furthermore, cancer survivors are exposed to additional carcinogenic factors such 
as high-dose radiation for the first cancer7. Using the data from a long-standing cancer 
registry in southern Netherlands, we investigated the incidence of breast cancer among 
cancer survivors since 1975. We assessed the change in incidence of a second breast 
cancer over time according to age, stage and type of treatment of the first cancer.     
 
6.2. Methods 
Data on cancer patients were obtained from the Eindhoven Cancer Registry (ECR), a 
population-based registry with follow-up data since 1970, including clinical aspects such as 
stage and initial treatment. The coverage area of the registry in the southern Netherlands 
has gradually increased, covering about 0.9 million people between 1975 and 1985 and over 
2 million people since 1988. 
 
The change in breast cancer incidence among cancer survivors over time was calculated 
using the fixed inception cohort method3. We defined 2 patient cohorts: women diagnosed 
with a primary cancer between 1975 and 1979 and those diagnosed between 1990 and 
1994. We included all cancer types diagnosed in women aged 30 years or older within the 
given periods, excluding premalignant or in-situ cancer and basal cell carcinoma of the skin. 
The rules for multiple primary cancers from the International Agency for Cancer Research 
were used8. Only patients who survived six months or longer were included in the cohort. 
The follow-up time extended from the date of the initial cancer diagnosis to the date of a 
second cancer, death, loss to follow-up, or end of the study, whichever occurred first. We 
applied a 10-year follow-up for each patient cohort. Thus, the 1975-1979 cohort was 
followed until 1989 and the 1990-1994 cohort until 2004. We computed incidence rates per 
100,000 person-years for each cohort of female cancer survivors, categorizing each 
subsequent breast cancer according to age (30-49 years, 50-74 years and 75+ years) and 
TNM-stage9. Furthermore, we stratified according to type of first primary cancer (breast and 
non-breast cancer) and treatment of the first primary (surgery, radiotherapy with or without 
surgery, systemic therapy with or without surgery, radiotherapy and systemic therapy with or 
without surgery, and no therapy). Rates were adjusted for age using the European standard 
population10. Risk ratio, rate (adjusted by age) ratio and their 95% confidence intervals 
(95%CI) were computed to assess the difference between the patient groups in the two 
periods10.  
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6.3. Results 
Within 10 years of the first cancer diagnosis, 100 of 3368 (3%) and 182 of 5507 (3%) female 
cancer survivors diagnosed in the 1970s and in the 1990s, respectively, were subsequently 
diagnosed with a second breast cancer. Cancer survivors diagnosed with a first cancer in 
the 1990s were 2.1 years older at first cancer diagnosis, and they received systemic 
treatment more often than patients diagnosed in the 1970s (risk ratio: 1.5; 95%CI: 1.3-1.6 
and risk ratio: 2.1; 95%CI: 1.8-2.4, for systemic therapy and for systemic therapy in 
combination with radiotherapy, respectively) (Table 6.1).  
 
Table 6.1. Characteristics of female cancer survivors diagnosed in 1975-1979 and in 1990-1994 with a 10-year follow-
up.  
Period of first primary cancer diagnosis 1975-1979 1990-1994   
Number of cancer survivors  3368 5507   
Women-years of follow-up 29,132 28,024   
Mean age at first cancer, years 60.6 62.7   
Mean follow-up time, years 5.7 4.9   
 N % N % Risk ratio* 95%CI 
Age at diagnosis of first cancer        
  30-49 years 791 23 1200 22 0.9 0.86-1.00 
  50-74 years 2070 61 3086 56 0.9 0.88-0.94 
  75+ 507 15 1221 22 1.5 1.3-1.6 
       
Treatment of first cancer        
  Surgery 1417 42 2248 41 0.97 0.92-1.02 
  Radiotherapy ± surgery  1245 37 1450 26 0.7 0.7-0.8 
  Systemic therapy ± surgery 322 10 767 14 1.5 1.3-1.6 
  Radio- + systemic-therapy ± surgery 220 6 760 14 2.1 1.8-2.4 
  No therapy 164 5 282 5 1.0 0.9-1.3 
       
Type of first cancer        
  Breast cancer  1436 43 2199 40 0.94 0.89-0.99 
  Non-breast cancer**  1932 57 3308 60 1.05 1.01-1.09 
N indicates number of cases and % indicates column’s percentage  
*Risk ratio compares proportion in 1990s with that in 1970s  
** Non-breast cancer in 1970s consisted of 3% respiratory cancers, 40% digestive cancers, 34% urogenital cancers, 9% 
haematopoetic cancers and 15% other cancers, and in 1990s 7% respiratory cancers, 33% digestive cancers, 30% 
urogenital cancers, 10% haematopoetic cancers and 19.3% other cancers. 
 
Compared with the first period, a 90% increase in breast cancer incidence for female cancer 
survivors was observed (rate ratio: 1.9; 95%CI: 1.5-2.4, Figure 6.1). After age-adjustment 
according to the European standard population, this ratio was attenuated to 1.5.  
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Figure 6.1. Rates of incidence of primary breast cancer in female cancer survivors 
 RR (rate ratio) compares incidence rate in 1990s with incidence rate in 1970s: for crude rate 1990s vs. 1970s 95%CI= 
1.5-2.4, and for adjusted rate 1990s vs. 1970s 95%CI= 1.1-2.1. 
 
There appeared to be a similar increase in breast cancer incidence across most treatment 
groups, albeit with wide confidence intervals. The incidence rate for stage I breast cancer 
increased by 60% (age-adjusted rate ratio (RR-adj): 1.6; 95%CI: 1.01-2.6) between the 
1970s and the 1990s, whereas it tripled for stage II breast cancer (RR-adj: 3.1; 95%CI: 1.2-
7.0). The largest increase in incidence of breast cancer was found for older cancer survivors 
(RR-adj: 3.6; 95%CI: 2.0-6.3) and those previously diagnosed with non-breast cancer (RR-
adj: 2.1; 95%CI: 1.1-3.9).  
 
Figure 6.2 illustrates the stage distribution of breast cancer for female survivors diagnosed 
with a first cancer in 1990-1994 categorized according to age at second breast cancer 
diagnosis and type of first cancer. A significant difference in stage distribution (p-value of chi-
square test: 0.043) was found for the non-breast cancer survivors younger than 75 years at 
second breast cancer diagnosis compared to those with a previous breast cancer. 
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Table 6.2. Number (N) and European standardised incidence rates of second breast cancer per 100,000 women-years 
for female cancer survivors (breast and non-breast cancer) 
 
Period of first primary cancer diagnosis 1970s 1990s 
Mean age at breast cancer, years 60.8 63.2 
 N Incidence 
(100,000) 
N Incidence 
(100,000) 
Rate 
ratio* (95%CI) 
Age at breast cancer (second primary - age-specific 
rates) 
      
  30-49 years 23  659 43  880 1.3 0.8-2.2 
  50-74 years 61  371 94 590 1.6 1.2-2.2 
  75+ 16  174 45 624 3.6 2.0-6.3 
       
Stage of breast cancer (second primary)       
  I  41  175 82 285 1.6 1.01-2.6 
  II 13  69 57 212 3.1 1.2-7.0 
  III 11  30 18 71 2.3 0.96-5.6 
  IV 9  71 14 49 0.7 0.3-2.0 
  Unknown 26  90 11 38 0.4 0.2-1.1 
       
Type of first primary cancer  
  Breast cancer 77  664 127 1009 1.5 1.0-2.2 
  Non-breast cancer 23  142 55 292 2.1 1.1-3.9 
       
Treatment of first primary cancer  
  Surgery 39  290 74 519 1.8 1.0-3.2 
  Radiotherapy ± surgery  48  576 64 844 1.5 0.9-2.4 
  Systemic therapy ± surgery 5  249 15 468 1.9 0.5-6.5 
  Radiotherapy + systemic therapy ± surgery 7  801 25 796 0.99 0.4-2.7 
  No therapy 1  13 4 244 18.5 1.8-192.0 
N indicates number of cases. *ESR: European Standardised Rates**Rate ratio compares incidence rate in 1990s with 
incidence rate in 1970s, if adjusted rates are presented than rate ratio is based on the standardised rates. 
Figure 6.2. Stage distribution of breast cancer in female cancer survivors diagnosed with a first cancer in 1990-1994 
according to type of first cancer and age at (second) breast cancer diagnosis 
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6.4. Discussion 
 
The incidence of breast cancer among female cancer survivors has doubled within a period 
of 20 years, especially among the elderly and for second breast cancer stage II. Part of this 
increase can be attributed to the fact that patients have become older. Ageing of the patient 
population accounted for approximately 43% of the observed increased trend in breast 
cancer incidence among female cancer survivors, because adjusting for age reduced the 
increase from 89% to 51% in the 20-year period. The increase in breast cancer incidence 
among cancer survivors may also be due to other changes such as: (1) application of more 
combined therapies with higher carcinogenic potential; (2) mass screening, started in the 
early 90’s in our population and (3) lifestyle, reproductive and hormonal factors, such as a 
longer interval between menarche and date of first birth and alcohol use.   
 
Changes in therapy for first primary cancer may have modified the incidence of second 
breast cancer over time. Radiotherapy has been associated with an approximately 40% 
higher risk of developing subsequent breast cancer compared to systemic hormonal or 
cytotoxic treatment11, 12. A similar increase in the incidence of breast cancer was observed 
over time for those who were irradiated and those who only underwent surgery. The 
increasing incidence of breast cancer among those who were irradiated could therefore not 
be attributed to radiotherapy. However, because we followed patients for only 10 years, we 
may have missed late adverse effects of radiation13. Although the use of systemic cancer 
treatment had doubled during the last 20 years, the increase in the incidence of breast 
cancer was similar for those who received systemic treatment and surgically treated 
patients, whereas a decrease in incidence was expected14, 15. Thus, application of new 
carcinogenic therapy may have taken place in the meantime. 
 
In the early 1990’s, biennial mass screening for breast cancer was implemented for all 
women aged 50-69 years and in 1998 this program was expanded to include women up to 
the age of 7516. Due to the intensified use of mammography for mass screening the 
incidence of breast cancer increased by about 30%17 and may thus also be responsible for 
the increased incidence of breast cancer among cancer survivors. We observed a significant 
increase in the proportion of female survivors diagnosed with early breast cancer (stage I 
and II being 54% in 1970s versus 76% in 1990s, risk ratio: 1.4; 95%CI: 1.2-1.7) and a 60% 
(95%CI: 1.2-2.2) increase in rate for the screening age group, i.e. those aged 50-74 years. 
However, a much larger increase in the incidence of breast cancer over time was observed 
among those older than 74 years (rate ratio: 3.6 95%CI: 2.0-6.3), suggesting a role of risk 
factors other than screening, e.g. older age at first childbirth, fewer children, alcohol and 
other determinants of post-menopausal obesity18.  
 
In the Netherlands, patients with breast cancer are generally subject to enhanced 
surveillance: annual mammography until the age of 60, followed by a biennial 
mammography up to the age of 7419. This intense surveillance pattern is likely to contribute 
to an increase in detection rates for slow-growing tumours that would have remained in the 
pre-clinical phase longer without screening mammography20. Thus, breast cancer survivors 
are probably diagnosed more often and earlier with a low-grade breast cancer, that may 
require less aggressive treatment than survivors of other cancers21. 
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In view our results, the following groups may need a more intensive follow-up for breast 
cancer. Firstly, the non-breast cancer survivors. These patients had a larger proportion of 
stage II cancers than with patients with a first diagnosis of breast cancer. Among non-breast 
cancer patients diagnosed in 1990-1994 and followed-up for 10 years, 29% of second breast 
cancers was stage 1, 44% stage 2, 18% stage III, and 5% stage IV. For breast cancer 
patients, the corresponding percentages were 52% for stage I, 26% for stage II, 6% for stage 
III, and 9% for stage IV (p-value of Chi-square: 0.005). Thus, although the absolute risks (2% 
during 10-years follow-up) remain small, female survivors of non-breast cancer would 
probably benefit from a more intensive follow-up than just the mass screening program, such 
as an additional biennial clinical breast examination.22 A second group is female survivors 
older than 75 years.23 Survivors of this age group exhibited the largest increase in breast 
cancer incidence over time. Furthermore, compared to the general population, they had a 3-
fold higher risk of breast cancer than the general population.24 Given a worse stage 
distribution especially among those diagnosed with a non-breast cancer, it seems logical to 
extend the screening program to include these women. However, mortality due to other 
causes is high25 and the existence of comorbidities would probably limit treatment choices.26 
Thus, a detailed cost-effectivity study, preferably adjusting for Quality of Life, is warranted. A 
last group is cancer survivors younger than 50 years. Although the incidence of breast 
cancer has not increased much over time, incidence was highest for survivors aged 30-49 
years. This group may merit the same screening regimen as women with a genetic 
predisposition towards breast cancer, i.e. with an MRI.   
 
In summary, we found a considerable increase in the incidence of breast cancer among 
female cancer survivors, especially for survivors aged 75 and above. The increase in second 
breast cancers was most striking for stage II cancers. These observations mean there is 
ample room for improvement of follow-up strategies in order to detect breast cancer at an 
early stage in the elderly.  
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Abstract 
 
Background and objectives: To assess the risk of second primary cancers among women 
with previous breast cancer and calculate the excess burden of second cancer in the 
population.  
 
Material: A population-based longitudinal study was conducted using the Eindhoven cancer 
registry data on 9919 breast cancer patients diagnosed in the period 1972-2000 and 
followed until 2001. Standardized Incidence Ratios (SIR) and Absolute Excess Risks (AER) 
were calculated. 
 
Results: In total, 1298 (13%) women developed a second primary cancer. The risk of overall 
second cancer was higher among breast cancer patients compared to the general 
population (SIR: 2.4; 95%CI: 2.3-2.5), with an absolute excess risk (AER) of 115 second 
cancers for every 10,000 breast cancer patients per year. High SIR and AER were observed 
for breast cancer (SIR: 3.5; 95%CI: 3.2-3.8; AER: 64/10,000 patients/year), colon cancer 
(SIR: 1.5; 95%CI: 1.1-1.5; AER: 4.5/10,000 patients/year) and ovarian cancer (SIR: 1.7; 
95%CI: 1.3-2.4; AER: 2.8/10,000 patients/year).  
 
Conclusions: Our recent data show that women with previous breast cancer have an 
elevated risk of developing a second cancer compared to the general population. Excess 
burden for the population is especially high for second cancers of the breast, ovary and 
colon. Closer monitoring of breast cancer patients may be justified for second breast cancer 
and for ovary cancer in women diagnosed with breast cancer before menopause and for 
colon cancer in breast cancer patients diagnosed after 50 years old.  
 
Second cancer in breast cancer patients 
105 
7.1. Introduction 
Breast cancer is one of the most prevalent diseases among women in the developed world. 
Improvements in breast cancer treatment have prolonged life among cancer patients 1. In 
Eindhoven, the 5-year relative survival of breast cancer patients increased from 60% in 
1970-1978 to 80% in 1988-1997 2. This longer survival after the occurrence of a first cancer 
resulted in an increased risk to develop a second cancer 3.  
 
The study of second cancer risk has important implications for public health. Firstly, the 
study of second cancer risk is necessary for assessment of the short- and long-term effects 
of breast cancer treatment. Secondly, an association between the first and second cancer 
may exist. Thus, the study of this relationship may provide information about the possible 
determinants or risk factors for second cancers 3.  
 
Some studies suggest that women with a history of breast cancer have an elevated risk of 
developing a second cancer, particularly ovarian and endometrium cancer 4-8. Increased 
risks of tumours of the salivary gland 9;10, connective tissue  8;11;12, lung 5;9;13, oesophagus 
14;15, stomach 7;16, colon 17;18 and thyroid 5;14;19 have been reported less consistently. There 
are indications that the risk of liver 16 and gall bladder cancer 6;20 may be lower among 
patients with a history of breast cancer compared to the general female population.  
 
Our cohort comprises the most recent data on second breast cancer, with a long follow-up 
and a sufficient number of cases. The aim of this population-based cohort study was to 
assess the incidence of second primary cancers among breast cancer patients and compare 
it to the incidence expected in the general population. Furthermore, we examined the excess 
burden of second primary cancer among these patients in relation to the age at diagnosis of 
the primary breast cancer. For this purpose, relative and absolute risks of developing second 
cancer following breast cancers were calculated.  
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7.2. Materials and methods 
 
The cohort 
Breast cancer patients were obtained from the Comprehensive Cancer Center South in 
Eindhoven, situated in the south of the Netherlands. This is a population-based cancer 
registry covering 2.4 million inhabitants in 2004. The cancer registries in the Netherlands 
receive lists of newly diagnosed cases on a regular basis from the Pathology and 
Haematology Departments in the region. All pathology laboratories have a combined 
automated archive (PALGA). In addition, lists of all hospitalised cancer patients were 
obtained. These lists are based on data from the national Registry of Hospital Discharge 
Diagnoses, which collects data from hospital medical records. Active follow-up of vital status 
through municipal population registries and the Central Bureau for Genealogy was 
conducted. All malignant and in situ malignancies diagnosed since 1972 in individuals 
residing in Eindhoven were registered (including superficial bladder cancer), with the 
exception of carcinomas in situ of the cervix 2.  
 
Eligible participants for this study were Dutch women older than 25 years at the time of 
breast cancer diagnosis in the period 1972-2000 (n=11835). Patients with other 
malignancies diagnosed before breast cancer and patients with a secondary cancer that 
were metastasis were excluded beforehand. Among the eligible women we excluded breast 
cancer patients with less than 1 year of follow-up time (n=1458), as well as patients with in 
situ primary breast cancer (n=458).  For the calculation of secondary ovarian cancer, 
patients who were oophorectomised as treatment for breast cancer were not included in the 
analyses (n=9). Thus, 9919 patients which 1298 of them diagnosed with a second primary 
cancer after breast cancer remained for analysis.  
 
Methods 
We used the person-years analysis to study the incidence of second neoplasms after 
diagnosis of breast cancer. We compared the incidence of second tumours among patients 
with a diagnosis of breast cancer (the observed incidence) with the incidence of the same 
tumours in the reference population (the expected incidence). We took into account the 
amount of time that had passed between the diagnosis of the first and second tumour, 
adjusting for age (in 5-year categories) and calendar year of breast cancer diagnosis 21;22. 
Through the adjusted person-years obtained, we calculated the expected subsequent 
primary cancer relative risk for the general population. The observed and expected numbers 
were compared in order to determine the standardised incidence ratio (SIR). The statistical 
significance and 95% confidence intervals were calculated using exact Poisson probability 
23. Additionally, we calculated the absolute excess risk (AER) in order to assess the excess 
incidence of overall second cancers. This measure estimates the excess number of second 
malignancies per 10,000 patients per year 3. Risk estimates were calculated for the total 
study population and for pre- and postmenopausal patients separately. All statistical 
analyses were performed using SPSS 11.5 for Windows (Statistical Products and Service 
Solution, Inc, Chicago, USA). 
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7.3. Results 
Between 1972 and 2000, 9919 women were diagnosed with primary breast cancer, yielding 
65,938 person years. Average age at diagnosis of primary breast cancer was 58.8 years, 
whereas average follow-up time was 6.6 years. 
 
Overall, 1298 breast cancer patients developed a second cancer, in contrast to 468 
expected cases in the population (SIR: 2.4; 95%CI: 2.3-2.5). This resulted in an annual 
excess of 115 tumours per 10,000 persons. Breast cancer patients had a significantly 
increased risk of developing a second breast cancer (SIR: 3.5; 95%CI: 3.2-3.8), salivary 
gland cancer (SIR: 4.6; 95%CI: 1.2-12.5), and connective tissue cancer (SIR: 3.2; 95%CI: 
1.2-7.3). Almost two-fold elevated risks were evident for cancer of colon, ovary, skin 
(melanoma) and bladder.  
 
The SIR and AER were considerably higher among women diagnosed with breast cancer 
before the age of 50 compared to women diagnosed after age 50 (SIR: 4.5 and 2.0; AER: 
143.0 and 100.5, respectively). Three to seven-fold increased risks of developing salivary, 
stomach, bone, skin, breast and ovarian cancer were found for the younger age group. In 
contrast, among women diagnosed after the age of 50 only slightly increased risks of breast, 
colon and bladder cancer were observed.  Of all second cancers, breast cancer represented 
the highest AER in both age groups (AER: 95.2 and 47.6) (Table 7.1). 
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Table 7.1. Relative (SIR)* and absolute risks (AER)** among breast cancer patients in the south of Netherlands.  
 
  All Patients Pre-menopause ﻿﻿‌| Post-menopause† 
Num. of patients 9919 2950 6969 
Num. of person years 65,938 22,546 43,392 
Site of second cancer Obsa SIR 95% CIb AER Obs SIR AER Obs SIR AER 
All second cancers 1298 2.4‡ 2.3-2.5 115.0 415 4.5‡ 143.0 883 2.0‡ 100.5 
           
Mouth and pharynx 12 1.7 0.9-3.1 0.8 4 2.9 1.2 8 1.4 0.6 
      Salivary glands 4 4.6‡ 1.2-12.5 0.5 3 18.9‡ 1.3 1 1.4 0.1 
      Pharynx 3 2.0 0.4-6.4 0.2 0 E 0.4§ -0.2 3 2.7 0.4 
           
Digestive tract 196 1.3‡ 1.1-1.5 7.2 27 1.9‡ 5.8 169 1.3‡ 8.0 
      Oesophagus 7 1.5 0.6-3.3 0.4 1 2.1 0.2 6 1.5 0.4 
      Stomach 33 1.3 0.9-1.8 1.1 8 4.4‡ 2.7 25 1.1 0.3 
      Colon 90 1.5‡ 1.1-1.8 4.5 10 1.8 2.0 80 1.5‡ 5.9 
      Rectum 36 1.3 1.0-2.0 1.1 7 2.0 1.5 29 1.2 0.9 
      Gall bladder 12 1.1 0.6-2.0 0.2 0 E 0.6§ -0.3 12 1.2 -0.4 
      Pancreas 16 1.1 0.6-1.8 0.2 1 0.7 -0.2 15 1.1 0.5 
           
Respiratory tract 36 1.2 0.9-1.7 1.0 12 2.0 2.6 24 1.0 0.1 
      Lung 34 1.3 0.9-1.8 1.1 11 2.0 2.5 23 1.1 0.4 
      Pleura 2 3.5 0.4-14.4 0.2 1 10.9 0.4 1 2.1 0.1 
           
Bone 2 3.2 0.4-13.5 0.2 2 21.6‡ 0.8 0 E 0.5§ -0.1 
Connective Tissue  6 3.2‡ 1.2 - 7.3 0.6 2 4.3 0.7 4 2.8 0.6 
Melanoma 21 1.8‡ 1.1 - 2.7 1.4 12 3.2‡ 3.7 9 1.1 0.2 
           
Breast 588 3.5‡ 3.2-3.8 63.9 255 6.3‡ 95.2 333 2.6‡ 47.6 
           
Urogenital tract 137 1.5‡ 1.2-1.7 6.6 40 2.5‡ 10.6 97 1.3 4.5 
     Cervix uteri 9 0.9 0.4-1.7 -0.2 5 1.8 1.0 4 0.5 -0.8 
     Corpus uteri 40 1.4 1.0- 1.9 1.8 8 1.6 1.4 32 1.4 2.0 
     Ovarium 43 1.7‡ 1.3-2.4 2.8 21 3.9‡ 6.9 22 1.1 0.6 
     Vagina Vulva 6 1.3 0.4-2.6 0.1 1 2.6 0.3 5 1.0 0 
      Kidney 17 1.2 0.7-2.0 0.5 2 1.1 0.1 15 1.2 0.7 
      Bladder 22 1.9‡ 1.2-2.9 1.6 3 3.5 0.9 19 1.8‡ 1.9 
           
Brain 6 1.2 0.5-3.2 0.2 3 2.6 0.8 3 0.8 -0.2 
Thyroid 2 0.8 0.1-3.3 -0.1 2 2.9 0.6 0 E 2.3§ -0.5 
           
Non-Hodgkin’s 
lymphoma 12 0.8 0.4-1.4 
 
-0.5 
 
3 
 
1.3 
 
0.3 
 
9 
 
0.7 
 
-1.0 
Myeloma 4 0.5 0.1-1.4 -0.6 1 1.4 0.1 3 0.4 -1.0 
Leukaemia 15 1.3 0.9-2.6 0.8 1 0.8 -0.1 14 1.7 1.3 
* SIR: standardised incident ratio 
** AER: Absolute excess risk per 10,000 person per year 
a Obs: Observed numbers of second primary cancers diagnosed in 1972-2001 
b 95% CI: 95 % confidence interval 
﻿ | Age at primary breast cancer diagnosis less than 50 years old 
† Age at primary breast cancer diagnosis more than or equal to 50 years old 
‡  95 % Confidence interval excludes 1 
§ E: Expected numbers of second primary cancers in the south of Netherlands 
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7.4. Discussion 
Our results confirm that women with a history of breast cancer have an elevated risk of 
secondary cancer. Every year, 115 excess cancers were diagnosed among 10,000 breast 
cancer patients. Higher risks of cancer of the salivary gland, bone, colon, breast, ovary, 
connective tissue and skin (melanoma) were observed for women with a previous diagnosis 
of breast cancer, particularly those diagnosed before the age of 50. Increased risks of 
second breast, colon and bladder cancer were evident for women diagnosed with breast 
cancer after the age of 50. 
 
We observed an elevated risk of second breast, ovarian, connective tissue and stomach 
cancer among breast cancer patients. Genetic factors may play a role in the explanation of 
these findings. The growth of breast 1 and ovarian cancer 24 has been found to be related to 
mutation of BRCA1 or BRCA2. However, genetic factors account for only 5-10% of cancer 
cases in the population, especially in young and middle-aged patients 25;26. Similarly, Li and 
Fraumeni identified a familial tendency for connective tissue cancer and breast cancer 27 and 
Dhillon observed the same familial pattern for gastric and breast cancer 28.  
 
The increased risk of salivary gland, bone, stomach, breast and connective tissue cancer 
could be related to the radiotherapy undergone by breast cancer patients as initial therapy 
8;11;12;15;29. Radiotherapy has been shown to cause second cancer especially in younger 
patients as might be demonstrated in our study 1. Unlike other studies, no elevation in the 
risk of endometrial cancer was found. 8;30-33. Use of tamoxifen, which is related to an 
increased risk of endometrial cancer, by breast cancer patients over 50 years was not 
initiated until the late 1980s 34. Our study began earlier, which might underestimate the risk 
of second endometrial cancer.  
 
The results of our study are consistent with findings from previous studies suggesting a 
higher risk of ovarian and colon cancer among breast cancer patients. The association 
between breast cancer and these cancers may be explained by the risk factors shared by 
these conditions, such as reproductive and dietary factors 35-38.  
 
An increased risk of melanoma was observed among breast cancer patients, particularly 
those diagnosed with breast cancer before menopause. Mutation of BRCA2 has been 
suggested as a possible determinant of the higher incidence of melanoma among breast 
cancer patients 39;40. In addition, elevated levels of oestrogen in women, which induced 
breast cancer in the first place, might stimulate melanogenesis resulting in an increased risk 
of melanoma 41;42. Finally, higher levels of radiation exposure during breast cancer treatment 
may partly contribute to the elevated risk of melanoma among these patients 43.  
 
The elevated SIR for bladder cancer observed in our study remains unexplained. Scattered 
radiation during breast cancer radiotherapy 13 and cyclophosphamide could possibly cause 
an increased risk of bladder cancer 3. However this treatment combination is more common 
among breast cancer patients below 50 years, whereas we observed a higher risk of bladder 
cancer among older women.  
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We found an excess of 115 second cancers for every 10,000 breast cancer patients per 
year, a slightly lower excess than that observed in a previous study in the United States 44. 
Our study comprises more recent data, which may indicate a reduction in second cancer 
risk. This may be due to an improvement in breast cancer treatment during recent decades 
or an increased awareness of second cancer in the population. Furthermore, our results 
indicate that a high risk for a certain cancer does not necessarily mean a substantial excess 
burden in the population. For instance, we found a marked increase in the risk of second 
salivary and bone cancers among women diagnosed before the age of 50. However, the 
absolute excess risks are rather low. On the other hand, AER for second breast and ovarian 
cancer in the same group are much higher, although their SIR’s are not as high as those for 
salivary or bone cancer.  This shows that monitoring for second breast and ovarian cancer 
may benefit the population more.  
 
Some limitations of our study should be considered. Firstly, we were able to collect data on 
the occurrence of second cancers, but we did not have individual exposure data on the most 
important risk factors associated with cancer. Thus, we were not able to assess the role of 
the prominent risk factors in the explanation of the increased risk of second cancer among 
breast cancer patients. Secondly, during the long follow-up period in our study, the approach 
to breast cancer treatment may have changed. For instance, intensive radiotherapy may 
have become less common during the last years of our study. Therefore, due to the fact that 
patients may have received different types of treatment during the study period, we may 
have underestimated the effect of some specific treatments on the second cancer risk.  
 
7.5. Conclusion 
Our study suggests that breast cancer patients have an elevated risk of second cancer of 
the breast, ovary, salivary gland, colon, connective tissue and skin, particularly at younger 
ages. On the other hand, an increased risk of certain cancers does not always correlate with 
a high absolute excess risk and burden for the population. Surveillance should be directed 
towards early detection of second breast and ovarian cancers among women diagnosed 
before the age of 50. Among older breast cancer patients, awareness of second breast and 
colon cancer should be increased. Further epidemiological research on possible 
explanations of multiple cancers is necessary. Such studies may serve as guidelines for 
rational follow-up programs for breast cancer patients.   
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Abstract 
 
Background and objectives: Incidence of breast carcinoma in situ (BCIS) has increased 
dramatically. However, studies on risk of cancer after BCIS diagnosis are scarce. We 
examined the risk patterns and determinants of second malignancies after BCIS and 
compared them with those after breast carcinoma.  
 
Methods: We calculated SIR (standardized incidence ratio), AER (absolute excess risk) and 
cumulative risk of second cancer after BCIS in 1972–2003 in Southern Netherlands.  
 
Results: Among 1276 primary BCIS patients diagnosed in 1972-2002, 11% developed a 
second cancer. BCIS patients exhibited a two-fold risk of second cancer (SIR: 2.1, 95% 
confidence interval [95% CI]: 1.7-2.5). The highest risk was found for a second breast cancer 
(SIR: 3.4; 95% CI: 2.6-4.3, AER: 66 patients/10,000/year) followed by skin cancer (SIR: 1.7; 
95% CI: 1.1-2.6, AER: 17 patients/10,000/year). The increased risk of second breast cancer 
was similar for the ipsilateral (SIR: 1.9; 95% CI: 1.3-2.7) and contralateral (SIR: 2.0; 95% CI: 
1.4-2.8) breast.  
 
Conclusions: Risk of second cancer was independent of age at diagnosis, type of initial 
therapy, histologic type of BCIS and period of diagnosis. SIR of second cancer after BCIS 
(SIR: 2.3 95% CI: 1.8-2.8) resembled that of after invasive breast cancer (SIR: 2.2 95% CI: 
2.1-2.4). Surveillance should be directed towards second (ipsi- and contralateral) breast 
cancer. 
 
 
Keywords: breast carcinoma in situ, population-based, risk, second cancer. 
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8.1. Introduction 
Diagnosis of in situ and early stage breast carcinoma has increased over the past decades 
in the Netherlands, partly as a consequence of screening 1. The incidence rate of DCIS 
(ductal carcinoma in situ) has increased from 0.3 per 100,000 in 1975 to 13.4 per 100,000 in 
1997 2. Women with previous breast cancer are known to carry a 2-fold risk of second 
cancer in comparison to the general population 3, 4. Studies assessing the risk of second 
cancer following the diagnosis of BCIS (breast carcinoma in situ) are however scarce or only 
focused on the risk of second breast cancer 5-9.  
 
Research has shown an increased risk of 2.0-7.2 for breast cancer following the diagnosis of 
BCIS 6, 10. The probability that a breast cancer will develop in BCIS patients is 26% after 20 
years of follow-up 9. This is as high as the risk of second breast cancer found for patients 
with malignant breast carcinoma 11. Excess risk of second breast cancer is not explained by 
treatment choice (i.e. radiotherapy) for BCIS 8, suggesting the role of a shared aetiology 
(hereditary or lifestyle) for both first and second cancer. In addition to second breast cancer, 
other cancers were diagnosed in 17% of DCIS and 3.2% of lobular carcinoma in situ (LCIS) 
patients 12. However, no previous studies assessed the risks of different types of second 
cancer in BCIS patients.  
 
The aim of the study is to assess the risk pattern for second cancer after diagnosis of BCIS 
and to compare it with that found for malignant breast carcinoma, thereby examining the 
impact of age, breast cancer screening policy at the time of primary BCIS diagnosis and 
treatment for various subtypes of BCIS.  
 
 
8.2. Materials and methods 
 
Data collection  
Data were obtained from the population-based ECR (Eindhoven Cancer Registry) that is 
located in southern Netherlands and covered 2.4 million inhabitants in 2004.  The cancer 
registry receives lists of newly diagnosed cases on a regular basis from the Pathology 
Departments in the region. In addition, lists of all hospitalised cancer patients were obtained. 
Active follow-up of vital status was conducted through the Central Bureau for Genealogy that 
receives data from municipal population registries. In the ECR, any new tumour, not 
classified as a recurrence or direct extension of a previously known tumour, is recorded as a 
new primary tumour. This registry is unique because it contains incidence data on first BCC 
(basal cell carcinoma) of the skin. A detailed description of the data collection has been 
presented elsewhere 3.  
 
Study population 
We identified 1402 women older than 25 years diagnosed with in situ breast cancer (ICD-O 
behaviour code /2) from 1 January 1972, through 31 December 2002. Among patients 
eligible for the study, those with less than 1 year follow-up time (n = 174) and those with 
unknown morphological code (n = 5) were excluded. End of follow-up was 31 December 
2003, date of death, date of last follow-up or date of second cancer diagnosis, whichever 
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occurred first. Thus, 1223 women remained for analysis, 143 of whom (11.2%) developed a 
second cancer, 170 (13.3%) died and 2 (0.2%) were lost to follow-up. The maximum follow-
up time was of 32 years. 
 
Statistical methods 
We calculated SIR (standardised incidence ratio) to measure the relative risk of developing 
second tumours by comparing the incidence of second cancer among patients with a 
diagnosis of BCIS to the incidence of similar cancer in the general population. We adjusted 
for age (in 5-year categories) and calendar year of BCIS diagnosis. The 95% confidence 
intervals (95% CI) were calculated using exact Poisson probability 13. We also calculated the 
absolute excess risk (AER) examining the excess incidence of second cancers per 10,000 
patients in each year 14. Furthermore, the cumulative risk of developing second cancer, 
which is the proportion of patients alive at time t who can be expected to develop a second 
cancer, was calculated using the life table method 15.  
 
The following categorization of BCIS histological type was made; LCIS (ICD-O 8520/2) and 
DCIS including Paget’s disease (ICD-O 8500/2, 8010/2, 8050/2, 8140/2, 8201/2, 8230/1, 
8501/2, 8503/2, 8504/2, 8507/2, 8521/1, 8523/2, 8540/2) 16. Year 1993 was considered the 
starting point of breast cancer screening, that was fully implemented in 1996 1, 17. Calculation 
of risk for the ipsilateral and contralateral second breast cancer was performed using only 
patients with information on laterality of first BCIS and second breast cancer (excluded for 
this analysis n = 52).  
 
SIRs for selected cancers after malignant breast cancer were obtained from a previous study 
done in ECR 3 and compared with that of BCIS in  the current study. In the earlier study, we 
estimated the risk of subsequent cancers in 9919 women diagnosed with malignant breast 
cancers in 1972-2000 followed until 2001. To allow comparison, we added second non-
melanotic skin cancer cases (BCC: 192 & Squamous Cell Carcinoma: 42) for the analysis of 
second skin cancer. We used similar method to calculate SIR and 95% confidence interval 
as explained before. A detailed description of this study has been described elsewhere 3. 
 
All statistical analyses were performed using SPSS 11.5 for Windows (Statistical Products 
and Service Solution, Inc, Chicago, IL, USA). 
 
 
Second cancer after in situ breast cancer 
117 
8.3. Results 
The mean follow-up time for the cohort was 6.3 years. A large proportion of BCIS patients 
was older than 50 years and was diagnosed with DCIS (95%) in 1993-2002 (table 8.1).  
 
Table 8.1. Characteristics at diagnosis of BCIS (breast carcinoma in situ) 
 
 BCIS 
Mean age at BCIS diagnosis 57.1 years 
Mean follow-up time 6.3 years 
 Subsequent cancer Total (%) 
 No (%) Yes (%)  
Age at BCIS diagnosis 
   ≤49 years  
   ≥50 years 
 
288 (26) 
822 (74) 
 
30 (27) 
83 (73) 
 
318 (26) 
905 (74) 
Initial treatment 
   No Radiotherapy 
   With Radiotherapy 
 
765 (69) 
345 (31) 
 
68 (60) 
45 (40) 
 
833 (68) 
390 (32) 
Follow-up 
   1-4 years 
   5-9 years 
   ≥10 years 
 
549 (49) 
396 (36) 
165 (15) 
 
64 (57)  
34 (30) 
15 (13) 
 
613 (50)  
430 (35) 
180 (15) 
Subtype of initial cancer 
   DCISa  
   LCISb 
 
1052 (95) 
58 (5) 
 
105 (93) 
8 (7) 
 
1157 (95) 
66 (5) 
Time of diagnosisc 
   1972-1992 
   1993-2002 
 
165 (15) 
945 (85) 
 
41 (36) 
72 (64) 
 
206 (17) 
1017 (83) 
Total 1110  113   1223 (100) 
 
a DCIS: ductal carcinoma in situ; b LCIS: lobular carcinoma in situ; c breast cancer screening in southern Netherlands 
began to have impact in 1993 1.  
 
 
 Table 8.2 shows the SIRs and AERs for second breast and other cancers. We found an 
increased risk of second breast cancer (SIR: 2.1 95% CI: 1.7-2.5) and other non-breast 
cancers (SIR: 1.4 95% CI: 1.1-1.9). An excess of 66 patients with second breast cancer for 
every 10,000 BCIS patients per year was observed. An increased risk of second breast 
cancer was found for both the ipsilateral (SIR: 1.9 95% CI: 1.3-2.7) and contralateral breast 
(SIR: 2.0 95% CI: 1.4-2.8). Almost a two-fold elevated risk of skin cancer (SIR: 1.7 95% CI: 
1.1-2.5) was found. 
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Table 8.2. SIR (standardized incidence ratio) and AER (absolute excess risk) for all second cancers diagnosed in 1972-
2003 following BCIS (breast carcinoma in situ) in southern Netherlands  
 
Relative and absolute risksa Site of second cancer 
Observed Expected SIR 95% CI AER 
All sites 113 54.4 2.1b 1.7-2.5 90 
All sites excluding breastc  52 36.2 1.4b 1.1-1.9 24 
Digestive Tractd 11 10.4 1.1 0.5-1.9 1 
   Stomach 3 1.6 1.8 0.4-5.3 2 
   Colon 6 5.2 1.2 0.4-2.5 1 
Lung 5 3.5 1.4 0.5-3.3 2 
Skine 27 15.8 1.7b 1.1-2.5 17 
   Melanoma 4 1.4 3.0 0.8-7.6 4 
   Basal Cell Carcinoma 22 12.8 1.7b 1.1-2.6 14 
Breast 61 18.1 3.4b 2.6-4.3 66 
    Ipsilateralf 29 15.5 1.9b 1.3-2.7 24 
    Contralateralf   31 15.5 2.0b 1.4-2.8 28 
Urogenital Tractg 4 7.2 0.6 0.2-1.4 -5 
    Ovary 2 2.5 0.8 0.1-2.8 -1 
Lymphoma and Multiple Myeloma 2 2.5 0.8 0.1-2.9 -1 
 
 
a excluding patients with less than 1-year follow-up; b 95 % confidence interval excludes 1; c 3 observed are primary 
cancers of unknown origin; d also includes: pancreas [1] and rectum [1]; e also includes: squamous cell carcinoma of the 
skin [1]; f only includes patients with known laterality of BCIS and second breast cancer; g also includes: corpus uteri [1] 
and bladder [1].   
 
A three- to four fold increased risk of second breast cancer was found during the first ten 
years of follow-up (table 8.3), which was relatively higher than the SIR for the last follow-up 
period (≥ 10 years). As for the risk of second non-breast cancer, we observed similar SIRs 
across all follow-up periods.  
 
Table 8.3. SIR (standardized incidence ratio) and AER (absolute excess risk) for second breast cancer and second 
other cancers after BCIS (breast carcinoma in situ), according to follow-up time.   
 
Second breast cancer Other second cancers Period of 
follow-up 
PYRa 
Obsb Expc SIR AER Obsb Expc SIR AER 
  1-4 years 3596 33 9.7 3.4d 65 31 18.9 1.6d 34 
  5-9 years 1815 22 5.0 4.4d 94 12 10.1 1.2 11 
  ≥ 10 years 1127 6 3.3 1.8 24 9 7.4 1.2 14 
 
a PYR: person-years; b Obs: observed numbers of second primary cancers; c Exp: expected numbers of second primary 
cancers; d 95% confidence interval excludes 1 
 
Increased risks of second breast or other cancers were not influenced by age at BCIS 
diagnosis, type of initial therapy, histological type of BCIS and time of BCIS diagnosis (table 
8.4). Ipsi- and contralateral breast cancer risks were slightly higher for BCIS patients who 
received radiotherapy (SIR: 2.1 95% CI: 1.0-4.0 & SIR: 2.4 95% CI: 1.2-4.3, respectively), 
compared to patients who did not receive radiotherapy (SIR: 1.7 95% CI: 1.1-2.8 & SIR: 1.8 
95% CI: 1.1-2.8). The cumulative 10-year risk of developing any second cancer was 17% 
(±5%), whereas the 15-year corresponding risk was 21% (±8%) (figure 8.1). 
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Figure 8.1. Cumulative risk of second cancer after the diagnosis of carcinoma in situ of the breast. a) All sites. b) Breast 
cancer. c) Other sites excluding breast. No. at risk represented patients still at risk at the beginning of each period  
a)
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Table 8.4. SIR (standardized incidence ratio) and AER (absolute excess risk) for all second cancers diagnosed 1972-
2003 following BCIS (breast carcinoma in situ) in southern Netherlands, according to women’s characteristics at the 
time of BCIS diagnosis   
 
Second breast cancer Second other cancers 
Characteristic PYRa 
Obsb Expc SIR AER Obsb Expc SIR AER 
Age at diagnosis 
   ≤ 49 years 
   ≥ 50 years 
 
2334 
4204 
 
20 
41 
 
4.9 
13.1 
 
4.0d 
3.1d 
 
65 
66 
 
10 
42 
 
6.6 
29.8 
 
1.5 
1.4d 
 
15 
29 
Treatment 
   No Radiotherapy 
   With Radiotherapy 
 
4474 
2064 
 
39 
22 
 
12.4 
5.6 
 
3.1d 
3.9d 
 
59 
79 
 
29 
23 
 
25.2 
11.1 
 
1.1 
2.1e 
 
8 
57 
Subtype of initial cancer 
   DCIS  
   LCIS 
 
 
6106 
432 
 
 
58 
3 
 
 
16.8 
1.2 
 
 
3.4d 
2.5 
 
 
67 
42 
 
 
47 
5 
 
 
34.3 
2.1 
 
 
1.4d 
2.4 
 
 
21 
67 
Time of diagnosis e 
   1972-1992 
   1993-2002 
 
2708 
3830 
 
24 
37 
 
7.0 
11.0 
 
3.4d 
3.4d 
 
63 
68 
 
17 
35 
 
14.4 
21.9 
 
1.2 
1.6d 
 
9 
34 
 
a PYR: person-years; b Obs: observed numbers of second primary cancers; c Exp: expected numbers of second primary 
cancers; d 95% confidence interval excludes 1; e breast cancer screening in southern Netherlands began to have impact 
in 1993 1.  
 
Figure 8.2 compares the SIRs for second cancer after BCIS with those after invasive breast 
cancer for selected malignancies. The SIRs for second cancer of the lung, colon, skin and 
breast after BCIS were similar to those after invasive breast cancer. The risk pattern of 
second cancer at all sites after BCIS (SIR: 2.3 95% CI: 1.8-2.8) were similar to that of 
second cancer after invasive breast cancer (SIR: 2.2 95% CI: 2.1-2.4). 
 
 
Figure 8.2. SIR (standardized incidence ratio) for second cancer among women diagnosed with breast carcinoma in situ 
and with invasive breast carcinoma 3 
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8.4. Discussion 
Women previously diagnosed with in situ breast carcinoma had an increased risk of second 
cancer, in particular second breast and skin cancer. An excess of 90 second cancers per 
10,000 BCIS patients was found. Similar to previous studies,10 we observed a 21% 
increased risk for a second cancer after 15 years of survival.  
 
Some limitations of our study should be considered. Firstly, as most women were diagnosed 
after 1993, the majority had less than 10 years of follow-up. Furthermore the absolute 
numbers of our study is relatively small. Thus, we may not have estimated correctly the long-
term risk of less common cancers such as ovarian cancer which exhibits an increased risk 
among long-term survivors of invasive breast cancer 18. Secondly, increased medical 
surveillance of women with a diagnosis of BCIS may have increased detection of second 
cancers 14. In our cohort 60% (30 patients) were diagnosed with second cancer within the 
first year after BCIS diagnosis. Therefore, we excluded patients with less than 1-year of 
follow-up and those with a second carcinoma in situ. Thirdly, AER in this article should be 
interpreted with caution because BCIS accounts for only approximately 13% of all breast 
cancer diagnoses 1. Thus, given the same AER, the absolute number of second cancers 
after BCIS will be considerably smaller than that after invasive breast cancer at the 
population level. Lastly, no individual data were available on risk factors for cancer 18. 
Hence, the contribution of these factors to the risk of second cancer could not be assessed. 
 
Risk pattern 
After the diagnosis of BCIS, there was an increased risk of second breast and skin cancer. 
The question is whether second malignancies share a common aetiology with the first 
cancer or whether they are associated with treatment for the first cancer 14. It is likely that 
factors including reproductive characteristics, lifestyle and genetic predisposition such as 
BRCA2 play a more important role in the excess risk of both second breast and skin cancer 
after BCIS 19, 20. We did not find an increased risk of second ovarian cancer among BCIS 
patients as in patients with malignant breast cancer. However, most patients in this study 
had less than 10 years of follow-up and the risk of ovarian cancer after breast cancer was 
highest after more than 15 years of follow-up 18.  
 
Determinants 
Age 
Age at the time of BCIS diagnosis did not seem to influence the risk for second cancer, 
although we observed a slightly higher risk of second breast cancer among women 
diagnosed with BCIS before age 50. A higher risk of second breast cancer has been found 
among in situ and malignant breast cancer patients diagnosed before the age of 50 6, 18. This 
is partly due to genetic predisposition, which usually becomes manifest at a relatively young 
age.  
Treatment 
The risk for second (ipsi- and contralateral) breast and other cancers was slightly higher 
among BCIS patients who received radiotherapy. Radiation after breast-conserving 
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treatment reduces recurrences in the ipsilateral breast, 21, 22 but its effect on the risk of new 
(ipsi- or contralateral) breast cancer is less conclusive 8, 23. We found only a slightly 
increased risk of second breast cancer after radiation that was not significantly different from 
that of patients without radiotherapy. Thus, the benefit of radiation after surgery for the 
overall survival of DCIS patients seems to outweigh the increased risk of second breast 
cancer 21.  
Screening 
The risk of second cancer after BCIS remained elevated and of a similar magnitude after 
implementation of the national screening policy in the Netherlands. In Sweden, the risk of 
second breast cancer increased at the beginning of the screening period and only 
decreased after long implementation of national screening 6. Thus, in the coming decades, 
we might observe a decrease in the risk of second cancer after BCIS.  
 
Comparison with invasive breast cancer cohort 
The pattern of second cancer after BCIS seems to be similar to that after malignant breast 
cancer. Cancers of the colorectum, ovarium, lung and skin were some of the most common 
cancers in women previously diagnosed with an invasive breast cancer 3. In the USA, 
colorectal, cervical and endometrial cancer were reported as the most prevalent cancers 
among BCIS patients 12. Thus, we could probably expect an increased incidence of second 
cancers resembling that of malignant breast cancer within a larger study population and a 
longer follow-up of BCIS cases.  
 
In conclusion, we found increased relative and absolute risks of second cancer after BCIS 
diagnosis, similar to that after invasive breast cancer. Monitoring for second breast cancer 
should be conducted in both the ipsilateral and the contralateral breast. Furthermore, 
prevention, such as lifestyle changes, maybe relevant for these patients and might lower the 
risk of second other cancers such as skin, lung and colorectal cancer. Nonetheless, our 
findings highlight the need to conduct further research on the determinants of second 
malignancies after BCIS in order to contribute to the development of strategies for the 
prevention of subsequent cancer. 
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Abstract  
 
Background and objectives: A cohort of 9919 breast cancer patients registered in the 
population-based Eindhoven registry was followed for vital status and development of 
second cancer.  
 
Methods: Person-year analysis was applied to determine the risk of second primary breast 
or urogenital cancer among breast cancer patients and to assess its relationship to age, 
treatment and time since the first breast cancer diagnosis.  
 
Results: Women with previous breast cancer have an elevated risk of overall second breast 
or urogenital cancer. The largest relative risk was observed for second breast cancer (SIR 
[Standardised Incidence Ratio]: 3.5; 95%CI: 3.2-3.8) and second ovarian cancer (SIR: 1.7; 
95%CI: 1.2-2.3). The absolute excess rate was highest for second breast cancer (64/10,000 
patients per year). On the other hand, breast cancer has an inverse relationship to risk of 
cervical cancer.  
 
Conclusion: Changes in behavioural risk factors are important for lowering the risk of 
second cancer after breast cancer.  
 
Keywords: breast cancer, long term, second primary breast or urogenital cancer, treatment.
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9.1. Introduction 
A history of breast cancer is a risk indicator for second primary cancer among women, 
especially for second primary breast and genital cancer. Higher risks of second breast 
cancer1;2, subsequent ovarian cancer2 and uterine cancer3;4 after primary breast cancer5 
have been found. However, the association with cervical cancer and cancer of the vagina-
vulva has not been well studied in detailed2. Only a few studies have shown an increased 
risk of second primary kidney and bladder cancer among breast cancer patients6;7. 
 
Examination of the association between breast cancer and second primary cancer may 
contribute to the development of preventive interventions. Understanding these issues may 
also help identify the treatment that carries the lowest risk of second cancer for breast 
cancer patients. In addition, it may also contribute to early detection of second cancer. 
Common risk factors, such as dietary habits, reproductive characteristics, exogenous 
oestrogen exposure and genetic factors play an important role in the aetiology of second 
female cancers, particularly breast, uterine and ovarian cancer8. Breast cancer treatments, 
such as radiotherapy, systemic chemotherapy6;9 and hormonal therapy, may be associated 
with a higher risk of certain second primary cancers among breast cancer patients. In 
addition, hormonal therapy with tamoxifen has been found to increase the risk of cancer of 
the uterine, in particular mixed mullerian tumours10-12.  
 
The effect of factors such as latency time, cancer treatment and the age at diagnosis, on the 
risk of second female cancer remains unknown. Our cohort comprises the most recent data, 
with a long follow-up time and a large number of cases. This enables us to assess the role of 
important risk factors in the development of second primary cancer. The aim of this 
population-based cohort study was to determine the incidence of second primary breast and 
urogenital cancers among breast cancer patients in the south of the Netherlands, compared 
to the incidence expected in the general population, and to relate this incidence to the initial 
breast cancer treatment, follow-up time, and age at breast cancer diagnosis.  
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9.2. Patients and methods 
Patients 
Breast cancer patients were obtained from the Eindhoven Cancer Registry in the south of 
the Netherlands. This is a population-based cancer registry, which covered almost 2.3 
million individuals in 2004. A detailed description of the data collection has been reported 
elsewhere 13.  
 
We excluded patients with less than 1 year of follow-up time (n=1458), patients with in situ 
primary breast cancer (n=458), patients with other malignancies diagnosed before breast 
cancer as well as patients with a second cancer that appeared to be a metastasis (n=44).  
For the calculation of risks of second ovarian cancer, patients who were oophorectomised as 
treatment for breast cancer were not included in the analyses (n=9). As a result, in the 
period 1972-2000, 9919 breast cancer patients older than 25 years were available for 
analysis. 
 
Analyses were stratified according to age at diagnosis of the initial tumour (categories: 
premenopause [age < 50 years] and postmenopause [age ≥ 50] years); initial treatment 
combination of breast cancer (categories: Surgery [S], radiotherapy ± S, chemotherapy ± S, 
hormonal therapy ± S, radiotherapy and chemotherapy ± S, radiotherapy and hormonal 
therapy ± S; and other treatments [chemotherapy and hormonal therapy ± S, radio- and 
chemo- and hormonal therapy ± S, no treatment and unknown treatment); and follow-up time 
after diagnosis (categories: 1-4 years, 5-9 years, 10-14 years and longer than 15 years). 
 
Methods  
The risk of developing a second cancer was investigated by means of person-years 
analysis, corrected for age and calendar-year period to the date of death, date of last follow-
up, date of diagnosis of the second cancer or end of the study (December 31, 2001) which 
ever came first 14. We compared the incidence of second primary tumours among patients 
with a diagnosis of breast cancer (the observed incidence) with the incidence for the same 
tumours in the general population (the expected incidence), which is expressed as the 
Standardised Incidence Ratio (SIR). Calculation of the expected subsequent primary cancer 
was derived from the same population, using EUROCIM 4.2. The statistical significance and 
95% confidence intervals were determined by means of exact Poisson probability15. The 
Absolute Excess Risk (AER) was calculated by subtracting the expected number from the 
observed number and then dividing the difference by person-years at risk (per 10,000 breast 
cancer patients/year)8. All statistical analyses were performed using SPSS 11.5 for Windows 
(Statistical Products and Service Solution, Inc, Chicago, USA). 
  
9.3. Results  
Our cohort yielded 65,938 person-years. General characteristics at the time of primary 
breast cancer diagnosis are shown in table 9.1. The average age at breast cancer diagnosis 
was 58.8 years, the average follow-up time was 6.6 years, and the median follow-up time 
was 4.9 years. Overall, 725 breast cancer patients developed second breast and urogenital 
cancer, compared to the expected 266 patients in the population (SIR: 2.7; 95%CI: 2.5-2.9) 
Second female cancer in breast cancer patients 
129 
(table 9.2). The relative risk of developing second urogenital cancer after excluding all 
second breast cancers was higher among breast cancer patients than in the general 
population (SIR: 1.9; 95%CI: 1.6-2.3). Markedly increased risks of second breast cancer 
(SIR: 3.5; 95%CI: 3.2-3.8) and ovarian cancer (SIR: 1.7; 95%CI: 1.2-2.3) were also observed 
among these patients. The absolute excess risk (AER) was highest for second breast cancer 
(64/10000 person years).   
 
Table 9.1. Characteristics at diagnosis of first primary female breast cancer patients, diagnosed in the south of the 
Netherlands, 1972-2000. 
 
Characteristics  Number (%) Second cancer  
(% of first primaries) 
Period of diagnosis of first primary 
   1972-1981  
   1982-1991 
   1992-2000 
 
2676 (27.0) 
3590 (36.2) 
3653 (36.8) 
 
267 (10.0) 
273 (7.6) 
185 (5.1) 
Age at diagnosis 
   < 50 years 
   ≥ 50 years 
 
2950 (29.7) 
6969 (70.3) 
 
295 (10.0) 
430 (6.2) 
Treatment combination 
    Surgery (S) 
    Radiotherapy ± S 
    Chemotherapy ± S 
    Hormonal therapy ± S 
    Radio- and chemotherapy ± S 
    Radio- and hormonal therapy ± S 
    Others  
 
2163 (21.8) 
4534 (45.7) 
301 (3.0) 
609 (6.1) 
865 (8.7) 
1214 (12.2) 
233 (2.3) 
 
181 (8.4) 
398 (8.8) 
12 (4.0) 
21 (3.5) 
52 (3.4) 
48 (4.0) 
13 (5.6) 
Follow-up period 
    1-4 years 
    5-9 years 
    10-14 years 
    ≥ 15 years 
 
5004 (50.4) 
2758 (27.8) 
1215 (12.2) 
942 (9.5) 
 
367 (7.3) 
205 (7.4) 
79 (6.5) 
74 (6.4) 
Total 9919 725 (7.9) 
 
 
Table 9.2. Observed (Obs) and expected (Exp) numbers of second primary female urogenital and breast cancers 
diagnosed in 1972-2001 and standardised incident ratio (SIR) with 95 % confidence interval (CI) for breast cancer 
patients in the south of the Netherlands, diagnosed 1972-2000. 
 
Site of second cancer Obs Exp SIR CI AER* 
All second cancer 725 265.9 2.7‡ 2.5 – 2.9 69.6 
     Female Urogenital  137 70.4 1.9‡ 1.6 – 2.3  10.1 
      
Breast 588 167.6 3.5‡ 3.2 - 3.8 63.8 
      
Female Genital tract      
     Cervix uteri 9 9.8 0.9 0.4 - 1.8 -0.1 
     Corpus uteri 40 31.1 1.3 0.9 – 1.8 1.4 
     Ovarium 43 25.2 1.7‡ 1.2 - 2.3 2.7 
     Vagina Vulva 6 4.2 1.4 0.5 - 3.2 0.3 
Female Urinary tract      
      Kidney 17 13.8 1.2 0.7-2.0 0.5 
      Bladder 22 16.7 1.3 0.8-2.0 0.8 
*   AER: Absolute Excess Risk per 10,000 patients/year 
‡   95 % Confidence interval excludes 1 
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Age 
In general, the increased risk of overall second urogenital cancer (SIR: 2.1; 95%CI: 1.9-2.3), 
second breast cancer (SIR: 2.6; 95%CI: 2.4-2.9) and second ovarian cancer (SIR: 1.1; 
95%CI: 0.7-1.7) was more marked among patients who were diagnosed with breast cancer 
before menopause (table 9.3). In contrast, no differences in the SIR were observed between 
patients diagnosed before and after menopause for second uterine, cervix, vagina-vulva, 
kidney and bladder cancer. A higher incidence rate and absolute excess of second breast 
and ovarian cancer were observed among women diagnosed before menopause.  
 
Table 9.3. Observed (Obs) and expected (Exp) numbers of second primary urogenital and breast cancers diagnosed in 
1972-2001, standardised incident ratio (SIR) and absolute excess risk (AER) among breast cancer patients according to 
age at breast cancer diagnosis in the south of the Netherlands, diagnosed 1972-2000. 
 
Pre-menopausal primary Post-menopausal primary 
Person years: 22,546 Person year: 43,392 Site of second cancer 
Obs Exp SIR AER† Obs Exp SIR AER† 
All second cancer 295 58.2 5.1‡ 105.0 430 207.7 2.1‡ 51.2 
     Female Urogenital  40 14.5 2.7‡ 11.3 97 55.8 1.7‡ 9.5 
         
Breast 255 40.8 6.3‡ 95.0 333 126.8 2.6‡ 47.5 
         
Female Genital tract         
     Cervix uteri 5 2.9 1.7 0.9 4 6.9 0.6 -0.7 
     Corpus uteri 8 5.7 1.4 1.0 32 25.3 1.3 1.5 
     Ovarium 21 5.5 3.8‡ 1.0 22 19.8 1.1 0.5 
     Vagina and vulva 1 0.5 2.2 0.2 5 3.8 1.3 0.3 
Female Urinary tract         
     Kidney 2 1.8 1.1 0.09 15 12.0 1.2 0.7 
     Bladder 3 1.8 1.7 0.5 19 14.9 1.3 0.9 
*  AER: Absolute Excess Risk per 10,000 patients/ year 
‡  95 % Confidence interval excludes 1 
 
Treatment  
The risk of second breast cancer was elevated for breast cancer patients receiving any 
treatment, compared to those undergoing surgical treatment (SIR: 3.4; 95%CI: 2.9-4.0). 
Treatment was not associated with the elevated risks of cervix, endometrial, vagina-vulva, 
kidney or bladder cancer compared to patients treated surgically (table 9.4).  
 
Furthermore, we assessed whether the excess risk of second breast and endometrial cancer 
among women aged 50 years and older receiving hormonal treatment ± radiotherapy was 
higher than the excess risk among women undergoing surgical treatment (data are not 
shown). We observed a significantly lower SIR for second breast cancer among women who 
received hormonal treatment ± radiotherapy (SIR: 1.6 95%CI: 1.2-2.2) than those who were 
treated surgically (SIR: 2.8; 95%CI: 2.3-3.4). In contrast, we observed a higher SIR for 
second endometrial cancer (SIR: 1.7; 95%CI: 0.7-3.4) among patients receiving hormonal 
treatment ± radiotherapy than among those undergoing surgical therapy (SIR: 0.7 95%CI: 
0.2-1.8).  
 
Second female cancer in breast cancer patients 
 
131 
Ta
bl
e 
9.
4.
 
Ob
se
rv
ed
 (O
bs
) a
nd
 
ex
pe
ct
ed
  (E
xp
) n
um
be
rs
 
of
 
se
co
nd
 p
rim
ar
y 
ur
og
en
ita
l c
an
ce
rs
 
di
ag
n
os
ed
 in
 1
97
2-
20
01
 
an
d 
st
an
da
rd
ise
d 
in
cid
en
t r
at
io
 (S
IR
) a
cc
or
di
ng
 
to
 
br
ea
st
 
ca
nc
er
 
tre
at
m
en
t f
or
 p
at
ie
nt
s 
dia
gn
os
ed
 
w
ith
 
br
ea
st
 
ca
nc
er
 
in
 th
e 
so
ut
h 
of
 
th
e 
Ne
th
er
la
nd
s 
in
 1
97
2-
20
0 
 
S
ur
gi
ca
l  
R
ad
io
th
er
ap
y 
a  
C
he
m
ot
he
ra
p
y 
b  
H
or
m
on
al
 th
er
ap
y 
c  
R
ad
io
- 
&
 C
h
em
ot
he
ra
p
y 
d
 
R
ad
io
- 
&
 
H
or
m
on
al
 
th
er
ap
y 
e  
O
th
er
s 
f  
Pe
rs
on
 
ye
ar
s:
 
17
,3
23
 
Pe
rs
on
 
ye
ar
s:
 3
3,
44
4 
 
Pe
rs
on
 
ye
ar
s:
 
16
76
 
Pe
rs
on
 
ye
ar
s:
 
24
89
   
Pe
rs
on
 
ye
ar
s:
 
45
90
 
Pe
rs
on
 
ye
ar
s:
 
56
11
 
Pe
rs
on
 
ye
ar
s 
: 
81
7 
S
ite
 o
f 
se
co
n
d 
ca
n
ce
r 
Ob
s 
Ex
p 
SI
R 
Ob
s 
Ex
p 
SI
R 
Ob
s 
Ex
p 
SI
R 
Ob
s 
Ex
p 
SI
R 
Ob
s 
Ex
p 
SI
R 
Ob
s 
Ex
p 
SI
R 
Ob
s 
Ex
p 
SI
R 
Al
l c
an
ce
r 
18
1 
72
.5
 
2.
5‡
 
39
8 
13
2.
6 
3.
0‡
 
12
 
5.
1 
3.
5‡
 
21
 
11
.5
 
1.
8‡
 
52
 
12
.
7 
4.
1‡
 
48
 
27
.
3 
1.
8‡
 
13
 
2.
8 
4.
6‡
 
Fe
m
al
e 
ur
og
en
ita
l 
29
 
19
.1
 
1.
5 
71
 
35
.
5 
2.
0‡
 
4 
1.
3 
3.
1 
3 
3.
2 
0.
9 
8 
3.
2 
2.
5‡
 
21
 
7.
3 
2.
9‡
 
1 
0.
7 
1.
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Br
ea
st
 
15
2 
45
.1
 
3.
4‡
 
32
7 
83
.
5 
3.
9‡
 
8 
3.
5 
2.
3 
18
 
8.
0 
2.
3‡
 
44
 
8.
8 
5.
0‡
 
27
 
17
.
0 
1.
6‡
 
12
 
1.
9 
6.
3‡
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fe
m
al
e 
ge
ni
ta
l  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ce
rv
ix 
ut
er
i 
2 
2.
7 
0.
8 
6 
5.
0 
1.
2 
0 
0.
2 
0 
0 
0.
4 
0 
1 
0.
6 
1.
6 
0 
0.
8 
0 
0 
0.
1 
0 
Co
rp
us
 u
te
ri 
7 
8.
4 
0.
8 
20
 
15
.
7 
1.
3 
1 
0.
6 
1.
8 
1 
1.
4 
0.
7 
3 
1.
3 
2.
3 
8 
3.
5 
2.
3 
0 
0.
3 
0 
Ov
ar
ium
 
13
 
6.
8 
1.
9 
22
 
12
.
9 
1.
7‡
 
2 
0.
5 
4.
2 
0 
1.
1 
0 
2 
1.
2 
1.
7 
3 
2.
6 
1.
1 
1 
0.
3 
4.
0 
Va
gin
a 
 
 
Vu
lva
 
2 
1.
3 
1.
5 
1 
2.
0 
0.
5 
0 
0.
1 
0 
1 
0.
3 
3.
5 
1 
0.
1 
8.
4 
1 
0.
4 
2.
4 
0 
0.
0 
0 
Fe
m
al
e 
Ur
ina
ry
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ki
dn
ey
 
1 
4.
0 
0.
3 
10
 
6.
9 
1.
5 
1 
0.
2 
5.
1 
0 
0.
7 
0 
0 
0.
4 
0 
5 
1.
5 
3.
3‡
 
0 
0.
1 
0 
 
Bl
ad
de
r 
4 
4.
9 
0.
8 
12
 
8.
1 
1.
5 
0 
0.
2 
0 
1 
1.
1 
0.
9 
1 
0.
5 
2.
2 
4 
1.
9 
2.
2 
0 
0.
2 
0 
‡  
 
95
 
%
 
Co
nf
id
en
ce
 
in
te
rv
al
 e
xc
lu
de
s 
1;
 
a  
Ra
di
ot
he
ra
py
 
±
 
S;
 
b  
Ch
em
ot
he
ra
py
 ±
 
S;
 c
 
Ho
rm
on
al
 th
er
ap
y 
± 
S;
 
d  
Ra
di
ot
he
ra
py
 a
nd
 c
he
m
ot
he
ra
py
 ±
 
S 
e  
Ra
di
ot
he
ra
py
 a
nd
 h
or
m
on
al
 th
er
ap
y ±
 
S;
 
f C
he
m
ot
he
ra
py
 
an
d 
ho
rm
on
al
 th
er
ap
y 
± 
S,
 
ra
di
o-
 
an
d 
ch
em
o-
 
an
d 
ho
rm
on
al
 th
er
ap
y 
±
 
S,
 
no
 tr
ea
tm
en
t a
nd
 u
nk
no
w
n 
tre
at
m
en
t 
Chapter 9 
 
 132 
Follow-up time 
The SIR for second breast cancer was 4.6 (95%CI: 4.0-5.1) during the first 4 years of follow-
up then it decreased steadily to 14 years of follow-up and then increased again after 15 
years (SIR: 4.7; 95%CI: 3.5-6.1) (figure 9.1). The SIR for ovarian cancer increased after 5-9 
years of follow-up (SIR: 2.2 95%CI: 1.2-3.7) and again after 15 years of follow-up (SIR: 5.5 
95%CI: 2.7-10.4). The SIR for cervical, endometrial, vagina-vulva, kidney, and bladder 
cancer did not vary according to follow-up time. However, after 5 years of observation, the 
SIR for cervical cancer remained below 1. 
 
 
Figure 9.1.  Standardised Incident Ratio (SIR) with 95 % Confidence Interval for second primary breast cancer and 
urogenital cancer diagnosed in 1972-2001 among breast cancer patients in the south of the Netherlands, diagnosed 
1972-2000.  
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9.4. Discussion  
Our results suggest that women diagnosed with a primary breast cancer are at increased 
risk of developing a second breast and ovarian cancer. This is in line with previous studies1;4-
6;16;17. Elevated risks were particularly marked among pre-menopausal women. In the south 
of the Netherlands (area of Eindhoven Cancer Registry), every year, 11 of every 1000 breast 
cancer patients develop second a cancer (I. Soerjomataram, Netherlands Institute of Health 
Sciences), half of which are second primary breast cancers. Common risk profiles, side-
effects of the initial breast cancer treatment and genetic factors have been proposed to 
cause the elevated risk of second female cancer in breast cancer patients.   
 
Age at first breast cancer diagnosis is an important determinant of the incidence of second 
breast and ovarian cancers: the risk for women diagnosed before the age of 50 was 
significantly higher than that observed for those diagnosed at older ages, as reported in 
previous studies6;18. This highlights the importance of female hormones in the pathogenesis 
of second breast and ovarian cancer. Nonetheless, other common risk factors, which initially 
induced the breast cancer, may also be involved in the aetiology of the second breast 
cancer, including genetic factors. BRCA1 and BRCA2 mutation would explain 5-10 % of 
breast and ovarian cancer cases19;20. 
 
Age at breast cancer diagnosis was closely related to the treatment choice. A higher risk of 
second uterine cancer in post-menopausal breast cancer patients taking on hormonal 
therapy was found, as has been reported by other authors11;17. Tamoxifen, a hormonal 
therapy, which has been widely used since the late 80’s for post-menopausal women, has 
been suggested to cause the increase in uterine cancer in breast cancer patients, although 
controversy exists4;10. In our study we found a decreased risk of second endometrial cancer 
after 15 years of follow-up, which might suggest a latency period of less than 15 years for 
tamoxifen to induce second endometrial cancer. 
 
However, the risk of second breast cancer among post-menopausal breast cancer patients 
who received tamoxifen was lower in comparison to that for women who underwent surgical 
treatment (SIR: 1.6 vs. 2.8). In addition to the side-effects of tamoxifen in inducing cancer of 
the uterine, some potential beneficial effects in post-menopausal breast cancer patients are 
now being examined: for example, the anti-oestrogenic role of tamoxifen in mammary cells 
was found to protect against second breast cancer9;21.  
 
We found an elevated risk of second breast cancer during the total follow-up period. It has 
been reported that after radiation there is a latency period of at least 10 years22. During the 
last decades, both radiotherapy and chemotherapy for breast cancer treatment have 
improved. This includes lower radiation dose, better protection of the normal tissue and more 
effective polychemotherapy regimens. These changes have diminished some side-effects of 
radiotherapy in breast cancer patients23. Our result supported this fact by showing no 
difference in second breast cancer risk between women who underwent surgical or 
radiotherapy.  
 
We observed declining risks of cervical cancer during the follow-up period, which reached 0 
in the last follow-up period. This may be related to the human papilloma virus’s (HPV) 
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latency period of ± 17 years (the time needed from infection to formation of invasive 
cancer)24, suggesting sexual behaviour changes among breast cancer women. Some 
authors have also noticed the lowered risk of cervical cancer among breast cancer 
patients2;5;18;25. In contrast to cervical cancer, breast cancer is observed more often among 
women with a higher socio-economic position and among women who had their first child at 
an older age26;27. This may also relate to the lower risk of cervical cancer in breast cancer 
patients.  
 
During 28 years of follow-up only 6 patients developed carcinoma of the vagina and vulva. 
These cancers are rare and represent only 7-8 % of gynaecological cancers26. 
Consequently, we could not draw any conclusion on the association between breast cancer 
and cancer of the vagina and vulva. However, vagina and vulva cancer have been related to 
HPV infection. The risk of second vagina and vulva cancer became 0 after a follow-up of 
more than 15 years, as found for second cervical cancer in our study. This suggests a 
possible inverse relationship between breast cancer and second vagina-vulva cancer. Breast 
cancer patients may change their lifestyle towards a healthier one that protects against 
vagina and vulva cancer.  
 
We could not find an excess risk for second primary kidney or bladder cancer after breast 
cancer. A few studies found a slightly increased risk of second kidney and bladder cancer 
among breast cancer patients6;7. Elevated kidney and bladder cancer risk was found for 
women receiving high radiation exposure in the pelvic area such as radiotherapy for cervical 
cancer28. The bladder is one of the organs that receives a considerable amount of scattered 
radiation during radiotherapy for breast cancer treatment29. However, this seems to be 
insufficient to induce bladder or kidney cancer.  
 
We could not collect information for some of the main risk factors such as reproductive 
characteristics or lifestyles of the patients and did not adjust for potential confounders or 
effect modifiers. Also, there may be some bias caused by metastases of the primary breast 
cancer. We expect this bias to be minimal because trained personnel from the cancer 
registry checked each patient’s medical record. 
 
In conclusion, our results show that breast cancer patients are at increased risk of 
developing second breast and ovarian cancer. Initial breast cancer treatment plays a limited 
role in causing second breast cancer, this suggesting a bigger role for common risk factors 
that induce both primary and second primary breast cancer. This stresses the importance of 
behaviour modification among breast cancer patients, in addition monitoring in order to 
prevent increased morbidity and mortality caused by second breast cancer. As for second 
ovarian cancer, women diagnosed with breast cancer before menopause may benefit from a 
longer follow-up directed to the early detection of second ovarian cancer. As our 
understanding of the relationship between risk factors and the occurrence of a second 
cancer develops, more questions will arise. Thus, extensive studies on multiple cancers will 
continue to play an important role in the medical sciences. Such studies may serve as a 
foundation for understanding the environmental and genetic determinants of cancer. 
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10.1. A cohort of skin cancer patients: a source for aetiological studies  
Skin cancer has been and largely still is, a disease on the increase. In Caucasian 
populations, it is the most commonly occurring malignancy. In the Eindhoven cancer registry, 
new primary basal cell carcinoma of the skin accounted for 18.7%, squamous cell carcinoma 
for 3.5% and melanoma for 2.7% of the total number of incident cancers in 2000-02.1 Many 
skin cancers are detected at an early stage where they can be easily and effectively treated 
and consequently the mortality and morbidity of these tumours is limited. The majority of 
these cancers, the non-melanoma skin cancers (basal cell and squamous cell carcinomas) 
have a low malignant potential, which also reduces their fatality. The relatively rare 
melanomas have a high malignant potential and a relative mortality between 15% and 20%. 
Melanoma accounts for the vast majority of the skin cancer fatalities, even though 
comprising at most 10% of all newly diagnosed skin cancer patients.1 
 
Incidence of all types of skin cancer in the Netherlands is expected to continue to rise in the 
near future2, placing an ever increasing burden on dermatologists and other health 
practitioners involved in the detection and treatment of skin cancer.  
 
Aetiology: Sunlight and skin cancer 
There is a linear relationship between the degree of sun exposure and squamous cell 
carcinoma of the skin.3, 4 However, the relationship between melanoma, the most aggressive 
type of skin cancer, and sunlight, is more complicated.4, 5 Intermittent sun exposure at young 
age causing severe sunburn seems most important in people with fair skin types, whereas a 
certain degree of chronic exposure may have a preventive effect.6-8 Moreover, sun exposure 
might be associated with increased survival, independent of Breslow thickness, mitotic index 
and anatomic location from cutaneous melanoma.9  
 
In addition to sun exposure, endogenous factors such as fair skin type, ability to tan and the 
number of both normal and atypical naevi, both congenital and acquired determine the 
development of a skin cancer.10   
 
Possibilities for research: skin cancer cohort as a tool for aetiological studies 
The combination of its high incidence rates and low case-fatality rates makes skin cancer, 
besides being the most commonly occurring cancer, also the most prevalent cancer (figure). 
According to estimations, the age-standardised 20-year prevalence of melanoma in the 
Netherlands will be about 206 for males and 544 for females in the year 2015 a doubling 
since 2005.11 The prevalence of SCC and BCC is unknown, but should be much higher, 
because of the lower mortality and for BCC also much higher incidence.2 Cohorts of skin 
cancer patients can contribute to further research in a large group of patients i.e. for studies 
on the occurrence of multiple cancers. The interest in multiple cancer studies is derived from 
its use to give indication of follow-up strategies of patients, such as monitoring for new 
cancer occurrence or on adverse effects of the potentially carcinogenic treatment of the first 
cancer. It may therefore be of great value to provide etiological insight for cancer in general. 
The advantage of using a skin cancer cohort is its low case-fatality and non-aggressive 
treatment, hence a perfect cohort to study the role of environmental or genetic factors 
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without confounding of mostly surgical treatment. Radiotherapy or chemotherapy is applied 
only in a small proportion of patients with nodal involvement or metastasis.12-14  
 
 
Figure. 1-, 5-, 10-, and 20-years melanoma and squamous cell carcinoma of the skin prevalence on January 1st 2003 in 
the Eindhoven Cancer Registry East.1 
 
Protective role of UV exposure on cancer  
There has been growing evidence on the beneficial effect of sun exposure on reducing the 
risk of some major cancers including prostate, colorectal and breast cancer. Knowing that 
skin cancer patients have received substantial amounts of UV-exposure during their lifetime, 
cohorts of skin cancer patients are a valuable starting point to test hypotheses regarding 
sunlight and cancer aetiology. 
 
A recent review of studies concerning sun exposure and cancer, excluding skin cancer, 
reported that the available evidence on a risk reducing effect of sun exposure for colon 
carcinoma is quite convincing15. For prostate, breast, and ovarian cancer, in addition to 
ecologic studies, several case-control and prospective studies were available, all showing a 
significantly inverse correlation between sunlight and mortality and/or incidence. In contrast, 
for non-Hodgkin lymphoma (NHL) mortality and sunlight conflicting results were reported, 
though all case-control and prospective studies found a significant inverse association 
between the incidence of NHL and sunlight. The north-south gradients showed in the 
ecologic studies and the finding that increased chronic exposure gave increased protection 
suggests a dose-response curve between sunlight and the incidence and/or mortality from 
these cancers: the more sunlight received, the higher the preventive effect.16  
 
As an explanation for the preventive effect of sunlight on cancer, usually the role of UVB in 
Vitamin D (Vit D) synthesis is given. Most humans obtain 80-90% of their requirement for Vit 
D through UV-exposure, mostly via sunlight; few types of food (mainly oily fish) naturally 
contain Vit D and only in fish-consuming populations a major part of Vit D is ingested with 
fish oil.  
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Vit D3 is synthesized from its precursor 7-dehydrocholesterol in the skin by the direct action 
of sunlight. The steroid hormone 1,25(OH)2D3 is much more active than its precursors and is 
produced by 25-hydroxylation of Vit D3 in the liver, followed by 1α-hydroxylation in the 
kidney.17 Vit D is a well-known regulator of cell proliferation and differentiation, apoptosis, 
tumour invasion and angiogenesis and consequently it is a potential candidate to regulate 
cancer progression. The risk of colorectal, prostate and breast cancer have been examined 
directly in relation to Vit D status exhibiting an inhibiting effect on colorectal 
carcinogenesis.15, 18, 19 In addition, both epidemiological and biological data support a role for 
Vit D in the prevention of breast20, 21 and probably prostate cancer.22 
 
Besides the above-described mechanism of a potential protective mechanism, there are 
other ways in which sun exposure may influence cancer risk. The Vit D production in the skin 
is controlled by a self-regulating mechanism, preventing hypervitaminosis D, which can 
cause liver- and kidney damage. As dose-response curves were found for sun exposure and 
cancer risk, it seems therefore likely that other mechanisms also play a role. Sunlight is 
known to influence the circadian rhythm of the body23 and the functioning of the immune 
system. 
 
Furthermore, multiple cancer studies within a skin cancer cohort may also provide clues on 
other aspects of the aetiology of skin cancer itself, by assessing the relationship with other 
cancers, with well-identified risk factors, such as smoking and viral infections.  
 
Smoking 
Smokers were reported to have a 2-fold increased risk of SCC as compared to non-
smokers.24 On the other hand, no clear association between smoking and basal cell 
carcinoma25 or melanoma was found.24 Consistently, a 20-50% higher risk of lung cancer 
has been observed among cohorts of SCC patients.26-29 This supports the studies reporting 
the association between cigarettes smoking and risk of squamous cell carcinoma of the 
skin.24 In contrast to melanoma, which is most prevalent among higher socio-economic 
classes, smoking prevalence and lung cancer incidence are more common among the lower 
socio-economic groups. Moreover, melanoma and lung cancer do not share known risk 
factors,30 therefore, risk of second lung cancer in CM patients is expected to be close to 
unity.31  A similar observation was reported in BCC patients.29, 32 
  
Viral infections 
Current evidence is clear on the role of human papillomavirus as the main cause of 
anogenital cancers such as cervical cancer and probably also head and neck cancers. 
Studies have demonstrated a clustering of cervical, head and neck cancer, rectal and 
squamous cell carcinoma of the skin, leading to the hypothesis that skin cancer (SCC) might 
be related to viral infection such HPV.33 Consistently, SCC patients exhibited a 3-fold risk of 
anogenital and oral cancer. Though here smoking may have biased the results as it is 
correlated to oral, anogenital and SCC, this finding presents a starting point to investigate 
the role of HPV infection in the development of SCC.34  
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Hereditary factors in the occurrence of skin cancer 
Many studies have shown the importance of a hereditary component in the development of 
melanoma. A family history of melanoma confers to 2-fold risk of melanoma.35 In contrast to 
patients with only one primary melanoma, those who suffered from multiple melanomas had 
a higher familial occurrence of this cancer: only 3.8% of patients with one primary melanoma 
had a positive family history as compared to 15% among patients with multiple 
melanomas.36 Patients with a family history of melanoma had a 5 times higher risk of 
multiple melanomas as compared to those lacking family history.36 On the other hands risk 
of a second melanoma among those without a family history was also higher than expected. 
The majority of cases with multiple melanoma lacked a family history, suggesting the 
stronger role of common risk factor and/or a polygenic model to explain their occurrence.  
 
Furthermore, an increased risk of melanoma among female breast cancer cohort,37 and vice 
versa, has been, among others, attributed to mutations in BRCA2 and CDKN2A.38, 39 Among 
young breast cancer patients the increased risk of melanoma is higher than that of the older 
patients with breast cancer, being consistent with a genetic-related cancer risk profile.40 
Such finding may enable us to identify a group of patients with a higher risk of a second 
cancer and may ultimately improve survival by early detection.  
 
10.2. Conclusion 
Most population-based cancer registries in the world collect information on cutaneous 
malignant melanoma and squamous cell skin cancer; fewer collect reliable information on 
the occurrence of basal cell non-melanoma skin cancers. Because of the presence of a 
dermatologist in the initiating phase the Eindhoven cancer registry who attempted to record 
all newly diagnosed first primary skin cancer cases since the 1950’s, this registry constitutes 
an important source of data for studies in the field of skin cancer.  
 
Due to the large number of patients inflicted with skin cancer, this group has become a 
valuable group to study the occurrence of multiple cancers. Beside of clinical importance 
serving as base for follow-up strategy, such study may provide etiological clue of skin cancer 
or other cancers in general.  
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Abstract  
 
Background and objectives: UV exposure may reduce the risk of colorectal and breast 
cancer due to rising vitamin D levels. Because skin cancer is positively related to sun 
exposure, we hypothesized a lower incidence of breast and colorectal cancer after skin 
cancer diagnosis. 
 
Method: Using data collected by the population-based cancer registry in the southern 
Netherlands, we analysed the incidence of colorectal and breast cancer among 26,916 
newly diagnosed skin cancer patients (4089 squamous cell carcinoma (SCC), 19,319 basal 
cell carcinoma (BCC), 3,508 cutaneous melanoma (CM)). Standardized incidence ratios 
(SIR) were calculated to compare cancer risk with that of the general population.    
 
Results: A markedly decreased risk of colorectal cancer was found for subgroups 
supposedly associated with the highest accumulated sun exposure i.e. men (SIR:0.83, 
95%CI:0.71-0.97), patients with SCC (SIR:0.62; 95%CI:0.43-0.93), older patients at SCC 
diagnosis (SIR:0.59, 95%CI:0.37-0.88), and patients with a SCC or BCC lesion on the head 
and neck area (SIR:0.59, 95%CI:0.36-0.92 for SCC and SIR:0.78, 95%CI:0.63-0.97 for 
BCC). This reduced risk was most pronounced during the first year after diagnosis, gradually 
normalizing. Furthermore, patients with CM exhibited an increased risk of developing a 
subsequent breast cancer, especially advanced breast cancer (SIR:2.20, 95%CI:1.10-3.94), 
mainly patients who developed CM after the age of 60 (SIR:1.87, 95%CI:1.14-2.89). 
 
Conclusions: Decreased risk of colorectal cancer was most pronounced for males and SCC 
cases, suggesting a protective role of continuous sun exposure. The higher risk of breast 
cancer among CM patients may be related to socio-economic class, both being more 
common in the affluent group. 
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11.1. Introduction 
 
Colorectal and breast cancer are two of the most common cancers worldwide.1 
Geographical variation in their occurrence has led to the theory of a beneficial effect of 
greater sun exposure on the incidence of and mortality from breast and colorectal cancer.2, 3 
Because the majority of skin cancers are caused by exposure to ultraviolet (UV) radiation, 
we expect a lower risk of colorectal and breast cancer for skin cancer patients compared to 
the general population.4, 5  
 
The inverse association between UV exposure and some cancers - including breast and 
colorectal cancer - was derived mainly from ecological studies, reporting a north-south 
gradient with higher cancer occurrence or mortality in less sunny areas compared to sunnier 
areas.2, 3, 6 These studies may have been confounded at the group level, being unable to 
adjust for regional differences between other risk factors. For example, fish intake may 
reduce the risk of colorectal cancer 7 and fish is probably more widely available in coastal 
areas where it is sunnier. Studies on the association between sunlight and cancer incidence 
or mortality with information on individual sun exposure generally found a preventive effect 
on breast and colorectal cancer.6 However, out of 5 case-control and cohort studies only one 
demonstrated a significant reduction of death from breast or colorectal cancer. A meta-
analysis of the risk of cancer after skin cancer showed a significant reduction of colon cancer 
among patients with previous squamous cell carcinoma of the skin, but not when stratified 
according to gender and not for breast cancer.8    
 
In this study we investigated the association between sun exposure and risk of colorectal 
and breast cancer by assessing the risks of these cancers following skin cancer. Analyses 
were performed for all skin cancer patients combined as well as stratified according to skin 
cancer type (squamous cell carcinoma (SCC), basal cell carcinoma (BCC), and cutaneous 
malignant melanoma (CMM)). We expected to observe lower risks of colorectal and breast 
cancer among patients who are typically associated with more chronic sun exposure: 
patients with SCC, elderly skin cancer patients and patients with skin cancer on the head or 
the neck area.9 Furthermore, we also examined the relative risk of breast and colorectal 
cancer according to time since skin cancer diagnosis and stage of breast and colorectal 
cancer at the time of their diagnosis: if sunlight not only protects against the occurrence of 
cancer but also slows down the progression, then one would expect to see a decreased 
incidence of specifically advanced disease. In addition we analysed separately the risk for 
colon and rectal cancer following diagnosis of the three skin cancer types.  
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11.2. Methods 
 
Data  
We retrieved data on patients with skin cancer who were diagnosed with a first primary in 
southern Netherlands between 1972 and 2002. Patient data were recorded within the 
framework of the population-based Eindhoven Cancer Registry that now covers almost 2.4 
million inhabitants. The registry is regularly notified about new cancer cases by the 
pathology and haematology departments in the region. Detailed patient data were obtained 
from the hospitals and active follow-up of vital status for each patient was conducted through 
the Central Bureau for Genealogy. Within this study patients were followed until January 1, 
2004, date of a second primary cancer diagnosis, date of death or lost to follow-up. Follow-
up for vital status of patients with basal cell carcinoma (BCC) was started in 1990, thus for 
this cohort time at risk began in that year. Coding of multiple tumours was adopted from the 
rules proposed by the IARC (International Agency for Research on Cancer).10   
 
Statistical analysis 
In order to determine whether skin cancer patients were at a higher or lower risk of 
developing cancers than the general population, we compared the incidence of breast 
(females only) and colorectal cancer (both sexes) among these patients (observed 
incidence) to the incidence of the same tumours in the reference population. The expected 
incidence was calculated adjusting for gender, age (in 5-year age categories) and calendar 
time at skin cancer diagnosis. Standardized incidence ratios (SIR) were computed by 
dividing the observed incidence rates by the expected incidence rates. Confidence interval 
(95%) was calculated using exact Poisson probability.11     
 
We computed SIR for: (1) skin cancer type (SCC, BCC and CM) (2) sex (male and female); 
(3) age at diagnosis of skin cancer (aged <60 vs. ≥60 years); (4) location of skin cancer (the 
head and neck area (not including lip cancer) vs. other body sites); (5) colon and rectum, 
separately (6) duration of follow-up until occurrence of breast or colorectal cancer (0-1 year, 
1-2 years, 2-3 years, 3-4 years, 4-5 year, and 5+ years); and (7) stage of colorectal and 
breast cancer (colorectal: stage I and II vs. stage III and IV vs. unknown; similar for breast). 
 
The tumour, node and metastasis (TNM) classification system was used. We excluded 
patients with missing information on body site (unknown-location squamous cell carcinoma: n 
= 20 (0.5%), basal cell carcinoma: n = 60 (0.3%), cutaneous malignant melanoma: n = 122 
(3.4%); this exclusion did not significantly influence results). We finally had 26,916 patients 
with a previous skin cancer diagnosis in our analysis. 
 
In addition, we calculated the risk of lung cancer for our skin cancer cohort to test the 
consistency of our hypothesis, since lung cancer has not been observed to be associated 
with sun exposure. On the contrary: we expected an increased risk of lung cancer in the 
cohort of SCC patients since cigarette smoking is a risk factor for both 12. A decreased risk of 
lung cancer was expected among CM patients because the higher socio-economic group, 
which has the highest CM incidence, smoked less.13  
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11.3. Results 
Women were diagnosed more frequently with CM but less often with SCC. Nonmelanoma 
skin cancer patients (NMSC: SCC and BCC) were generally older than CM patients and 
lesions were found more often on the head and neck area (table 11.1). Of the 4089 patients 
with SCC, 43 and 22 were diagnosed with colorectal and breast cancer, respectively, during 
21,098 person-years of follow-up. Among 19,319 BCC cases with a follow-up of 111,098 
person-years, a total of 224 colorectal and 174 breast cancers were diagnosed, and among 
3508 CM patients 24 and 40 were subsequently diagnosed with colorectal and breast 
cancer, respectively.  
 
Table 11.1. Characteristics of patients with skin cancer diagnosed in southern Netherlands in 1972-2002* 
Skin cancer types   
SCC BCC CM Total 
No. of person-years 21,098 111,098 24,091 156,287 
No. of patients (% of total) 4089 (15) 19,319 (72) 3508 (13) 26,916 
Median age (years)     
  At skin cancer diagnosis 74.1**  65.6 50.8 65.6 
  At colorectal cancer diagnosis  75.4 74.7 68.0 74.3 
  At breast cancer diagnosis  72.6 68.1 64.4 67.9 
Median follow-up (years) 3.8  5.2 5.4 5.0 
     
Gender      
  Male (%) 2620 (64) 9501 (49) 1420 (40) 13,541 (50) 
  Female (%) 1469 (36) 9818 (51) 2088 (60) 13,375 (50) 
     
Age at diagnosis     
   <60 years (%) 610 (15) 7094 (37) 2422 (69) 10,126 (38) 
   ≥60 years (%) 3479 (85) 12,225 (63) 1086 (31) 16,790 (62) 
     
Location     
   Head and neck (%) 2975 (73) 14,248 (74)  497 (15)  17,720 (67) 
   Others (%) 1094 (27) 5011 (26) 2889 (85) 8994 (33) 
     
Second cancers     
  Colorectal (%) 43 (66) 224 (56) 24 (37) 291 (55) 
  Female breast (%) 22 (34) 174 (44) 40 (63) 236 (45) 
  Total  (% of total) 65 (12) 398 (75) 64 (12) 527 (100) 
* BCC patients derived from patients diagnosed in 1990-2002 
** Female patients with SSC who developed second breast cancer were diagnosed with SCC at (median) age of 69.7 
years 
 
Table 11.2 shows the numbers of colorectal cancer cases occurring in the skin cancer 
cohorts and the corresponding SIR for men and women together and separately according 
to various tumour characteristics. We observed a decreased risk of colorectal cancer 
especially among men with a previous SCC compared to the general population (SIR: 0.62 
95%CI: 0.43-0.93). Men who were older than 60 years at SCC diagnosis (SIR: 0.59 95%CI: 
0.37-0.88) and who were diagnosed with SCC on the head or neck area (SIR: 0.59 95%CI: 
0.36-0.92) showed a significantly lower risk of colorectal cancer. In addition, males 
diagnosed with BCC on the head and neck exhibited a lower risk of colorectal cancer 
compared to the general population (SIR: 0.78; 95%CI: 0.63-0.97). SCC and BCC patients 
exhibited a significantly decreased risk of stage I and II colorectal cancers. The separate risk 
estimates for colon and rectal cancer after skin cancer are presented in table 11.3. A 35% 
reduction in the risk of colon cancer was observed (SIR: 0.64; 95%CI: 0.42-0.94).   
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Table 11.2. Primary colorectal cancer in skin cancer patients diagnosed between 1972 and 2002* and followed until 
2004, according to gender 
Total Men Women  
Cases SIR 95%CI Cases SIR 95%CI Cases SIR 95%CI 
All skin cancers 291 0.89 0.79-0.99 162 0.83 0.71-0.97 129 0.97 0.81-1.15 
 SCC 43 0.69 0.50-0.94 28 0.64 0.43-0.93 15 0.81 0.45-1.34 
 BCC 224 0.93 0.81-1.06 122 0.87 0.73-1.04 102 1.01 0.82-1.22 
 CM 24 0.95 0.61-1.42 12 1.05 0.54-1.83 12 0.87 0.45-1.52 
          
SCC          
 Age at diagnosis          
   <60 years 8 1.38 0.60-2.72 5 1.15 0.37-2.69 3 2.05 0.42-6.00 
   ≥60 years 35 0.62 0.43-0.87 23 0.59 0.37-0.88 12 0.71 0.36-1.23 
 Location          
   Head and neck 32 0.70 0.48-0.99 20 0.59 0.36-0.92 12 0.98 0.51-1.71 
   Others 11 0.70 0.35-1.26 8 0.83 0.36-1.64 3 0.50 0.10-1.45 
 Colorectal cancer stage         
   1 & 2 20 0.63 0.38-0.98 12 0.53 0.27-0.94 8 0.87 0.38-1.77 
   3 & 4 16 0.71 0.40-1.16 10 0.64 0.30-1.19 6 0.87 0.32-1.98 
   Unknown 7 0.93 0.37-1.99 6 1.19 0.44-2.71 1 0.41 0.01-2.98 
          
BCC          
 Age at diagnosis          
   <60 years 39 1.08 0.77-1.48 23 1.12 0.71-1.68 16 1.03 0.59-1.68 
   ≥60 years 185 0.90 0.78-1.04 99 0.83 0.68-1.01 86 1.00 0.80-1.24 
 Location          
   Head and neck 167 0.88 0.75-1.02 87 0.78 0.63-0.97 80 1.01 0.80-1.25 
   Others 56 1.13 0.85-1.47 35 1.25 0.87-1.74 21 0.98 0.61-1.50 
 Colorectal cancer stage         
   1 & 2 94 0.75 0.61-0.92 57 0.77 0.58-0.99 37 0.72 0.51-1.00 
   3 & 4 114 1.19 0.99-1.44 56 1.03 0.78-1.34 58 1.42 1.08-1.84 
   Unknown 16 0.79 0.45-1.30 9 0.83 0.38-1.62 7 0.75 0.30-1.60 
          
Melanoma          
 Age at diagnosis          
   <60 years 11 1.06 0.53-1.89 6 1.37 0.50-2.99 5 0.83 0.27-1.94 
   ≥60 years 13 0.88 0.47-1.50 6 0.85 0.31-1.85 7 0.90 0.36-1.85 
 Location          
   Head and neck 5 0.95 0.31-2.22 3 1.05 0.22-3.07 2 0.83 0.10-3.01 
   Others 19 0.97 0.58-1.51 9 1.07 0.49-2.03 10 0.89 0.43-1.65 
 Colorectal cancer stage         
   1 & 2 13 1.01 0.54-1.72 5 0.84 0.27-1.96 8 1.15 0.50-2.27 
   3 & 4 11 1.06 0.53-1.89  7 1.52 0.61-3.12 4 0.69 0.19-1.76 
   Unknown - - - - - - - - - 
* BCC patients derived from patients diagnosed in 1990-2002 
 
 
The risk of breast cancer among women previously diagnosed with skin cancer is given in 
table 11.4. SCC patients showed a lower breast cancer risk compared with the other skin 
cancer types, with SIR: 0.87 vs. 0.99 vs. 1.19, among SCC, BCC and CM patients, 
respectively. Risks tended to be lower among those diagnosed with SCC after the age of 60 
(SIR in patients ≥60: 0.66 vs. SIR in patients <60: 1.98) and when SCC was located on the 
head and neck area (SIR SCC on head and neck area: 0.79 vs. SIR SCC on other body 
parts: 0.92). More than two-thirds of the women were diagnosed with stage I and II breast 
cancer. Those diagnosed with BCC showed a decreased risk of breast cancer stage III and 
IV (SIR: 0.53; 95%CI: 0.30-0.88). In contrast, CM patients had an increased risk of stage III 
and IV breast cancer (SIR: 2.20; 95%CI: 1.10-3.94). Older CM patients exhibited a 90% 
higher risk of breast cancer compared to the general female population in southern 
Netherlands (SIR: 1.87; 95%CI: 1.14-2.89). 
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Table 11.4. Primary female breast cancer in skin cancer patients diagnosed between 1972 and 2002* and followed until 
2004 
 
 Cases SIR 95%CI 
All skin cancers 236 1.01 0.88-1.14 
 SCC 22 0.87 0.54-1.31 
 BCC 174 0.99 0.85-1.15 
 CM 40 1.19 0.85-1.63 
    
SCC    
 Age at diagnosis    
   <60 years 8 1.98 0.85-3.89 
   ≥60 years 14 0.66 0.36-1.10 
 Location    
   Head and neck 13 0.79 0.42-1.35 
   Others 8 0.92 0.40-1.81 
 Breast cancer stage    
   1 & 2 16 0.86 0.49-1.40 
   3 & 4 5 0.97 0.31-2.27 
   Unknown 1 0.60 0.02-3.32 
    
BCC    
 Age at diagnosis    
   <60 years 60 1.01 0.77-1.30 
   ≥60 years 114 0.98 0.81-1.18 
 Location    
   Head and neck 124 0.95 0.79-1.13 
   Others 50 1.12 0.83-1.48 
 Breast cancer stage    
   1 & 2 154 1.09 0.92-1.27 
   3 & 4 15 0.53 0.30-0.88 
   Unknown 5 0.83 0.27-1.94 
    
Melanoma    
 Age at diagnosis    
   <60 years 20 0.88 0.53-1.35 
   ≥60 years 20 1.87 1.14-2.89 
 Location    
   Head and neck 6 1.38 0.50-2.99 
   Others 34 1.18 0.82-1.65 
Breast cancer stage    
   1 & 2 26 0.94 0.62-1.38 
   3 & 4 11 2.20 1.10-3.94 
   Unknown - - - 
* BCC patients derived from patients diagnosed in 1990-2002 
 
 
When considering time since non-melanoma skin cancer (NMSC: SCC and BCC) diagnosis 
(table 11.5), the risk of developing a subsequent colorectal or breast cancer slowly increased 
with time and was lowest during the early years after skin cancer diagnosis. Within the first 
year of skin cancer diagnosis the risk of colorectal cancer was 30% lower than that of the 
general population (SIR: 0.71 95%CI: 0.49-0.99). After 4 years the risk became similar to 
that of the general population. For CM patients we found a 40% reduced risk of colorectal 
cancer during the first two years after diagnosis, followed by an increased risk in later years, 
but these results were not significant (data not shown). For breast cancer, we observed a 
significantly increased risk during the first year after diagnosis of CM (10 breast cancer 
cases, SIR: 2.62 95%: 1.25-4.81).  
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Table 11.5. Risk of second colorectal or female breast cancer following nonmelanoma skin cancer according to time 
since skin cancer diagnosis 
Site of second primary cancer 
Colorectum Female breast 
Time since 
skin cancer 
diagnosis  
Cases SIR 95%CI Cases SIR 95%CI 
0-1 year 35 0.71 0.49-0.99 31 0.95 0.65-1.36 
1-2 years 37 0.78 0.55-1.08 26 0.83 0.54-1.22 
2-3 years 33 0.78 0.53-1.10 28 0.98 0.65-1.43 
3-4 years 32 0.90 0.62-1.28 24 1.00 0.64-1.50 
4-5 years 34 1.14 0.79-1.60 22 1.09 0.68-1.67 
≥5 years 96 0.97 0.79-1.19 65 1.01 0.78-1.29 
 
 
In our skin cancer cohorts 361 patients developed lung cancer, 86, 263, and 12 in SCC, 
BCC and CM patients, respectively (data not shown). We observed an increased risk of lung 
cancer after SCC (SIR: 1.21 95%CI: 0.97-1.49), a significantly decreased risk for CM 
patients (SIR: 0.47; 95%CI: 0.24-0.84) and a risk similar to that of the general population for 
BCC patients (SIR: 1.09; 95%CI: 0.96-1.23).  
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Table 11.6. Overview of population-based studies on breast or colorectal cancer after skin cancer a 
 
Author, country 
(reference) 
Skin cancer/ 
patient’ 
characteristic 
No. of 
skin 
cancer 
patients 
No. of 
colorectal 
cancer 
patients 
SIR 95%CI No. of 
breast 
cancer 
patients 
SIR 95%CI 
Levi, Switzerland BCC39 11,878 Colon : 103 
Rectum: 47 
1.0 
0.8 
0.8-1.2 
0.6-1.0 
126 1.2 1.0-1.4f 
 SCC24 4,639 Colon: 29 
Rectum: 19 
0.7 
0.8 
0.5-1.0 
0.5-1.3 
32 1.0 0.7-1.4 
 CM40 1,780 Colon: 12 
Rectum: 6 
1.6 
1.3 
0.8-2.7 
0.5-2.7 
16 1.3 0.7-2.0 
Bhatia, USA23  CM, women 287 - - - 3 0.7 0.1-1.6 
Hemminki, 
Sweden21 
SCC        
   Men, <1 yr  
  Men, >1 yr 
11,409 Colon: 8 
Colon: 123 
0.6 
1.2 
0.2-1.0 
1.0-1.55   
- - - 
   Women, <1yr 
  Women, >1yr 
6,228 Colon: 3 
Colon: 50 
0.4 
1.0 
0.1-1.1 
0.7-1.3 
- - - 
Milan, Finland41 BCC        
   Men 29,727 Colon: 258 1.26 1.2-1.3 - - - 
   Women 42,197 Colon: 402 1.23 1.1-1.3 949 1.23 1.2-1.3 
  Head & neck 52,536 Colon: 496 1.21 1.1-1.3 716 1.2 1.1-1.3 
Friedman, USA42b BCC        
  Men 1,648 30 0.9 0.6-1.4 - - - 
  Women 1,516 30 1.1 0.7-1.7 87 2.1 1.3-3.6 
Bower, UK43 BCC 13,961d - - - 120 0.80 0.7-0.96 
Efrid, US44b SCC 822 15 1.7 0.9-3.2 8 0.8 0.3-1.8 
Crocetti, Italy45 CM 1835 Colon: 4 
Rectum: 3 
0.5 
0.8 
0.2-1.4 
0.2-2.4 
14 1.5 0.8-2.5 
Maitra, UK46 SCC        
   Men 16,962 Colon: 187 1.2 1.0-1.4e - - - 
  Women 8,769 Colon: 83 1.2 1.0-1.5e 140 1.0 0.8-1.1 
Nugent, Canada26 BCC        
  Men  15,586 Colon: 253 
Rectum: 116 
1.00 
0.78 
0.9-1.1 
0.6-0.9 
- - - 
  Women 13,370 Colon: 216 
Rectum: 63 
1.02 
0.85 
0.9-1.2 
0.6-1.1 
447 1.22 1.1-1.3 
 SCC        
  Men 4,973 Colon: 86 
Rectum: 38 
1.07 
0.85 
0.9-1.3 
0.6-1.2 
- - - 
  Women 2,860 Colon: 36 
Rectum: 11 
0.81 
0.75 
0.6-1.1 
0.4-1.3 
73 1.07 0.8-1.3 
Freedman, SEER, 
US20 
CM        
  Men 34,949 Colon: 313 
Rectum: 114 
1.00 
0.84 
p>0.05 - - - 
  Women 31,110 Colon: 215 
Rectum: 66 
0.97 
0.92 
p>0.05 765 1.09 P<0.05 
Tuohimaa, 
worldwide 13 
registries47c 
CM        
  Sunny-countries 98,051 494 1.13 1.0-1.2 318 1.03 0.9-1.2 
  Less sunny 42,049 875 1.13 1.1-1.2 1035 1.26 1.2-1.3 
 BCC 148,885       
  Sunny-countries - 566 0.93 0.7-1.2 80 1.04 0.8-1.3 
  Less sunny - 2511 1.35 1.3-1.4 3062 1.41 1.4-1.5 
 NMSC excl. BCC 127,149       
  Sunny-countries - 29 0.73 0.5-1.1 10 0.9 0.4-1.7 
  Less sunny - 2612 1.27 1.2-1.3 1150 1.26 1.2-1.3 
 
a studies were performed between 1997 and 2007. b nested case control study; analysis was corrected for smoking 
status, marital status, alcohol consumption, occupational exposure (chemicals etc.). c Ratio of colorectal after CM in 
sunny/less sunny countries: 0.99 (0.89-1.11), after BCC: 0.69 (0.53-0.85), after nonmelanoma skin cancer excl BCC: 
0.58 (0.39-0.92); ratio of female breast cancer after CM in sunny/less sunny countries: 0.82 (0.73-0.93), after BCC: 0.74 
(0.58-0.92), after nonmelanoma skin cancer excl BCC: 0.71 (0.34-1.32) d total number of cohorts, includes men and 
women. e 95% confidence interval did not include 1. f 95% confidence interval included 1. 
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11.4. Discussion 
In this large, population-based study of nearly 27,000 skin cancer patients, we found for the 
first time a decreased risk of colorectal cancer, especially for men. The decreased risk was 
most apparent among those diagnosed with SSC, with a 29-36% lower risk of colorectal 
cancer for women and men compared to the general population. Older patients with SCC 
and patients with a lesion on the head and neck area also exhibited a reduced risk of 
colorectal cancer. Another novel result is the increasing risk over time after nonmelanoma 
skin cancer diagnosis, with the lowest risk in the early years. For women with a previous CM 
at ages older than 60, we observed almost a 2-fold increased risk of breast cancer. This 
increased risk was most marked for advanced stage breast cancer among female CM 
patients.   
 
The beneficial influence of sun exposure on cancer is generally presumed to be through 
vitamin D.14 Sunlight increases the synthesis of pre-vitamin D. Active vitamin D regulates cell 
growth and differentiation by binding to vitamin D receptors on various tissues.15 The inverse 
association between dietary vitamin D intake and colorectal or breast cancer;16-18 has not 
always been confirmed by others.19 Out of 14 studies investigating the risk of colorectal or 
breast cancer after skin cancer diagnosis performed within the last 10 years, 4 and 5 studies 
demonstrated increased risks of colorectal and breast cancer after skin cancer, respectively 
(table 6). One observed a significantly reduced risk of rectal cancer and another for breast 
cancer. Several factors may explain the different findings across the studies. Firstly, many 
studies did not stratify according to gender; in our study men seemed to exhibit a larger risk 
reduction than women.20, 21 Secondly confounding by age, those younger at their first cancer 
diagnosis showed higher risks of developing a second cancer.22-24 Thirdly, skin cancer sub-
site was not investigated separately, i.e. patients with a lesion on the head and neck area 
had the highest risk reduction. Finally, the studies listed had a long follow-up period25, and 
the protective effect was most pronounced in the early period.20, 21, 26 Thus, by including 
patients with longer follow-up, the risk may have been elevated back to that of the general 
population.  
 
SCC has been related to cumulative sun exposure9 and is more common in men probably 
due to their history of outdoor labour and the fact that women often have longer (and more) 
hair than men, protecting their scalp better against the sun. This high sun exposure would 
explain the highest protective effect of sunlight on colorectal cancer found for this group of 
patients. Physical activity may have been a confounding factor: more physical exercise 
lowers the risk of colorectal cancer,27 and is related to more sun exposure and therefore a 
higher skin cancer risk.28 However, physical activity increases intermittent sun exposure, 
which is related to the risk of CM28 and not SCC, which exhibited the lowest colorectal 
cancer risk. As for BCC, compared to SCC, BCC patients have been reported to have the 
lower lifetime accumulated UV exposure, thus also the weaker risk reduction in our study.29 
Furthermore, the stronger beneficial effect of vitamin D was observed in the distal colon and 
the rectum16, 30. Like others18, our finding did not indicate a different association for rectal 
cancer, though the low number of cases restricted our conclusion.     
 
Although not significant, after a diagnosis of skin cancer we saw a similar pattern for breast 
cancer as that for colorectal cancer: SCC patients who were older than 60 years at diagnosis 
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with a lesion on the head and neck area had the lowest risk of breast cancer. Similar 
reasoning as that for colorectal cancer may apply here: greater sun exposure for these 
patients. Moreover, when the risk was compared for SCC vs. BCC vs. CM, an increasing 
trend was observed, which is in line with the amount of sun exposure among these cancer 
patients: highest for SCC and lowest for CM patients.9 Previous studies reported an 
increased risk of breast cancer for CM patients.20, 22 A reciprocal association was observed 
for women with breast cancer who have a higher risk of CM.22, 31, 32 This may reflect a higher 
socio-economic status, thus having more intermittent sun exposure33 but also fewer children, 
younger age at the first child's birth34 and probably higher awareness of breast cancer 
leading to higher screening attendance rate. This clustering of risk factors among the more 
advantaged may explain the relationship between CM and breast cancer. In addition, genetic 
predisposition to both CM and breast cancer may have contributed to the elevated risk.35, 36  
 
Vitamin D has been shown to delay cancer progression.14, 37 We found a lower risk of less 
advanced stage colorectal cancer for patients with SCC and BCC but not for patients with 
CM. The risk of more advanced colorectal cancer was decreased among patients with SCC 
but not among patients with BCC and CM. Chronic sun exposure seems to protect against 
any stage of colorectal cancer, and as the lifetime UV exposure becomes lower, as in the 
case of BCC patients, the protective effect is only evident for early colorectal cancer. In 
addition, we demonstrated a significantly decreased risk of advanced stage breast cancer for 
BCC patients. Yet, patients with CM experienced a higher risk of advanced breast cancer. 
Genetic predisposition to both CM and breast cancer may partly explain this finding, e.g. 
BRCA2 mutation. Mutation carriers have been shown to have a higher grade of breast 
cancer compared to those without.38 An elevated risk of breast cancer was also found for 
elderly CM patients, usually contrary to genetic-related cancer. However the breast cancer 
risk for BRCA2 carriers has been reported to persist even after menopause.38          
  
The strength of this study is its population-based nature, enabling comparisons with the 
same population from which the cases were obtained from and avoiding selection bias of the 
control group. A population-based study also provides larger numbers for statistical analyses 
even after categorisation of the factors studied. In addition, the Eindhoven Cancer Registry 
is unique in that it systematically collected data on various skin cancer types, allowing us to 
compare the risk of second cancers among these groups with different sun exposure 
patterns.   
 
Limitations of our study include the lack of individual breast or colorectal cancer risk factor 
data such as reproductive factors, external hormone or supplement intake, dietary 
information and physical activity level. Skin cancer was taken as a proxy for higher sun 
exposure and no information on actual sun exposure or other modifying factors such skin 
type was available. Methodological artefact seems to be an unlikely explanation because 
additional analyses showed an increased risk of lung cancer for SCC patients and a lower 
risk for CM patients than we had hypothesized. Furthermore, the decreased risk during the 
early period after skin cancer diagnosis does not seem to be biased. Cancer patients have 
higher alertness for cancer and may undergo a more intensive medical surveillance, which 
would have, theoretically, elevated their cancer risk compared to the general population. 
Finally, the registration of basal cell carcinoma may not be as complete as that of the other 
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skin malignancies. However, primary tumour tissues are sent for pathological review and the 
registry would be informed. In addition, it is highly unlikely that underreporting is related to 
the risk of breast or colorectal cancer. 
 
For the first time we have reported a lower risk of colorectal cancer after skin cancer, 
especially among those who are most chronically exposed to the sun, probably due to sun-
induced high levels of vitamin D. The beneficial influence of sun exposure in women was 
less evident, probably because it was diluted by other factors that might have increased the 
risk of skin as well as colorectal or breast cancer. Studies are needed to clarify the benefit of 
sun exposure and supplementation of vitamin D in preventing (as well as reducing) the 
progression of colorectal as well as breast cancer, so that public health measures and 
chemoprevention strategies can be adapted accordingly.  
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Abstract 
 
Background and objectives: Ultraviolet radiation (UVR) causes skin cancer, but may 
protect against prostate cancer. We hypothesized that skin cancer patients had a lower 
prostate cancer incidence than the general population.  
 
Methods: In the southeast of the Netherlands, a population-based cohort of male skin 
cancer patients diagnosed since 1970 (2620 squamous cell carcinomas, 9501 basal cell 
carcinomas and 1420 cutaneous malignant melanomas) was followed-up for incidence of 
invasive prostate cancer until January 1, 2005 within the framework of the Eindhoven cancer 
registry. Incidence rates of prostate cancer amongst skin cancer patients were compared to 
those in the reference population, resulting in Standardised Incidence Ratios (SIR).  
 
Results: Skin cancer patients were at decreased risk of developing prostate cancer 
compared to the general population (SIR 0.89 (95% CI: 0.78, 0.99)), especially shortly after 
diagnosis. The risk of advanced prostate cancer was significantly decreased (SIR 0.73 (95% 
CI: 0.56, 0.94)), indicating a possible anti-progression effect of UVR. Patients with a skin 
cancer in the chronically UVR exposed head and neck area (SIR: 0.84 (95% CI 0.73, 0.97)) 
and those diagnosed after the age of 60 (SIR 0.86 (95% CI 0.75, 0.97)), had decreased 
prostate cancer incidence rates.  
 
Conclusions: These results support the hypothesis that UVR protects against prostate 
cancer.  
 
Keywords: skin neoplasms, cohort study, prostatic neoplasms, registries, second primary 
neoplasms 
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12.1. Introduction 
Ultraviolet radiation (UVR) causes skin cancer, but has been hypothesized to protect against 
prostate cancer development and possibly progression. If this hypothesis were true, one 
would expect skin cancer patients to have a lower prostate cancer incidence than the 
general population and, more specifically, to have a lower incidence of advanced stage 
prostate cancer. 
 
A striking epidemiological feature of prostate cancer is a gradient of increasing mortality 
rates among Caucasians with latitude (i.e. inverse correlation between geographic 
distributions of ultraviolet radiation (UVR) and prostate cancer mortality). Mortality from 
prostate cancer was found to increase with latitude in the USA 1-3 and Europe 4. This is 
consistent with the hypothesis of an UVR-induced ‘protective’ effect on prostate cancer 
incidence and/or survival, because annual average UVR levels decrease with increasing 
latitude. A case-control study conducted in the United Kingdom found risk of prostate cancer 
to be two-thirds less in men with high than men with low lifetime sun exposure 5, 6, and risk of 
advanced prostate cancer was reduced by half in the group with the highest quintile of sun 
exposure index compared to the lowest quintile in a San Francisco Bay area population-
based case-control study 7. Risk of prostate cancer among white men was decreased by 
about one-third for men with a high solar radiation at their place of longest residence and 
was halved for men with a low solar radiation at the place of birth in a follow-up study 
conducted in the United States 8    
 
Most of these studies used measures of residential sun exposure 1, 2, 4, 8, sometimes 
combined with job histories 3, 7 as indicator of individual sun exposure, whereas individual 
behaviour can hugely influence the amount of sun exposure received. The case-control 
study 5, 6 collected individual sun exposure data using questionnaires, in which recall bias 
may influence exposure estimates.   
 
In this study, we compared incidence of prostate cancer in the general male population to 
incidence of prostate cancer in cohorts of male skin cancer patients. It is generally accepted 
that the majority of skin cancers are caused by exposure to UVR 9, 10. Therefore, although 
we do not have individual information on sun exposure, we may assume that these skin 
cancer cases had on average a higher UVR exposure than the general population in the 
same area. The association with UVR is most straightforward for squamous cell carcinomas 
of the skin (SCC) 9, which are related to cumulative UVR exposure. The association is less 
strong for basal cell carcinomas of the skin (BCC), which has been hypothesized to be 
etiologically more similar to melanoma 9. Intermittent exposure to sunlight, especially during 
childhood, is thought to be the main risk factor for cutaneous malignant melanoma (CM)11, 
particularly for people with a light skin phototype. Generally, skin cancers occurring in the 
head and neck region and those diagnosed at older age are associated with chronic 
exposure and skin cancers occurring at other body sites and at younger ages are associated 
with intermittent exposure and probably have a larger genetic component 12, 13. To our 
knowledge, no previous study has investigated prostate cancer incidence after skin cancer 
taking into account body site of the skin cancer, age at and time since skin cancer diagnosis, 
and prostate cancer stage.  
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12.2. Materials and methods 
 
Cohort 
Data on skin cancer patients were obtained from the Eindhoven Cancer Registry, situated in 
the southeastern part of the Netherlands and serving a population of 2.4 million inhabitants. 
The Eindhoven Cancer Registry serves more than 12 general hospitals that are served by 
six pathologic laboratories, all participating in a nationwide pathology-network (PALGA), 
which also notifies the regional cancer registries. The registry receives lists of newly 
diagnosed cases on a regular basis from the pathology departments, including cases whose 
material was sent in by general practitioners. In addition, the medical records departments of 
the hospitals provide lists of outpatients and hospitalised cancer patients. Following this 
notification, the medical records of newly diagnosed patients (and tumors), often only 
available from the outpatient departments, are collected and trained registrars from the 
cancer registry abstract the necessary information. Data are checked for duplicate records. 
Records are assumed to be complete 14, 15. Active follow-up of vital status until January 1, 
2005 was conducted through municipal registries and the Central Bureau for Genealogy. 
The rules of the International Association of Cancer Registries (IACR) for coding multiple 
tumours were adopted 16. A primary cancer is defined as a cancer that originates in a 
primary site or tissue and is thus neither an extension, nor a recurrence nor a metastasis. 
Only patients with a first primary skin cancer were included. Those diagnosed with a cancer 
before the skin cancer diagnosis were excluded.  
 
Eligible participants for this study were Dutch males with an invasive SCC (n=2752) & CM 
(n=1449) diagnosed in the period 1972-2002, for patients with an invasive BCC the period of 
inclusion was 1990-2002 (n=9544) since active follow-up for BCC patients was initiated in 
1990. Among the eligible men we excluded skin cancer patients with 0 follow-up time (SCC 
n=132, BCC n=43, CM=29), as they would have had no ‘time’ to develop a second tumour. 
Patients with 0 follow-up time were usually diagnosed with another (usually skin) cancer at 
the same day of the skin cancer diagnosis or were discovered during post-mortem 
examination. We excluded them because they would increase the nominator (number of 
patients with a second cancer) without contributing any follow-up time, and therefore would 
overestimate the relative risk. Included patients were followed for the development of 
invasive prostate cancer until January 1, 2005. In case of a diagnosis of another second 
tumour (not prostate cancer), follow-up ended at the date of diagnosis of this second tumour. 
 
Clinical stage of prostate cancer was recorded according to the TNM classification 17. Since 
pathological stage is only available after radical prostatectomy and treatment decisions are 
based on clinical stage, only the latter was used (except for lymph node involvement and 
distant metastasis which was based also on pathological stage, because this can still 
influence treatment decisions). The clinical tumour classification was simplified as T1, T2, 
T3, T4 or as ‘unknown’ if sufficient information was not available for accurate staging.  
 
Thus, 2620 patients diagnosed with a SCC, 9501 patients with a BCC and 1420 diagnosed 
with CM were included for analysis. 
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Statistical methods 
We used the person-years analysis to study the incidence of second neoplasms after 
diagnosis of skin cancer 18. We compared the incidence of prostate cancer as a second 
tumour among patients with a diagnosis of skin cancer (the observed incidence) with the 
prostate cancer incidence in the reference population (the expected incidence), the 
reference population being the population served by the Eindhoven Cancer Registry. We 
took into account the amount of time that had passed between the diagnosis of the first and 
second tumour, adjusting for age (in 5-year categories) and calendar period of the skin 
cancer diagnosis. Through the adjusted person-years obtained, we calculated the expected 
subsequent relative risk for prostate cancer for the general male population. The observed 
and expected numbers were compared in order to determine the standardised incidence 
ratio (SIR). Statistical significance and 95% confidence intervals (CI) were calculated using 
exact Poisson probability 19. Risk estimates were calculated for the total study population 
and sub-analyses were performed for incidence of skin cancer in the head and neck area 
(chronically sun-exposed) and the other body sites (intermittently exposed), for age at 
diagnosis of skin cancer (age <60 vs ≥60 years) and for incidence of prostate cancer by 
stage (I & II compared to III & IV). Patients with missing information on body site were 
excluded from analysis (unknown location SCC: N=11, BCC: N=32, CM: N=69, this 
exclusion did not significantly influence results). 
 
In the first years after a skin cancer diagnosis, patients are likely to decrease their sun 
exposure. If the hypothesized protective effect of sun exposure would be effective on the 
short term, one would therefore expect a more markedly decreased risk of second prostate 
cancer among skin cancer patients shortly after their initial diagnosis than at a longer follow-
up time. Therefore we performed an additional analysis, calculating SIRs for prostate cancer 
incidence by time since skin cancer diagnosis divided in 6 periods; 0-1 year, 1-2, 2-3, 3-4, 4-
5 and 5 or more years since skin cancer diagnosis.  
 
 
12. 3. Results 
We included 13,541 skin cancer cases eligible for analysis, with a total of 75,047 person-
years. Table 12.1 gives the results of the analyses. Average age at diagnosis of SCC was 
73, of BCC 66 and of melanoma 53 years; the average follow-up time was 5.0, 5.6 and 6.0 
years, respectively.  
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Table 12.1. Subsequent prostate cancers observed in a cohort of skin cancer patients diagnosed in 1972-2002, 
Eindhoven Cancer Registry Area, the Netherlands 
 
 N Cases Median age (yrs) at 
diagnosis of 
PY† Obs‡ Exp§ SIR#  95% CI 
  Skin 
cancer 
Prostate 
cancer 
     
All skin cancers 
13541 66.4 69.3 75,047 272 307 0.89  0.78, 0.99 
Non-melanoma 
skin cancers 
 
12121 67.4 74.2 66,564 253 291 0.87  0.77, 0.98 
Melanoma 
1420 52.7 68.3 8,483 19 16 1.16  0.71, 1.85 
SCC 
2620 73.2 77.0 13,204 56 66 0.84  0.64, 1.10 
BCC 
9501 65.7 73.0 53,360 197 224 0.88  0.76, 1.01 
 
All skin cancers 
       
Age at diagnosis        
< 60 years 4650 51.2 61.6 31,886 42 38 1.10  0.80, 1.50 
≥ 60 years 8891 72.5 75.2 43,182 230 269 0.86  0.75, 0.97  
Location         
Head & Neck 9461 68.6 74.8 51,293 197 235 0.84  0.73, 0.97  
Others 3968 59.8 71.4 23,357 75 71 0.85  0.64, 1.10 
Prostate cancer stage        
1 & 2 13541 67.7 72.7 75,047 188 199 0.94  0.81, 1.09 
3 & 4 13541 70.6 74.9 75,047 61 84 0.73  0.56, 0.94  
Unknown 
 
13541 75.6 76.6 75,047 23 24 0.95  0.60, 1.42 
Non melanoma skin cancers       
Age at diagnosis        
< 60 years 3719 52.1 62.3 25,401 37 33 1.12  0.79, 1.55 
≥ 60 years 8402 72.6 75.4 41,164 216 258 0.84  0.73, 0.96  
Location of NMSC         
Head & Neck 9197 68.7 74.8 49,871 19 230 0.85  0.73, 0.98 
Others 2881 63.1 71.9 16,426 58 59 0.98  0.74, 1.27 
Prostate cancer stage        
1 & 2 12121 68.3 72.9 66,564 174 188 0.92  0.79, 1.07 
3 & 4 12121 70.6 75.0 66,564 58 79 0.73  0.56, 0.95  
Unknown 
 
12121 75.6 76.6 66,564 21 23 0.92  0.57, 1.40 
Melanoma        
Age at diagnosis        
< 60 years 931 45.4 58.7 6,465 5 5 1.01  0.33, 2.37 
≥ 60 years 489 69.8 72.1 2,018 14 11 1.23  0.67, 2.06 
Location of melanoma        
Head & Neck 264 65.1 75.0 1,422 2 4 0.46  0.06, 1.66 
Others 1087 51.3 68.3 6,931 17 12 1.44  0.84, 2.34 
Prostate cancer stage        
1 & 2 1420 63.3 67.7 8,483 14 11 1.31  0.72, 2.20 
3 & 4 1420 53.7 60.3 8,483 3 4 0.69  0.14, 2.03 
Unknown 1420 73.2 74.6 8,483 2 1 1.49  0.18-5.39 
†: number of person-years of observation between date of diagnosis of skin cancer and date of diagnosis of prostate 
cancer 
‡: observed number of prostate cancer patients 
§: expected number of prostate cancer patients 
#: Standardised Incidence Ratio 
 
For all skin cancers combined, there was a decreased risk of subsequently developing 
prostate cancer (SIR 0.89, 95% CI: 0.78, 0.99). This risk was significantly decreased for 
patients with a previous diagnosis of non-melanoma skin cancer (NMSC) (SIR 0.87, 95% CI: 
0.77, 0.98), but not for melanoma patients. All male skin cancer patients with a skin cancer 
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diagnosis after age 60 (SIR 0.86, 95% CI: 0.75, 0.97) and those with any skin cancer in the 
head and neck region (SIR 0.84, 95% CI: 0.73, 0.97) had a significantly decreased risk of 
subsequent prostate cancer incidence. Among skin cancer patients, advanced prostate 
cancer (stage 3&4) incidence rates were significantly decreased compared to the general 
population (SIR 0.73, 95% CI: 0.56, 0.94). 
 
After analysing the cohorts separately for NMSC patients and patients diagnosed with a 
melanoma, risks remained significantly lower in the group of NMSC for those aged >60 at 
diagnosis (SIR 0.84 (95% CI: 0.73, 0.96) and those with a head and neck NMSC (SIR 0.85 
(95% CI: 0.73, 0.98). Risk of developing an advanced prostate cancer was especially 
decreased (SIR 0.73 (95% CI: 0.56, 0.95). Melanoma was positively associated, though not 
significantly, with subsequent prostate cancer risk (SIR 1.16, 95% CI: 0.71, 1.85), except for 
head and neck melanomas (SIR 0.46, 95% CI: 0.06, 1.66) and advanced prostate cancer 
(SIR 0.69 (95% CI: 0.14, 2.03) for which point estimates were smaller than 1. 
 
Table 12.2 describes the results of the analyses by period since diagnosis of NMSC, but not 
for melanoma due to small numbers of prostate cancer cases after an initial melanoma 
diagnosis. Though point estimates did not always reach statistical significance, the results 
clearly demonstrate that the risk of developing prostate cancer was lowest in the time period 
shortly after NMSC cancer diagnosis (during the first year: SIR=0.53, 95% CI 0.34, 0.78), 
gradually increasing with time (≥5 years after NMSC diagnosis: SIR=1.10, 95% CI 0.90, 
1.34).  
 
Table 12.2. Standardized Incident Ratio (SIR) with 95% confidence interval of second prostate cancer among non 
melanoma skin cancer patients diagnosed in the Eindhoven Cancer Registry in the South of the Netherlands 
Time since skin 
cancer diagnosis 
BCC SCC Non-melanoma skin 
cancer 
 SIR* 95% CI SIR* 95% CI SIR*  95% CI 
0-1 year 0.51 0.30, 0.80 0.58 0.23, 1,20 0.53 0.34, 0.78 
1-2 years 0.91 0.62, 1.29 0.66 0.26, 1,36 0.85 0.60, 1.17 
2-3 years 0.65 0.40, 1.00 0.56 0.18, 1.30 0.63 0.41, 0.93 
3-4 years 0.89 0.57, 1.32 0.97 0.39, 2.00 0.91 0.62, 1.29 
4-5 years 1.01 0.64, 1.51 0.90 0.29, 2.09 0.99 0.66, 1.43 
>= 5 years 1.10 0.87, 1.37 1.13 0.73, 1.66 1.10 0.90, 1.34 
* SIR = Standardized Incidence Ratio 
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12.4. Discussion 
Our results show that male NMSC patients are at a decreased risk of developing invasive 
prostate cancer. The decreased risk of developing prostate cancer was significant for skin 
cancers that are assumed to be related to chronic sun exposure: those occurring in the 
elderly and in the head and neck region. In patients with CM, which is assumed to be related 
to intermittent sun exposure 12, 13, a (non-significantly) increased risk of subsequent prostate 
cancer was exhibited, except for head and neck melanomas, which showed a (non-
significantly) decreased risk. CMs in the head and neck area are, in contrast to other 
melanomas, assumed to be more related to chronic sun exposure 12, 13.  
 
These observations are in line with the hypothesis that exposure to UVR protects against 
prostate cancer development and possibly against progression, as SIRs for advanced 
prostate cancer (stages 3&4) were lower than those for early (stage 1&2) disease.  
 
Although we did not have individual information on UVR of the included cases, it is generally 
accepted that most skin cancer cases in predominantly Caucasian populations like in the 
South of the Netherlands are caused by high UVR exposure 9, 10. This increased risk is 
mainly apparent for people with sun-sensitive skin. Other causes of non-melanoma skin 
cancer include immunosuppression 20, smoking 21 and exposure to pesticides 22. Apart from 
some rare familial syndromes, little is known about non-solar risk factors for melanoma; 
effects of contraceptive use 23 and swimming in polluted water 24 have been postulated but 
not confirmed. All these non-solar factors are, to our knowledge, not associated with a 
decreased risk of prostate cancer and thus cannot explain our observations. Therefore, our 
findings are in line with the hypothesis that exposure to UVR would decrease the risk of 
prostate cancer development.  
 
After their skin cancer diagnosis, skin cancer patients were likely to be under increased 
medical scrutiny and to reduce their sun exposure drastically, resulting in lower sun 
exposure shortly before the prostate cancer diagnosis.  If short-term sun exposure were 
important in determining the risk of developing a prostate cancer, one would expect the 
lowest SIRs to occur shortly after skin cancer diagnosis, as observed in our analyses: SIRs 
were lowest in the first year, gradually increasing to reach levels of around 1 after ≥5 years 
of follow-up. Of interest is the ‘drop’ in SIR estimates during the 3rd year of follow up (2-3 
years after diagnosis): possibly an effect of a decreasing intensity of medical surveillance. 
Due to the increased medical surveillance during the first years after skin cancer diagnosis, 
one would expect more (prostate) cancer cases to be detected in this period than in the 
average population – this may have artificially increased numbers of prostate cancer in our 
cohorts and diluted our results, but provides even stronger evidence for a ‘real’ decrease in 
risk shortly after prostate cancer diagnosis. 
 
A few studies have previously looked at incidence of tumours, amongst which prostate 
cancer, after skin cancer diagnosis 25-33(Table 12.3). Most of these did not find a significant 
association between skin cancer diagnosis and prostate cancer 26, 27, 29, 30, and did not 
investigate the effect of body site or the age at diagnosis of the skin cancer cases. Very few 
gave information on mean or median age at diagnosis and/or mean years of follow-up or 
person-years at risk. None of these studies investigated associations with prostate cancer 
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stage, and most suffered a problem of small numbers, like we did when only considering 
SCC or melanoma, causing a lack of power to show any statistically significant effects 25-29, 33 
. One large study investigating prostate cancer incidence after BCC found an increased risk 
31. This study had accumulated a mean follow-up time of about 9 years, against 5.6 years in 
our BCC cohort. As the SIRs tended to increase with time since skin cancer diagnosis, this 
possibly explains the observed increased risk in this study 31. Another study, which did not 
mention mean follow-up time, found a decreased risk, with estimates very similar to ours 32; 
the other two studies did not find any significant association 26, 29. None of the studies on 
BCC gave an indication of the completeness of their registry of (first primary) BCCs. In many 
countries BCCs are not routinely registered, therefore some of the populations of BCC 
patients may have been biased towards the clinically more complicated cases. As was the 
case in our study, all previous studies reporting the incidence of prostate cancer after SCC 
28, 30, 33 and CM 25, 27 had too low numbers to make reliable estimates. One Danish study 
observed a non-significantly decreased risk of prostate cancer after SCC with a SIR very 
similar to that observed in our study 33. One study found an increased risk of prostate cancer 
after a diagnosis of CM 27, another found an increased risk after CM for patients younger 
than 51, and a decreased risk for patients diagnosed after age 50 25.  
 
Table 12.3. Results of other studies reporting incidence of prostate cancer after skin cancer diagnosis 
 
Country, registry (ref nr) Localisation, age 
of skin cancer 
Number 
of 
(male) 
skin 
cancer 
patients 
Age at 
diagnosis 
of skin 
cancer 
Mean yrs 
of follow-
up 
Observed 
number 
of 
prostate 
cancer 
cases 
SIR† 95% CI 
BCC        
All BCC 29727 ‡ ±9  1121 1.2  1.2, 1.3 Finland, Finnish Cancer 
Registry 31 Head & neck only 20796 ‡ ‡ 839 1.2 1.2, 1.3 
Switzerland, Vaud & 
Neuchatel cancer registry 29 
BCC 5947 60-69 ‡ 155 1.1 0.9, 1.3 
USA, Kaiser Permanente 
Medical Care Program 26 
BCC 1648 45-64 11.3 108 1.1 0.9, 1.4 
UK, South&West Cancer 
Registry 32 
BCC 13961* ‡ ‡ 177 0.85 0.73, 0.99 
SCC        
UK, Thames Cancer 
Registry 30  
SCC 16962 ‡ ‡ 389 1.0 0.9, 1.1 
Switzerland, Vaud & 
Neuchatel cancer registry 28 
SCC 2529 60-69 ‡ 74 1.1 0.9, 1.4 
Danish Cancer Registry 33 SCC 3306 ‡ ‡ 49 0.8 0.6, 1.1 
CMM        
Switzerland, Vaud & 
Neuchatel cancer registry 27 
CMM 782 60-69 ‡. 16 2.1 1.2, 3.4 
CMM≤50 Median: 
43 
6.5 1 1.8 0.0, 7.0 USA, Hospital based 25 
CMM>50 
 298 
<150 
‡ ‡ 1 0.2 0.0, 0.9 
* No separate numbers for males and females were given, prostate risk was separately calculated within cohort of men 
skin cancer patients only  
†: Standardized Incidence Ratio 
‡: not available 
 
Unlike the situation in most cancer registries, reporting of both NMSC and CM to the 
Eindhoven Cancer Registry occurs routinely 14. A small degree of underreporting cannot be 
excluded since a high proportion of NMSC are treated in office settings where maybe not all 
tumour material will be sent for pathology review. However, material of all first primary BCCs 
and SCCs will be sent for pathology, and it is therefore unlikely that this cohort of patients 
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will have been subject to selection. As NMSC generally has a good prognosis, there are no 
severe biases expected based on survival time. 
 
The significantly decreased prostate cancer incidence in the group of BCC patients can 
hardly be explained by bias: patients with a cancer diagnosis are more intensely checked for 
subsequent tumours and might be regarded as being vulnerable for tumour development. If 
such higher vulnerability and/or stronger surveillance would play a role, this would have 
increased the level of prostate cancer detection, especially during the first years after skin 
cancer diagnosis, and would have diluted our results. In the Netherlands, there is no 
population-based prostate cancer-screening programme; voluntary PSA-screening in this 
population was quite low and even completely absent in the earlier years of follow-up. 
However, should skin cancer patients have been under a more frequent and closer medical 
scrutiny, then diagnosis of a subsequent prostate cancer would more likely have occurred at 
an earlier stage. Since the levels of PSA-screening were low in this population during the 
years of follow-up, any such effect would be minimal. Moreover, if this were true this would 
suggest a bias for more medical screening in skin cancer patients and a higher detection 
rate of prostate cancer in general, which was not the case. 
 
Although biases are unlikely to have caused the observed association, there is some 
potential for confounding, for example by physical exercise and/or selenium 
supplementation. Exercise might be associated with skin cancer through enhancing 
exposure to UVR and might also be associated with reduced prostate cancer risk. Similarly, 
selenium supplementation has been found to (non-significantly) increase the risk of recurrent 
skin cancer, while reducing prostate cancer occurrence 34. 
 
A growing body of evidence, including our findings, supports the hypothesis that UVR 
protects against the development of prostate cancer, possibly through the formation of 
vitamin D3 1-8, although some plasma studies do not clearly suggest a benefit of vitamin D 
levels on prostate cancer risk 35, 36. If the hypothesis of UVR having a protective effect 
against prostate cancer, and possibly other tumours and also some auto-immune diseases 
is confirmed 37, it will be important to modify public health messages regarding UVR 
exposure: levels of UVR that do not result in increased risk of skin cancers should be 
defined. Additionally, if indeed vitamin D is relevant, then recommendations to increase oral 
intake of vitamin D through supplementation and/or fortification should be made. 
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The problem of multiple cancers is increasing in magnitude. Currently about 10% of patients 
with cancer are expected to develop a second cancer. The numbers of people at elevated 
risk of multiple malignancies, i.e. the elderly and cancer survivors, are rising. Thus, in 
absolute terms, the number of patients with multiple primary cancers is expected to continue 
rising. Furthermore, due to intensified cancer detection efforts through screening and the 
increased awareness among patients and doctors towards cancer, the relative risk of 
multiple cancers has been increasing as well. In this work, our aim was to examine the risk 
of second malignancies among cancer survivors, in particular among those who were 
diagnosed with breast and skin cancer. We used data from a long-standing cancer registry in 
southern Netherlands. In this discussion, the main findings and their interpretation will be 
first summarized. This will be followed by a discussion of the drawbacks and biases in 
relation to interpretation of results. The third section of this chapter discusses the clinical and 
etiological implications of our studies. This part ends with recommendations for future 
research.  
 
13.1. Summary and interpretation of findings 
 
Risk of second cancer among patients previously diagnosed with primary breast 
cancer 
 
Determinants of breast cancer incidence  
The risk of developing a second primary malignancy may partly be attributable to the same 
factors that underlie the development of a first cancer. Therefore, it is important to shortly 
review the risk factors for breast cancer, as done in chapter 3 and 4. Increased risk of breast 
cancer has been related to the following risk factors:(1) family history of breast cancer or  
germline mutation of a cancer susceptibility gene; (2) reproductive history and hormonal 
factors, e.g. older age at first child, lower parity, and post-menopausal hormone intake; (3) 
physical characteristics, e.g. dense breast tissue, post-menopausal obesity or tall stature; 
and (4) nutritional factors, e.g. excess alcohol consumption and fat/energy intake1, 2. In an 
ecological study, we showed that there is a strong correlation between the overall excess 
incidence of breast cancer in 2002 and the average age of the mother at first birth in 1972-
2002. Both current and past average age at first childbirth were associated with recent 
excess risk of breast cancer. However, risk factors for breast cancer such as younger age at 
menarche, lower parity, higher obesity and use of post-menopausal hormones therapy, are 
also generally more frequent in countries with a high incidence of breast cancer. Besides 
being directly linked to an increased risk of breast cancer, older age at first child delivery is 
probably also a risk indicator of clustering of risk factors in western populations.  
 
Impact of a second cancer on the survival of breast cancer survivors 
A diagnosis of a new cancer among breast cancer survivors impairs their survival. An 
increased risk of second primary cancers among breast cancer patients remain even 
decades after the first diagnosis3. Therefore, we examined the impact of a second cancer 
diagnosis among patients with breast cancer surviving more than 10 years. We observed a 
better overall survival for women without second primary tumours as compared to women 
who developed a new primary cancer. In addition, based on our review, we concluded that 
conventional prognostic factors for survival such as tumour size, nodal status and grade 
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remain the most important factors for long-term survival, though their role decreases over 
time since diagnosis.  
 
Has the incidence of breast cancer among female cancer survivors changed? 
In the southern Netherlands a 20% increased in incidence of first primary breast cancer 
between 1975 and 1990 was reported4. To examine whether this pattern is also evident 
among female cancer survivors, we examined their incidence rate of breast cancer. We 
found that over a period of 20 years, the incidence of breast cancer among female cancer 
survivors has doubled. Population aging contributed to approximately 36% of this increased 
trend. The highest increase in incidence occurred among the elderly survivors (ages 75+), 
which increased by a factor of four over the study period.  
 
Female cancer survivors undergo higher surveillance and are probably more aware of breast 
cancer. Thus, we expected the stage distribution to be more favourable among second 
cancer patients as compared with first cancer patients. Unexpectedly, our results suggest 
that almost half of breast cancer survivors are stage II patients, whereas previous research 
shows that the majority of first cancer cases are stage I. This is particularly evident among 
survivors of non-breast malignancies (on study implication please see section 13.3). 
 
Risk of second cancer among patients with breast cancer 
During the 30 years of follow-up, 13% of breast cancer patients in our cohort were 
diagnosed with a second primary cancer. In contrast to the general population, patients with 
malignant breast cancer experienced a 2-fold increase risk of a new primary cancer. The 
most pronounced risks were found for a second breast, salivary gland and connective tissue 
cancer, approximately 3 times higher than that of general female population. Risks for 
cancer of colon, ovary, skin (melanoma) and bladder were also elevated though of a lower 
magnitude. Risk was especially high for those who were younger at first breast cancer 
diagnosis.  
Which risk factors may explain this pattern of increased cancer risk? Multiple cancer 
occurrences in younger patients are commonly linked to genetic predisposition to cancer.5 In 
our study, this is probably the case for some cases of multiple breast and ovarian cancers as 
well as melanoma of the skin. About 6% of women who were diagnosed with a breast cancer 
below the age of 50 had a BRCA1/2 mutation.5 The majority of these patients would later in 
life be diagnosed with a second breast or ovarian cancer.5 Besides the role of a single high 
penetrance gene mutation, a polygenic model probably explains part of the multiple cancers 
incidence.6 This hypothesis is supported by studies showing an increased risk of second 
cancers among those without a familial history of cancer. In addition, genetic predisposition 
towards cancer may interact with external risk factors increasing the risk of a second cancer 
among breast cancer patients. For example, younger patients show a higher risk of second 
cancer after irradiation compared to older patients7. Beside the fact that tissue cells among 
young patients are more sensitive towards radiation, interaction between genetic 
predisposition and radiation might increase the risk of developing a second cancer in these 
women7-10. 
 
Studies have shown that the majority of multiple cancer cases lack a family history6, 11. Thus, 
a second possible explanation of our findings points at the role of non-genetic risk factors, 
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particularly those related to lifestyle. Nutrition, high body mass index, physical inactivity and 
reproductive factors12-16 may be related to an increased risk of breast, colorectal and 
endometrium cancer in our cohort of breast cancer patients.  
 
In our study, we found a (non-significantly) decreased cervical cancer risk among breast 
cancer patients as compared with the general population. Previous studies have reported 
similar results17-19. A possible explanation of these findings is that higher socioeconomic 
status is associated with higher breast cancer incidence20 but lower cervical cancer 
incidence20. This may reflect antagonistic effects of risk factors related to socioeconomic 
status on breast and cervical cancer, which may in turn explain the lower risk of cervical 
cancer among breast cancer patients.  
 
A third explanation of our findings points to the role of first cancer treatment. Unlike the 
general population, breast cancer patients are exposed to cancer treatments that are often 
carcinogenic. For example, we found that breast cancer patients exhibit an increased risk of 
sarcoma, esophageal and salivary cancer, which is probably related to irradiation as part of 
the first breast cancer therapy9, 21-23. We also found a higher risk of endometrial cancer in 
those receiving hormonal treatment as compared with those who only underwent surgery. 
Consistent with these findings, tamoxifen (the most common hormonal breast cancer 
treatment), has been proven to increase the risk of endometrial cancer24, 25 On the other 
hand, we observed a lower risk of breast cancer among patients who received hormonal 
therapy as compared to those who received other type of cancer treatment. 
 
Second cancer risk in patients with in situ breast cancer 
During the last decade, a marked increased in the incidence of in situ breast cancer has 
been observed in the Netherlands, probably as a consequence of population-screening26. 
Therefore, we examined the risk of second cancer in patients with in situ breast cancer. 
Approximately 10% of these patients were subsequently diagnosed with a second cancer. 
We observed increased risks of second breast and skin cancer, 4- and 2-times higher than 
the general population, respectively. We found that this excess risk of second breast cancer 
is not explained by treatment choice (i.e. radiotherapy) for in situ breast cancer. This points 
to the role of a shared aetiology (lifestyle or hereditary) for both first and second cancer. 
Furthermore, we found that the pattern of increased cancer risk for patients with in situ 
breast cancer resembles that for patients with malignant breast cancer, as both groups of 
patients had an increased risk of colorectal, ovarium, lung and skin cancer as compared to 
the general population. Therefore, similar follow-up strategies may be required for patients 
with malignant breast cancer and patients with in situ breast cancer.  
 
Risk of colorectal, breast and prostate cancer among skin cancer patients: examining 
the protective role of sunlight 
Sun exposure appears to have a beneficial effect on the initiation and progression of some 
cancers including breast, colon and prostate cancer. This effect might be mediated by the 
production of vitamin D.27 On the other hand, solar radiation is a major risk factor for skin 
cancer.28, 29 Thus in the context of studying multiple cancers, we examined the risk of breast, 
colorectal and prostate cancer among patients previously diagnosed with a skin cancer. 
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There are 3 major types of skin cancer characterised by a different history of sun exposure: 
(1) Squamous cell carcinoma (SCC) of the skin, related to chronic sun exposure; (2) 
Cutaneous melanoma (CM), mostly associated with intermittent sun exposure; and (3) basal 
cell carcinoma of the skin, which is the most common skin cancer type, and appears to be 
associated with both chronic and intermittent sun exposure. If sunlight protects against 
others cancers, there should be a reduced risk of developing these cancers among patients 
with SCC, because the latter should have the largest cumulative sun exposure. 
 
Indeed, we found a decreased risk of colorectal and prostate cancer among male skin 
cancer patients, particularly among those with SCC. Furthermore, patients with SCC who 
were older than 60 at the time of diagnosis and who had the lesion in the head and neck 
area had the lowest risk of a second colorectal cancer. Older skin cancer patients have 
presumably been exposed to the sun longer than younger patients. In addition, skin cancer 
in the head and neck area is also associated to chronic sun exposure30. These findings are 
consistent with the sunlight hypothesis: the more chronic sun exposure the lower the risk of 
developing certain cancers.  
 
Although not significant, for breast cancer after skin cancer diagnosis, we observed a similar 
pattern as that for colorectal cancer: SCC patients who were older than 60 at diagnosis with 
a lesion on the head and neck area had the lowest risk of breast cancer. For CM patients a 
higher risk of breast cancer as compared to the general population was found. In our 
previous study where we assessed the risk of second cancer among breast cancer patients, 
we also observed a higher risk of melanoma. This may reflect a higher socio-economic 
status, which is related to higher intermittent sun exposure, but to lower number of children, 
younger age at the first child's birth and probably higher awareness for breast cancer leading 
to higher attendance rate for screening. A small fraction of this risk may also be explained by 
genetic predisposition towards both CM and breast cancer.  
 
We also found that the risk of colorectal or prostate cancer among skin cancer patients was 
lowest during the first year after skin cancer diagnosis, and increased gradually thereafter. 
Skin cancer patients may reduce their sun exposure soon after the skin cancer diagnosis. 
Thus, our findings may suggest that the protective effect of sun exposure diminished as 
soon as sun exposure was reduced. How is it possible that individuals who reduce their sun 
exposure experience a reduction in its protective in such a short period? Other studies have 
indicated that maintaining the Vitamin D level needed to effectively protect against cancers 
requires a continuous sun exposure. In a summer in Europe, level of Vitamin D is 50 % 
higher than in winter time31. Studies showing the seasonality in cancer survival, with 
improved survival among those diagnosed in summer and autumn as compared with those 
diagnosed in winter, further support the hypothesis of an immediate sunlight protective 
effect32, 33. Furthermore, incidence of melanoma also showed seasonal variation with highest 
incidence rates in the summer. This suggests an influence of recent sun exposure on 
melanoma risk, and possibly also on reducing the risk of other cancers34.   
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13.2. Study limitations 
 
Unavailability of individual exposure data  
Our studies are primarily based on cancer registry data. This type of studies is population-
based and provides a large number of cases. This allows detection of even a small increase 
in risk as well as providing a reference population. However, detailed data on risk factors are 
usually not available in registry data. Thus, we were not able to assess the role of prominent 
risk factors in the explanation of the increased risk of second cancer among breast cancer 
patients. A careful interpretation of results is thus warranted, because we did not adjust for 
potential confounding.  
 
For instance in our skin cancer study: higher physical activity has been related to higher sun 
exposure and thus a higher risk of skin cancer.35 Higher physical exercise is also known to 
lower the risk of colorectal cancer.36 It could be that the reduced risk of colorectal cancer is 
caused through higher physical activity. However, physical activity is more related to 
melanoma of the skin35 and among these patients no lower risk of colorectal cancer was 
observed. Thus, it is yet unlikely that that the reduced risk of colorectal cancer among 
patients with SCC or BCC is due to differences in physical activity.  
 
Another example is our study on excess breast cancer risk and mean age at first child. We 
found a strong correlation between national excess of breast cancer cases and the national 
average age when women previously had their first childbirth. The observed correlations 
may be due to other risk factors such as parity or duration of hormonal contraception use, 
which are also related to breast cancer risk. However, studies have demonstrated that after 
correcting for other breast cancer risk factors such as oral contraceptive use and number of 
children37, age at first birth remained an independent risk factor of breast cancer risk. On the 
other hand, that two thirds of the cross country difference is explained by the difference in 
the timing of first child seems to be an overestimation. Furthermore, though of a lower 
magnitude, there was also a correlation between age at first child in 2002 and excess breast 
cancer risk in the same period: women who had their first child in 2002 should not yet be at 
high risk of breast cancer, suggesting that this may simply be a spurious association.  
Ultimately, we concluded that although higher age at first childbirth is likely to be directly 
related to higher breast cancer risk, it is also associated with many other risk factors for 
cancer, which explains why such as high correlation is observed.  
 
Differentiating a new primary cancer from cancer recurrence 
A new primary cancer of the breast among patients with a previous breast cancer can be 
difficult to distinguish from a recurrence, in case of a synchronous ipsilateral breast cancer. 
A contralateral breast cancer seems to be correctly coded as a new primary cancer38. The 
IARC rules of multiple cancers of paired organs such as the breast request that only 
multicentric or cancers of different histology be considered as independent new tumors39, 40. 
Applying these rules, to some extent, reduces misclassification of recurrence and new 
primary cancer (please see 13.4 on future research).  
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Differentiating a new primary cancer from cancer metastasis 
We might have misclassified primary second cancers and metastases of the initial cancer. 
This is probably more of a problem in our breast cancer cohort, where about 5% of all cases 
had distant metastasis.41, 42 Skin cancer rarely metastasised except for approximately 11% of 
the melanoma cases,43 though more than half of the distant metastasised cases would be 
again occurring on the skin.44 We found little evidence of this problem, also because we did 
not observe increased risks of second cancers that are common metastasis sites of breast 
or skin cancer.  
 
The most common sites of distant metastasis among breast cancer patients are41, 45: 
• Bone (± 50%) 
• Liver (± 20%) 
• Brain (± 15%) 
• Others (± 15%) including epidural, leptomeningeal, ocular and  ovary  
 
The most common sites of distant metastasis among cutaneous melanoma patients are44:  
• Skin, subcutaneous tissues, and nonregional lymph nodes (± 60%) 
• Lung (± 15-36%) 
• Gastrointestinal tract (± 2-4%) mostly in the small bowel and less common in the colon 
and stomach 
• Others including hepatobiliary system and spleen 
 
 
13.3 Study implications 
 
Surveillance 
The increase of breast cancer incidence among female survivors was largest for patients 
with breast cancer stage II. In addition, those who were first diagnosed with a non-breast 
cancer in the end 1990s had a rather unfavorable stage distribution of second breast cancer 
with 44% of breast cancer stage II, and 18% of cancer stage III. Early diagnosis of a new 
breast cancer in (ex)-cancer patients might be more difficult due to their operated or radiated 
breast/chest, thus resulting in an increased incidence of stage II breast cancer. With respect 
to carcinogenesis, first cancer treatment may cause a more malignant cancer, thus leading 
to a higher proportion of stage II breast cancer. 
 
Nonetheless, our findings highlight the need for more intensive follow-up, particularly for 
women previously diagnosed with a non-breast cancer, e.g. through biennial clinical breast 
examination in addition to the standard mammography. A previous study showed that a 
biennial clinical breast examination can reduce breast cancer mortality for women with a 
moderately increased risk of breast cancer.46  
 
An important factor to be considered is the impact of increased surveillance on patients’ 
quality of life. It has been demonstrated that women who undergo a more intensive 
examination e.g., with MRI, have a higher proportion of intense anxiety (10.2%) as 
compared to those who only have mammography (5.2%) or clinical breast examination 
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(1.8%)47. However an analysis of health-related quality of life did not show a relevant impact 
of more intense screening among women with higher- breast cancer risk47. Thus, it seems 
that intensified screening may bring more benefit than harm to female cancer survivors, as it 
contributes to detect a second breast cancer at an early stage. 
 
We found that the risk of developing a new cancer among breast cancer patients is still 
increased even after 15 years, which stresses the need for long-term surveillance. However, 
we also showed that an increased risk of certain malignancies such as second salivary 
cancer (SIR: 5) does not always correlate with a high absolute excess risk (respective AER: 
0.5) and population burden. Thus, surveillance should be directed to second cancers that 
have both high relative increased risk and absolute excess risk. Examples of these are 
second breast and ovarian cancers among women diagnosed before the age of 50. Among 
older breast cancer patients, awareness of second breast and colon cancer should be 
increased.  
  
Cancer treatment and management 
 
Treatment of breast cancer among patients with a previous cancer 
As the proportion of elderly increases, so does the number of those with multiple primary 
cancers. Treatment of cancer among the elderly is complex due to the co-existence of other 
illnesses. Co-morbidity including a previous cancer diagnosis limits the possibilities for 
treatment, and may ultimately impair survival.48 As compared to younger patients, older 
patients with breast cancer generally receive less aggressive treatment with less radiation 
and lymph node staging48.  However, among older cancer patients, more aggressive 
treatment may cause more complications. Thus, whether applying a non-standard treatment 
is a good practice is questionable. Therefore, in particular for the elderly with a previous 
cancer diagnosis, treatment decisions need to balance between the achievement of the 
expected survival with ‘good’ quality of life, and the harm of a more aggressive treatment. 
Future studies are needed on this area (see section 13.4. for specific studies recommended)  
 
Breast cancer among breast cancer survivors are likely to be less aggressive than first 
cancer tumours, partly because breast cancer patients are subject to higher surveillance, 
with annual mammography until the age of 60 followed with a biennial mammography up to 
the age of 7449. Screen-detected breast cancers are more commonly slow-growing tumours 
that would otherwise have stayed longer in the pre-clinical phase if had not been detected50. 
Yet, current national guidelines for breast cancer treatment do not differentiate between 
treatment for a new primary breast cancer and for a recurrence and treatment51. Thus, 
although further research is required, patients with a second breast cancer may require a 
less aggressive treatment than patients with a first diagnosis or recurrent cancer.  
 
Reducing the risk of major second or first primary cancers 
Risk of second cancer among breast cancer patients has been related to lifestyle factors 
including body mass index. Obese breast cancer patients have approximately 2-fold greater 
hazard of contralateral breast tumours relative to women with normal-weight women.12-14 
Likewise, obesity and/or adult weight gain increases the risk of other second primary 
cancers including endometrial and colon cancer risk.12-14 Thus, modification towards a 
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healthier lifestyle may decrease the risk of a second cancer. Furthermore, overall survival 
can be improved through promotion of a healthier lifestyle among patients.  
 
A growing body of evidence27, including findings from our study, supports the hypothesis that 
sunlight protects against the development of colorectal and prostate cancer, possibly 
through the formation of vitamin D3. For breast cancer, our findings were less clear, but a 
similar pattern as observed for skin cancer patients with a second colorectal cancer was 
shown: skin cancer patients who theoretically had higher sun exposure had the largest risk 
reduction of breast cancer. If sunlight has a protective effect against colorectal and prostate 
cancer, it is important to balance the positive and negative effects of sun exposure in public 
health messages. Furthermore, sunlight may also protect against other malignancies such 
as ovarian and non-hodgkin lymphoma, as well against immune diseases such as multiple 
sclerosis.52 The level of sun exposure that does not result in increased risk of skin cancers 
should be defined. Additionally, if indeed vitamin D reduces the risk of colorectal, prostate 
and possibly breast cancer, recommendations to increase oral intake of vitamin D through 
supplementation and/or fortification should be developed.  
 
13.4. Recommendations for future research 
Improvements in early detection, diagnosis and treatment of cancer have increased survival 
of patients with many types of cancer including breast cancer. However, such improvements 
have also led to a major increase in the number of individuals with multiple malignancies. 
This problem will continue to grow dramatically in industrialized societies where the 
proportion of elderly continues to rise. Research action in several fronts is needed to tackle 
these increasing trends: 
Public health – prevention research 
Firstly, studies assessing the role of changing lifestyle after a cancer diagnosis are scarce, 
and therefore are needed. Current studies on lifestyle and the risk of a second primary are 
mostly based on lifestyle before or at cancer diagnosis. The type of intervention effective to 
gain a healthier lifestyle and ultimately decreased risk of second cancer is warranted. 
Secondly, the optimal strategies to follow cancer survivors and thus improve early detection 
of new cancer need to be better defined. Cost-effectiveness study of more intensive breast 
cancer screening among female cancer survivors especially those who had a non-breast 
cancer as first cancer should be considered, e.g., by including a clinical breast examination 
or a breast self-examination.  
 
Further studies comprising data on sun exposure and vitamin D blood levels are required to 
establish the role of sunlight in reducing the risk of colorectal, prostate or breast cancer. 
Within the cancer registry, a nested case-control study using questionnaires on lifestyle 
including sun exposure, eating habits and other risk factors of the corresponding cancer may 
shed light on the protective role of sunlight. Other studies could examine the risk of cancer 
before the occurrence of skin cancer and thus indirectly test the sunlight hypothesis. If 
sunlight does reduce the risk of some cancers, the incidence of these malignances should 
also be lower before the diagnosis of a skin cancer. Furthermore studies have reported a 
higher survival rate among colorectal, breast and prostate cancer patients who were 
diagnosed in the late summer. Thus suggests that more intensive sun exposure, and thus 
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higher vitamin D level, may improve disease prognosis. In population-based registries, 
studies could compare survival of colorectal, breast or prostate cancer among patients 
previously diagnosed with skin cancer, with survival among patients not diagnosed with skin 
cancer. If the sunlight hypothesis were true, we should observe a survival benefit mostly for 
those who were previously diagnosed with SCC, gradually decreasing for those who were 
previously diagnosed with melanoma. 
Clinical research 
Further research could be done in a number of different areas. Firstly, in particular among 
the elderly, descriptive studies are required on variation of treatment practices of a second 
cancer and its impact on survival. Population- or hospital-based registry studies can serve as 
basis for future clinical trials of optimal treatment of the elderly. Secondly, future studies that 
retrieve more detailed data from medical records e.g. detailed treatment choice and patients 
characteristics accompanied by examination of cause-specific death, will surely add much to 
our current knowledge on treatment of the elderly with multiple malignancies and its impact 
on survival. This will be the base of a case control study assessing the disease process 
including recurrences, metastases42, second cancer, other illness such as cardiovascular 
disease53, and ultimately cause of death3, 54. If possible, biological matters from patients 
should be collected and preserved in a biobank. Biomarkers assessment of the first primary 
cancer and the host themselves might help to improve early detection of multiple cancers or 
morbidity from other disease. Furthermore it will also add our knowledge on the 
pathogenesis of multiple cancers in general. Finally, qualitative research is warranted on the 
decision-making process for individual patients, including analysis of patients’ treatment 
preference, particularly among the elderly.55  
 
Patient perspective has long been taken care of more or less explicitly by the various  
medical doctors, as well as epidemiologists. But, more recently more attention was directed 
towards understanding of their concerns and quality of life. However, studies are still lacking 
examining quality of life among patients with multiple cancers, their relationships with the 
family, infertility problems, with chronic pain the assumed beneficial role of a healthier 
lifestyle or scalp cooling to reduce alopecia. Finally study findings need to be communicated 
to the patients, thus their involvement in clinical decision-making can be increased.     
 
In this thesis, we have focused our studies among breast and skin cancer patients. Future 
studies should also examine risks in other cancer patients, e.g. colorectal, lung, lymphomas, 
head and neck cancer, kidney and bladder cancers. Studies on the occurrence and course 
of multiple malignancies can improve our insight of the aetiology and genesis of cancer in 
general. Furthermore, cancer treatment will continue to improve possibly through emerging 
new therapies, which highlights the need for continuous surveillance. In addition, identifying 
those at risk of multiple cancers will provide input on detection strategies through which 
survival can be improved. Population-based registries can significantly contribute to improve 
monitoring and increase understanding of the causes and pattern of second cancer.  
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Summary  
 
The number of cancer survivors has been increasing with about 5% per year and is 
expected to grow in the near future due to rising detection and survival rates. Individuals who 
suffered from cancer exhibited a 20% higher risk of subsequent primary malignancies, 
possibly increasing over time (chapter 1). Thus studying multiple cancers has become of 
utmost importance, also because it currently comprises about 10% of all new cancer cases 
in most industrialized countries.  
 
The aim of this thesis is two-fold, firstly to assess the clinical aspect of cancer survivorship 
using a cohort of female cancer survivors with focus on breast cancer survivors and 
secondly exploring the use of multiple cancer studies in an etiological context using a cohort 
of patients with skin cancer.  
 
This thesis began with a review (chapter 2) on the epidemiology of multiple cancers, 
discussing the pattern and trends of multiple cancers as well as their possible determinants, 
which is also related to study design used. The determinants include an inherited 
predisposition to cancer, the usual carcinogenic and cancer promoting aspects of lifestyle, 
hormonal use and limited role of environmental factors, the major role of irradiation and 
systemic treatment of the previous primary cancer; last but not least there is the role of 
generally increased surveillance of cancer survivors.  
  
This thesis is divided into two sections each focusing on two major cancers: breast and skin.  
 
In chapter 3-5 general epidemiological aspects of breast cancer were discussed. Firstly, in 
an ecological study (chapter 3), we showed a very strong correlation between the overall 
excess incidence of breast cancer in 2002 and the average age of the mother at first birth in 
1972, 1982 and 1992, which seemed to persist in 2002. Both past and current average age 
at first childbirth at population-level were very strongly associated with recent excess risk of 
breast cancer. The association may be so strong, because risk factors for breast cancer 
such as younger age at menarche, lower parity, obesity and use of post-menopausal 
hormones, also generally cluster in populations with a high incidence of breast cancer. 
Besides being directly linked to an increased risk of breast cancer, older age at first child 
delivery can also be considered as a risk indicator of clustering of risk factors in western 
populations. Thus, this indicator might therefore a good tool in estimations of future 
incidence of breast cancer. 
 
In chapter 4 we described the recent trend in breast cancer incidence in women aged 50-69 
in the Netherlands compared to the USA. Recent trend has shown a decreased incidence of 
breast cancer in this age group attributable to reduced use of hormonal replacement therapy 
(HRT). However due to the smaller proportion of women using (HRT) in the Netherlands 
(only 13%), we only observed a flattening of the ever rising curves since the 50’s but did not 
(yet) observe a substantial reduction in the incidence of breast cancer at age 50-69 years. In 
the following chapter (chapter 5) we examined the prognostic factors for survival among 
patients with breast cancer surviving more than 10 years. Among others, the impact of a 
second cancer diagnosis among these patients was assessed: a better overall survival for 
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women without second primary tumours as compared to women who developed a new 
primary cancer. In addition, tumor size, nodal status and grade remained the most important 
prognostic factors for long-term survival, although their role decreased over time. Most 
studies agreed on the long-term prognostic values of MI (mitotic index), LVI (lymphovascular 
invasion), Her2-positivity, gene profiling and co-morbidity for either all patients or a subgroup 
(node-positive or negative).  
 
Trends in the incidence of a second breast cancer among female cancer survivors were 
examined in chapter 6. We found that over a period of 20 years, the incidence of breast 
cancer among female cancer survivors has doubled. Population aging contributed 
approximately 36% to this increased trend. The highest increase in incidence occurred 
among older survivors (age 75+), those diagnosed with a non-breast cancer and most of the 
increase was detected in stage 2, thus rendering a detection effect unlikely. Our findings 
warrant confirmation in other datasets and close exploration of a better follow-up strategy for 
female cancer survivors to detect subsequent breast cancer at an early stage. 
 
During the last decades, we found a 50% increased incidence of second breast cancer 
among the breast cancer survivors. Among the general female Dutch population a marked 
increase in the incidence of breast cancer has also been reported. Thus, we compared the 
incidence of second cancer among breast cancer survivors to that of the general population 
in the following 3 chapters (chapter 7-9). During 30 years of follow-up, 13% of breast cancer 
patients in our cohort were diagnosed with a second primary cancer. Compared with the 
general population, patients with malignant breast cancer experienced a 2-fold increased 
risk of another (new) primary cancer. Most pronounced is the risk of developing another 
breast, salivary gland and connective tissue cancer, approximately 3 times higher than that 
of general female population. Also elevated, albeit to a lesser extent, were the risks for 
cancer of colon, ovary, skin (melanoma) and bladder. Closer monitoring of breast cancer 
patients seems warranted for second breast cancer and for ovarian cancer in women 
diagnosed with breast cancer before menopause and for colon cancer in breast cancer 
patients diagnosed after age 50. Chapter 8 focused on the risk of second cancer among 
women with in-situ breast cancer. This was done because of the tremendously increased 
incidence of in-situ breast cancers during the last decade following mass mammography 
screening. Approximately 10% of these patients were subsequently diagnosed with a second 
cancer during a follow-up period of 30 years. Most evident, we observed an increased risk of 
second breast and skin cancer, 4- and 2-times higher than the general population, 
respectively. Furthermore, we found that the pattern of increased cancer risk for patients 
with in-situ breast cancer resembles that for patients with malignant breast cancer, as both 
groups of patients have an increased risk of colorectal, ovarian, lung and skin cancer as 
compared to the general population. Therefore, similar follow-up strategies may be required 
for patients with malignant breast cancer and patients with in-situ breast cancer.  
 
The following chapters (chapter 10-12) studied multiple cancers among patients with skin 
cancer. Chapter 10 shortly described the skin cancer cohort as well as the potential impact 
of its major risk factor, solar radiation in relation to the 3 types of skin cancer: BCC (Basal 
Cell Carcinoma), SCC (Squamous Cell Carcinoma) and CM (Cutaneous Melanoma). On the 
other hand, sun exposure might have a protective effect on the initiation and progression of 
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some cancers including breast, colon and prostate cancer, mediated by the production of 
vitamin D. Thus in the context of studying multiple cancers, we examined the risk of breast, 
colorectal (chapter 11) and prostate cancer (chapter 12) among patients previously 
diagnosed with a skin cancer. And indeed, we found a decreased risk of colorectal and 
prostate cancer among male skin cancer patients, particularly among those with SCC. 
Furthermore, patients with SCC, especially those who were older than 60 at the time of 
diagnosis; those with the lesion on the head and neck area had the lowest risk of a second 
colorectal cancer. Older skin cancer patients have supposedly been exposed to the sun 
longer than younger patients. In addition, skin cancer in the head and neck area is also 
associated to chronic sun exposure. These findings are consistent with the hypothesis: the 
more chronic sun exposure, the lower the risk of developing colorectal and prostate cancer. 
We also found that the risk of colorectal or prostate cancer among skin cancer patients was 
lowest during the first year after skin cancer diagnosis, and increased gradually thereafter. 
Skin cancer patients may reduce their sun exposure soon after the skin cancer diagnosis. 
Thus, our findings suggest that the protective effect of sun exposure is on progression and 
diminishes as soon as sun exposure was reduced. 
 
Although not statistically significant, for breast cancer after skin cancer diagnosis, we 
observed a similar pattern as that for colorectal cancer: SCC patients who were older than 
60 at diagnosis with a lesion on the head and neck area had the lowest risk of breast cancer. 
For CM patients a higher risk of breast cancer as compared to the general population was 
found. In our previous study where we assessed the risk of second cancer among breast 
cancer patients, we also observed a higher risk of melanoma. There are several 
explanations for this. This may reflect a higher socio-economic status, which is related to 
higher intermittent sun exposure, but to lower number of children, younger age at the first 
child's birth and probably higher awareness for breast cancer leading to higher attendance 
rate for screening. A small fraction of this risk may also be explained by genetic 
predisposition towards both CM and breast cancer e.g mutation in BRCA2.  
 
In conclusion (chapter 13), our findings highlight the need for more intensive follow-up, 
particularly for women previously diagnosed with a non-breast cancer, e.g. through biennial 
clinical breast examination in addition to the standard mammography in women older than 
50 years. Furthermore, our study showed the long-term increased risk of second cancer 
among breast cancer patients, which stresses the need for long-term surveillance. As for 
treatment decisions, a high proportion of multiple cancer patients is of advanced age, thus 
treatment needs to balance between the achievement of the expected survival with ‘good’ 
quality of life, and the harm of a more aggressive treatment. Second breast cancer among 
breast cancer survivors is likely to be less aggressive than first tumours, partly because of 
earlier detection by more intensive surveillance. Thus, future research is required to assess 
the effectiveness of a less aggressive treatment in this group of patients. Finally in the 
framework of patient management, the proportion of cancer survivors who will be affected by 
a second cancer is increasing, thus raising awareness and the need for more knowledge on 
an effective preventive strategy. Lifestyle modification after cancer diagnosis may decrease 
the risk of a second cancer, although such studies are still lacking.  
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As for the beneficial role of sunlight, our findings in skin cancer survivors who were most 
exposed to chronic UV-exposure support the hypothesis that sunlight protects against the 
development of colorectal and prostate cancer, possibly through the formation of vitamin D. 
If sunlight has indeed a protective effect against colorectal and prostate cancer, it is 
important to balance the positive and negative effects of sun exposure in public health 
messages. The levels of sun exposure that does not result in increased risk of skin cancers 
in the various groups of skin types should be defined. Additionally, if indeed vitamin D 
reduces the risk of colorectal, prostate and possibly advanced breast cancer, 
recommendations to increase various forms of intake of vitamin D, including orally, through 
supplementation and/or fortification should be implemented.  
 
Future studies may be warranted that retrieve more detailed data from medical records on 
e.g. treatment choice and patient characteristics and finally examination of cause-specific 
death. International collaborations would be of increasing value for such studies (nested 
case-control studies), not only by increasing the number of study subjects, but also by 
enhancing the generalizability of the results.  
 
We have to realize that we are, in a sense, the fortunate victims of our own success in the 
area of multiple cancers. Improved early detection of cancer and oncologic therapy have led 
to prolonged survival, and the risk of secondary malignancies has consequently increased. 
Therefore, the time may have come to take some counteraction against this increasing 
problem. Although it is widely known that lifestyle factors have a significant influence on the 
risk of developing a primary cancer, the influence of such changes on the risk of developing 
second cancers is largely unknown. Finally, as the numbers of patients with second cancers 
are increasing, further studies are warranted directed at various clinical and psycho-social 
aspects of these patients, including their survival and quality of life. The latter is also 
considered of major importance from the point of view of patients.  
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Het aantal mensen dat kanker overleeft is drastisch toegenomen en de verwachting is dat 
die groei nog verder zal toenemen in de nabije toekomst. Elke 10-jaar treedt ongeveer een 
verdubbeling op. Patiënten die ooit kanker hebben gehad, hebben een 20% hoger risico om 
nogmaals een vorm van kanker te krijgen. Dus het bestuderen van meervoudige tumoren is 
zeer belangrijk al was het alleen uit preventieve overwegingen. Het doel van dit proefschrift 
is tweeledig: ten eerste het in kaart brengen van de klinische aspecten van het overleven 
van kanker, gebruikmakend van een cohort van vrouwelijke (ex-)kankerpatiënten vooral (ex-
)borstkankerpatiënten, en ten tweede het verkennende gebruik van studies naar 
meervoudige tumoren in een etiologische context, gebruikmakend van een cohort van (ex-) 
huidkankerpatiënten.  
 
In hoofdstuk 2 wordt de epidemiologie van meervoudige tumoren beschreven. Hierbij 
spelen de volgende factoren een belangrijke rol. De erfelijke gevoeligheid voor het 
ontwikkelen van kanker, gedeelde risicofactoren (carcinogenen), hormonale en 
omgevingsfactoren, behandeling van de eerste tumor, en de toegenomen overleving van 
bepaalde groepen  kankerpatiënten. Inmiddels maken meervoudige tumoren wel 10% uit 
van alle nieuwe tumoren.  
  
Hoofdstuk 3 t/m 5 gaan over de algemene epidemiologie van borstkanker. In een 
ecologische studie (hoofdstuk 3) blijkt er een sterke correlatie te bestaan tussen een 
verhoogde kans op borstkanker in 2002 en de gemiddelde leeftijd waarop vrouwen hun 
eerste kind kregen in de periode 1972-2002. Bekend is dat de lengte van het interval in de  
periode tussen eerste menstruatie en het eerste kind er toe doet. Andere risicofactoren voor 
borstkanker, zoals een lagere menarche leeftijd, minder kinderen per vrouw, meer 
overgewicht en het gebruik van hormoonsuppletie therapie, komen ook vaker voor in landen 
met een hogere borstkankerincidentie. Naast een direct verband tussen de hogere leeftijd bij 
de geboorte van het eerste kind, is die leeftijd ook een indicator van een langer interval 
waarin deze risicofactoren in de westerse bevolking clusteren.  
 
In hoofdstuk 4 wordt de trend in borstkanker incidentie bij vrouwen tussen 50 en 69 jaar in 
Nederland vergeleken met die in de Verenigde Staten. Recentelijk werd daar sinds 2002 een 
afname geconstateerd in borstkankerincidentie die toegeschreven werd aan de vermindering 
van het gebruik van post-menopausale hormoonsuppletie. Deze reductie werd in Nederland 
in mindere mate waargenomen, waarschijnlijk omdat hormoonsuppletie hier veel minder 
frequent en korter van duur was dan in de Verenigde Staten (13% versus 38%). Inmiddels 
worden de aanwijzingen steeds sterker dat hier wel degelijk sprake is van een belangrijke 
ontwikkeling. 
 
De factoren die de prognose bepalen van borstkanker patiënten op de lange termijn (meer 
dan 10 jaar na diagnose) staan in hoofdstuk 5. Hierin werd een systematisch 
literatuuronderzoek verricht. Onder andere bleek de prognose van vrouwen met een nieuwe 
primaire tumor, na de eerste borstkanker diagnose, slechter te zijn dan van vrouwen zonder 
meervoudige tumoren. 
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De incidentie van borstkanker na een eerdere kwaadaardige tumor is in een periode van 
twintig jaar verdubbeld (hoofdstuk 6). Deze stijging is voor circa 36% toe te schrijven aan 
het vaker voorkomen van borstkanker in de ouder wordende bevolking. De hoogste toename 
van de incidentie werd gezien bij vrouwen van 75 jaar en ouder, vrouwen met een andere 
vorm van kanker dan borstkanker; de tweede diagnose borstkanker bleek vaker stadium II te 
zijn ondanks verbeteringen in de screening. Dit benadrukt het belang van follow-up van 
kankerpatiënten om vroegtijdig nieuwe primaire tumoren op te kunnen sporen.  
 
In een groep borstkanker patiënten die gedurende maximaal 30 jaar werden gevolgd 
(hoofdstuk 7 t/m 9), kreeg 13% opnieuw een primaire tumor. In vergelijking met de 
algemene bevolking hadden deze vrouwen een twee keer zo hoog risico om opnieuw kanker 
te krijgen. Met name het risico op een tumor in de andere borst, de speekselklieren en het 
bind- en spierweefsel waren ongeveer drie keer verhoogd. In iets mindere mate was ook het 
risico op darm-, eierstok-, huid-, en blaaskanker verhoogd. Een speciale follow-up van 
borstkankerpatiënten lijkt gerechtvaardigd gericht op tijdige opsporing van met name tweede 
mammacarcinoom en eierstokkanker bij premenopausale vrouwen en op dikkedarmkanker 
bij vrouwen ouder dan 50 lijkt gerechtvaardigd. 
 
De introductie van het bevolkingsonderzoek naar borstkanker heeft geleid tot een enorme 
toename in het voorkomen van in-situ borstkanker. Ongeveer 10% van deze patiënten krijgt 
vervolgens een invasieve vorm van kanker (hoofdstuk 8). Met name het risico op een 
invasief mammacarcinoom en huidkanker zijn respectievelijk 4 en 2 maal zo hoog als in de 
algemene bevolking. Het patroon van risico op een tweede tumor na een in-situ borsttumor 
vertoont grote gelijkenis met dat na een eerste invasief mammacarcinoom, met name 
verhoogde risico’s op dikkedarm-, ovarium-, long- en huidkanker. Daarom zou de 
surveillance gericht op andere kankers bij patiënten met een in-situ mammacarcinoom 
dezelfde moeten zijn aan de follow-up van een invasief mammacarcinoom. 
 
Hoofdstuk 10 t/m 12 gaan over het optreden van meervoudige tumoren bij 
huidkankerpatiënten. Hoofdstuk 10 bevat een beschrijving van het cohort en de 
belangrijkste risicofactor, te weten chronische en/of intermitterende blootstelling aan de zon.  
De gedachte is dat die blootstelling ook een beschermend effect kan hebben bij de initiatie 
en/of progressie van tumoren van sommige vormen van kanker, zoals borst-, colon- en 
prostaatkanker, door de invloed op de vitamine D productie. Het risico op borst-, dikkedarm- 
(hoofdstuk 11) en prostaatkanker (hoofdstuk 12) werd onderzocht bij patiënten die eerder 
huidkanker hadden. Inderdaad werd bij mannen een lager risico op dikkedarm- en 
prostaatkanker gevonden, vooral bij degenen met een plaveiselcelcarcinoom. Het risico op 
dikkedarmkanker was het laagst voor patiënten ouder dan 60 bij diagnose en waarbij het 
plaveiselcelcarcinoom in het hoofd-hals gebied was. Oudere patiënten zijn langer 
blootgesteld aan de zon en huidkanker in het hoofd-hals gebied is vooral gerelateerd aan 
langdurige zonblootstelling. Deze bevindingen komen overeen met de hypothese: bij meer 
chronische blootstelling aan de zon neemt de kans op sommige vormen van kanker af. Het 
risico op dikkedarm- en prostaatkanker bij huidkankerpatiënten was het laagst in het eerste 
jaar na de diagnose van de huidtumor en nam daarna geleidelijk toe. Mogelijk nam na het 
diagnosticeren van huidkanker de blootstelling aan de zon af en daarmee het 
beschermende effect. Eenzelfde patroon werd waargenomen voor borstkanker na 
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huidkanker, hoewel dit een zwakker verband bleek. Een verhoogd risico op borstkanker 
werd gevonden voor vrouwen met een voorafgaand melanoom van de huid. Dit kan 
gerelateerd zijn aan een hogere sociaal-economische status, die samenhangt met een 
hogere intermitterende zonblootstelling, maar ook aan een lager aantal kinderen, hogere 
leeftijd bij de geboorte van het eerste kind en een groter borstkanker-bewustzijn waardoor 
de kans op detectie groter is. Een klein deel van het risico is ook te verklaren door een 
gedeelde genetische aanleg voor zowel borstkanker als melanoom van de huid. 
 
Uit de studies beschreven in dit proefschrift blijkt het belang van een intensieve follow-up 
van vrouwen met een eerdere vorm van kanker vooral vrouwen met een andere vorm van 
kanker dan borstkanker, dus een tweejaarlijks klinisch onderzoek van de borst, naast de 
standaard mammogram. Omdat het risico op een tweede tumor lang na diagnose van de 
eerste tumor aanhoudt, zou ook de termijn van follow-up voldoende lang moeten zijn.  
 
Omdat een groot deel van de kankerpatiënten ouder is, moet de behandeling een balans 
zijn tussen het te behalen resultaat met een acceptabele kwaliteit van leven en de mogelijke 
schade van de behandeling. Meervoudige borsttumoren worden vaak minder agressief 
behandeld dan de eerste mammatumor, deels vanwege de meer intensieve follow-up. 
Vervolgonderzoek naar de effectiviteit van deze minder agressieve therapie is noodzakelijk. 
Bovendien moet benadrukt worden dat veranderen van de levensstijl het risico op een 
tweede tumor kan verminderen. 
 
Onze bevindingen bevestigen het mogelijk beschermende effect van zonblootstelling, 
waarschijnlijk door de bijdrage aan de vorming van vitamine D. Het is dus belangrijk de 
positieve en negatieve effecten van blootstelling aan de zon zorgvuldig te communiceren 
naar de bevolking. Het niveau waarop geen schade aan de huid optreedt dient te worden 
vastgesteld. Bovendien zouden, indien de bescherming werkt via de verhoogde vitamine D 
productie, aanbevelingen voor grotere vitamine D inname met de voeding, via supplementen 
of door toevoeging aan voedingsmiddelen moeten worden overwogen. Die zouden 
eveneens osteoporose tegen kunnen gaan, hetgeen bij vele kankerpatiënten een probleem 
vormt. 
 
Er is een behoefte aan studies met gedetailleerde gegevens uit medische dossiers, zoals 
behandelkeuze en patiëntgegevens, die ook informatie hebben over doodsoorzaken van de 
patiënten. Hierbij is wenselijk dat de patiënt verenigingen aan het CBS duidelijk maken dat 
deze gegevens ongehinderd ter beschikking komen van de kankerregistraties. Internationale 
samenwerkingsverbanden zijn in toenemende mate van belang voor dergelijke studies 
(ingebouwde (‘nested’) patiëntcontrole onderzoeken), niet alleen vanwege de grotere 
aantallen patiënten, maar ook om eventuele variatie op het spoor te komen dan wel tot  
generaliseerbare bevindingen te komen voor andere populaties. Benadrukt zij ook dat het 
optreden van meervoudige  tumoren tot op zekere hoogte een teken is van succesvolle 
behandelingen en langdurige overleving mede door de verbeterde vroege opsporing van 
kanker. Door deze langere overlevingsduur is de kans om een tweede maligniteit te 
ontwikkelen soms echter wel verhoogd. Het is dan ook tijd om dit in omvang toenemende 
probleem aan te pakken vanuit een preventieve optiek. Als leefstijl factoren in belangrijke 
mate de kansen op het ontwikkelen van een eerste primaire tumor  beïnvloeden, zou dit ook 
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het geval moeten zijn voor hierna optredende tumoren. Maar van de precieze effecten van 
leefstijl is niet zoveel bekend , en meer onderzoek op dit gebied is nodig.  
 
Tot slot, aangezien de aantallen patiënten met meervoudige tumoren aanzienlijk toenemen, 
zijn nieuwe studies nodig en ook beter mogelijk gericht op de kwaliteit van leven van deze 
patiëntengroepen.  
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